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About this thesis 
“A journey of a thousand miles begins with a single step (千里之行始于足下)”. Similarly, 
pharmacological effects are triggered by the initial step of drug-target binding. This thesis focuses on 
the kinetics of binding interactions between ligands (drugs) and various G protein-coupled receptors 
(GPCR). GPCR are one of the largest and most important drug target families; many drugs in use 
today target these pharmaceutically relevant proteins.1 However, many candidate drugs are still 
neither efficacious nor safe.2 Thus the traditional affinity- or potency-based rationale in the early 
phases of drug discovery may need to be reconsidered. Although binding kinetics. i.e. the rate with 
which a ligand associates to and dissociates from the target, has been studied on a few drug target 
classes, the concept of binding kinetics has been emerging over the last decade as an additional and 
relevant selection criterion in the drug discovery pipeline.3, 4  
To describe the importance and relevance of the research performed in this thesis, this chapter 
serves as a general introduction. First, the GPCR will be introduced. Second, the two families of 
human cannabinoid and human adenosine receptors will be mentioned; more specifically, both the 
human cannabinoid receptor 1 (hCB1) and the human adenosine A1 and A3 (hA1 and hA3) receptors 
will be outlined as prototypical GPCR as well as potential drug targets. These targets are then the 
main “actors” in the subsequent experimental chapters of this thesis. Furthermore, the concept of 
binding kinetics will be presented in a chronological way, including some practical requirements for 








What are GPCR ? 
GPCR are membrane bound proteins, composed of seven transmembrane helices with extracellular 
and intracellular loops and an extracellular (N-terminal) and intracellular (C-terminal) tail. They play 
key roles in physiology by detecting external stimuli (e.g. chemical small molecules, endogenous 
ligands, or photons) and activating internal signal transduction pathways and eventually physiological 
responses (Figure 1A). An agonist is able to bind to and activate a GPCR to produce a biological 
response. In contrast, a (neutral) antagonist blocks the action of the (endogenous) agonist, while an 
inverse agonist causes an action opposite to that of the agonist, i.e. decreasing the basal level of 
receptor activity (Figure 1B). Since GPCR are involved in various critical functions, it may not be 
surprising that GPCR are the target of about 30% of all drugs on the market.5 Much of the current 
understanding of the structure and function of GPCR results from the pioneering research on the 
rhodopsin and β2 adrenoceptor. As a result, Robert Lefkowitz and Brian Kobilka were awarded the 
2012 Nobel prize in chemistry.6, 7 However, key questions still remain unanswered in the GPCR field. 
For instance, although the ligand-GPCR complex can be observed, the detailed molecular recognition 
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Figure 1: Panel A) A simplified schematic of GPCR signaling by agonist (activating ligand) binding. One 
GPCR can be activated through G protein-dependent (G protein coupling) and G protein-independent 
(β-arrestin binding) pathways, adapted from the review of Ghosh et al.8 Panel B) Theoretical graph 
showing: 1) dose-dependent receptor activation by an agonist (blue curve); 2) a (neutral) antagonist 
that in this concept simply prevents the agonist from binding and, hence, from activating the 
receptor and more downstream signaling pathways (purple curve); and 3) an inverse agonist that in 
this concept also competes for binding with the agonist, however, it causes a subsequent decrease of 
basal receptor activity (red curve). 
     
GPCR studied in this thesis 
As recorded by the International Union of Basic and Clinical Pharmacology (IUPHAR) Committee on 
Receptor Nomenclature and Drug Classification, there are about 800 GPCR identified in the human 
body; The largest GPCR class is the one of rhodopsin-like GPCR, also known as class A GPCR.8 It would 
be a daunting task to study all of them. As a result, this thesis is focused on a few, as prototypical 
examples. 
Human cannabinoid 1 (hCB1) receptor  
Within the endocannabinoid system (ECS) two human cannabinoid receptor subtypes have been 
identified: the human CB1 (hCB1) receptor and the human CB2 (hCB2) receptor. They are primarily 




arachidonylethanolamine, AEA) and 2-arachidonoylglycerol (2-AG).9, 10 The hCB1 and hCB2 receptors 
show 44% overall sequence homology, and display different pharmacological profiles.11 Due to the 
long history of Cannabis sativa use,12 a diversity of effects initiated through hCB1 receptor activation 
by the plant’s main psychoactive component, Δ9-THC, has been described. These effects include 
feeling high, alteration of time perception, an increase in body sway and the munchies (i.e. the 
extreme desire for and enjoyment of food-intake).13  It has been shown that the latter can also be 
triggered through activation of the hCB1 receptor by endocannabinoids (ECs) from breast milk or 
other food products.14-16 
The hCB1 receptor is expressed in the central nervous system (CNS) and is also widely distributed in 
the peripheral nervous system (PNS) and peripheral tissues,10, 17 including heart, liver, lung, 
gastrointestinal tract, pancreas and adipose tissue.18, 19 The broad presence of the hCB1 receptor in a 
variety of complex physiological systems provides numerous opportunities for the development of 
new medications. In the particular case of obesity, the ECS, including the hCB1 receptor, is overactive 
with increased levels of endocannabinoids in plasma, and in central and peripheral tissues.20 
Therefore, blockade of the hCB1 receptor is a potential approach for the treatment of obesity. 
Rimonabant, a hCB1 receptor inverse agonist, was developed by Sanofi-Aventis and introduced on 
the market in Europe in 2006. However, it was quickly withdrawn from the market due to the risk of 
unacceptable psychiatric side effects.21-23 Many other hCB1 receptor antagonists entered clinical trials, 
such as taranabant 24 and otenabant,25 however, they were not developed further due to similar 
psychiatric side effects despite their different chemical structures. Although researchers have 
experienced many setbacks on this drug target, the intensive drug discovery efforts have never been 
terminated. Since 2016, a series of crystal-structures of the hCB1 receptor have been resolved with 
antagonists (i.e. AM6538 and taranabant, 26, 27 Figure 2A and 2B) or agonists (i.e. AM11542 and 




predicting the binding modes of hCB1 ligands, and may help in the future development of better 
drug candidates for the hCB1 receptor. 
 
 
Figure 2: Crystal structures of hCB1 receptor with various ligands. The typical seven helices of hCB1 
receptors are shown as ribbons and the intracellular and extracellular domains are present as loops. 
Panel A (upper left): Global structure of the hCB1 receptor in complex with the antagonist AM653826 
(PDB: 5TGZ). The receptor is shown in cyan cartoon representation. Panel B (upper right): Global 
structure of the hCB1 receptor in complex with the antagonist taranabant27 (PDB: 5U09). The 
receptor is represented as a yellow cartoon. Panel C (lower left): Global structure of the hCB1 
receptor in complex with the agonist AM1154228 (PDB: 5XRA). The receptor is represented as a green 
cartoon. Panel D (lower right): Global structure of hCB1 receptor in complex with the agonist AM841 
28 (PDB: 5XR8). The receptor is represented as a light yellow cartoon. All the ligands are presented in 
a space-filling style and their atoms color coded: black = carbon, red = oxygen, blue = nitrogen, green 





Human adenosine A1 and A3 (hA1 and hA3) receptor 
 Human adenosine A1 and A3 receptors belong to the family of human adenosine receptors with four 
distinct subtypes (hA1, hA2A, hA2B and hA3).29 Although all subtypes are activated by the endogenous 
and ubiquitous local hormone adenosine, these purinergic receptors differ in their distribution and to 
which G protein they are coupled. Classically, following agonist activation hA1 and hA3 receptors 
induce a decrease in cyclic adenosine monophosphate (cAMP) levels due to their primary coupling to 
Gi proteins, while hA2A and hA2B receptors couple to Gs proteins and stimulate cAMP formation.30  
Both hA1 and hA3 receptors have similar clinical potential for the treatment of ischemia-reperfusion 
injury,31 renal disease,32 and neuropathic pain.33, 34 Besides, two hA3 agonists have moved forward 
into a series of clinical trials: for IB-MECA, in total twelve completed or planned trials have been 
reported related to inflammatory conditions (e.g. keratoconjunctivitis sicca, rheumatoid arthritis, 
psoriasis, uveitis, etc.); for 2-Cl-IB-MECA, four trials have been registered for liver diseases (e.g. 
hepatocellular carcinoma, hepatitis C).35, 36 Nevertheless, distinct pharmacological effects related to 
hA1 and hA3 receptors (i.e. cardioprotection31, 37, 38 and neuroprotection39) can be ascribed to their 
different downstream effectors. For cardioprotection, the hA1 receptor is linked to the atrial cardiac 
myocyte potassium channel and to phospholipase C, while the hA3 receptor has been found to 
couple to not only phospholipase C but also phospholipase D; such plausible “hA1 receptor – PLC” 
and “hA3 receptor – PLD” signaling pathways may indicate distinct effects in the heart.40, 41 For 
neuroprotection, the hA1 receptor is activated acutely to inhibit neuronal calcium transients;42 
whereas hA3 receptor activation in astrocytes results in a release of neuroprotective CCL2.43  
Last but not least, the crystal structure of hA1 receptor has been resolved quite recently (Figure 3).44 
Such progress suggests that the binding interaction of ligands on the hA1 receptor will be better 
understood in the near future. Moreover, this structure also aids in understanding the binding modes 






Figure 3: Global crystal structure of hA1 receptor in complex with the antagonist DU172 (PDB: 
5UEN).44 The typical seven helices of hA1 receptors are shown as ribbons and the intracellular and 
extracellular domains are present as loops. The receptor is represented as a purple cartoon. DU172 is 
presented in a space-filling style and its atoms are color coded: black = carbon, red = oxygen, blue = 
nitrogen, yellow = sulfur. 
 
The concept of binding kinetics at these representative GPCR is not completely new. For example, a 
hCB1 antagonist and negative allosteric modulators have been studied in this context,45, 46 as are the 
human adenosine receptors.47 However, key questions are remaining:   
• Can we characterize ligands with a “good” kinetic profile on these receptors? 
• Can we establish structure-kinetics relationships (SKR) of ligands for these receptors? 
• Can we improve the technology of the kinetic assays on these receptors? 
• Can we confirm that a ligand with “good” kinetic profile leads to target selectivity and clinical 
efficacy and/or safety? 




Historical aspects of drug-target binding kinetics 
 
Figure 4: The emergence of binding kinetics studies. 
The concept and study of drug-target binding kinetics have emerged since the evolution of modern 
pharmacology (Figure 4). In the 19th century, the law of mass action was firstly described in chemical 
reactions, while in the year 1900, Paul Ehrlich introduced the term “receptor”, symbolizing the era of 
modern pharmacology. Later in 1913, Ehrlich also coined the phrase “corpora non agunt nisi fixata” 
(a drug will not work unless it is bound).48, 49 From then on, drug action in the human body is 
described as a kinetic event, not only in terms of transport of drug molecules to the environment of 
targets (e.g., receptors), but also with respect to the drug-target interaction itself. In other words, the 
lifetime of the drug-target complex is relevant to drug action. More specifically, the law of mass 





in which k1 and k2 represent the association (kon) and dissociation (koff) rate constant of a drug to and 
from its target, respectively.  This mathematical application was first reported in enzyme kinetics 
(since 1913) and, later (1937) more emphasis was placed on equilibrium parameters of drug-target 
binding interactions. It lasted until 1961, when Paton proposed that “the dissociation rate constant is 
the primary determinant of the activity of a drug”.53, 54 Kinetic and affinity parameters were 
intertwined as drug activity (i.e. affinity), which is the ratio of both association and dissociation rate 
constants:55 
Kinetic KD (an affinity parameter) = k2/k1 
Methodologies to determine kinetics (presented as various rate constants) have been explored and 
improved over the decades. One example is the invention of patch clamp technology in the late 
1970s which allowed (gating) kinetics of ion channels to be measured.56 Another active research field 
is enzyme kinetics which was pushed forward by the study of catalytic mechanisms.57 However, 
kinetics in the field of GPCR has often been overlooked or neglected. In 2004, a retrospective survey 
of 50 drugs on 17 different drug targets led to the conclusion that slowly dissociating or even 
irreversible ligands present better efficacy than relatively faster dissociating equivalents.58 
Noteworthy, GPCR were only a small fraction (~18%) among the investigated drug targets, in contrast 
to the fact that GPCR are one of the largest classes of drug targets.  
Steady-state potency metrics (i.e. Ki and IC50) are often used to characterize drugs targeting GPCR in a 
traditional early-phase drug discovery endeavor. However, there is mounting evidence to show that 
high affinity drug candidates cannot prevent high attrition rates in clinical trials.2 This may, among 
others, be due to the dynamic, non-equilibrium, conditions in vivo (like in the human body) that 
often are in contrast to the equilibrium conditions applied in in vitro assays.59 Therefore, other, 




collectively stands for the association (kon) and dissociation (koff) rate constants of a drug to and from 
its target. Particularly, over the last ten years, drug-target residence time (RT) has emerging as an 
additional parameter to assess the therapeutic potential of drug candidates with respect to drug 
efficacy and safety. RT is defined as the reciprocal of koff and is an indication for the life-time of a 
drug-target complex. 59-61 In the field of GPCR, a number of structure-kinetics relationships (SKR) 
studies has been published, and the results suggest that including binding kinetics data (or kinetics 
profiles) when triaging compounds can improve the resulting decision process.62-64 Following such 
rationale, appropriate binding kinetics experiments shall be incorporated in an early stage (in vitro) of 
drug design and discovery. Classical radioligand kinetic association and dissociation assays enable 
straightforward determination of association (kon = k1) and dissociation (koff = k2) rate constants. 
However, (radio)labeling every ligand of interest is impractical. In 1984, Motulsky and Mahan 
introduced an alternative strategy in which the kinetics of unlabeled ligands (cold ligands) can be 
quantified by using only one labeled tracer (hot ligand).65 Such so-called competition association 
assay was validated by a further developed mathematic model obeying the law of mass action:        
 
In brief, both a cold ligand of interest and a well-characterized (i.e. k1 and k2) hot ligand can 
competitively bind to the same receptor; the competitor may delay the time-dependent ascent of 
hot ligand binding or even produce a time-dependent decrease in hot ligand binding after an initial 
‘overshoot’.65 This method has been used to quantify the binding kinetics of cold ligands (i.e. k3 and 
k4) to several GPCR.62, 63, 66, 67 However, the competition association assay described above is quite 
laborious and time-consuming. Therefore, a so-called “dual-point competition association assay” was 




binding, a semi-quantitative measurement yielded a so-called kinetic rate index (KRI) of the cold 
ligand. Thereby, the throughput of kinetics assays can be improved greatly.  
 
Objectives and outline of this thesis 
Investigating ligand-GPCR binding kinetics is a leading theme in this thesis, which will be explored 
using hCB1, hA1 and hA3 receptors. Currently, the drug discovery paradigm is shifting from studying 
structure-affinity relationships (SAR) alone, to a combination of SAR and extensive structure-kinetics 
relationships (SKR). This strategy is firstly exemplified in a study of hCB1 receptor antagonists 
(Chapter 2). We provide evidence that, next to affinity, additional knowledge of binding kinetics is 
useful for selecting new hCB1 receptor antagonists in the early phases of drug discovery. Following 
this, another selection of hCB1 receptor antagonists with divergent residence times (RTs) was 
observed to have distinct modes of functional antagonism, in both G-protein dependent and G 
protein-independent signaling (Chapter 3).  
The other research chapters (Chapter 4-6) are devoted to adenosine receptors. Firstly, an SKR study 
on a series of hA3 receptor antagonists is performed in Chapter 4; furthermore, a “kon-koff-KD” kinetic 
map enables the division of the antagonists into three subgroups, providing a possible direction for 
further development of hA3 receptor antagonists. On the other hand, binding kinetics of hA3 receptor 
agonists is reported in Chapter 5, providing binding kinetics insights of GPCR agonists. In Chapter 6, 
the application of a novel radio-isotopic technology in binding kinetics is described for the hA1 
receptor. Its robustness and potential for high-throughput screening may render this technology a 
preferred choice for further kinetics studies.    
Last but not least, Chapter 7 provides a general conclusion of the novel findings presented in this 
thesis, and future perspectives and opportunities for this field of research. Hopefully, this thesis will 
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About this chapter 
Despite the plethora of human cannabinoid 1 (hCB1) receptor antagonists active in vitro that have 
been synthesized as potential antiobesity drugs, the withdrawal from the market of rimonabant 
caused the termination of virtually all clinical programs of such antagonists. This was due to 
rimonabant’s class-related serious central nervous system side effects. A better understanding of the 
molecular mechanisms of hCB1 antagonist action may, albeit retrospectively, shed some light on 
what went wrong. It is now emerging that drug target binding kinetics, next to traditional potency 
measures, may indeed contribute to a better understanding of drug action. Therefore, we now 
report on the synthesis and biological evaluation of a series of 1,2-diarylimidazol-4-carboxamide 
derivatives developed as hCB1 receptor antagonists. These were evaluated in a radioligand 
displacement binding assay, a [35S]GTPγS binding assay, and in a competition association assay that 
enables the relatively fast kinetic screening of multiple compounds. The compounds show high 
affinities and a diverse range of kinetic profiles at the hCB1 receptor, and their structure-kinetic 
relationships (SKR) were established. Using the recently resolved hCB1 receptor crystal structures, we 
also performed a modelling study that sheds light on the crucial interactions for both the affinity and 
dissociation kinetics of this family of ligands. We provide evidence that, next to affinity, additional 
knowledge of binding kinetics is useful for selecting new hCB1 receptor antagonists in the early 







Within the endocannabinoid system (ECS) two human cannabinoid receptor subtypes have been 
identified: the human CB1 (hCB1) receptor and the human CB2 (hCB2) receptor.1 They are members of 
the rhodopsin-like class A G-protein-coupled receptors (GPCR), and are primarily activated by 
endogenous cannabinoids (endocannabinoids, ECs), including anandamide (or N-
arachidonylethanolamine, AEA) and 2-arachidonoylglycerol (2-AG).1, 2 The hCB1 and hCB2 receptors 
show 44% overall sequence homology, and display different pharmacological profiles.3 The hCB1 
receptor is present in the central nervous system (CNS) and is widely distributed in the peripheral 
nervous system (PNS) and peripheral tissues,2, 4 including heart, liver, lung, gastrointestinal tract, 
pancreas and adipose tissue.5, 6 The presence of the hCB1 receptor within both the CNS and PNS 
mediates neurotransmitter release and controls various cognitive, motor, emotional and sensory 









Figure 1: Structure of a) Rimonabant; b) Taranabant; c) Otenabant and d) the scaffold of 1,2-diarylimidazol-4-
carboxamides as hCB1 receptor antagonists; the R1 substitution is defined as the “Left arm” of the scaffold 
while the R2 substitution defines the “Right arm” of the scaffold. The calculation of PSA values are reported in 






The broad presence of the hCB1 receptor in a variety of complex physiological systems provides 
numerous opportunities for therapeutic intervention. In the particular case of obesity, the ECS, 
including the hCB1 receptor, is overactive with increased levels of endocannabinoids in plasma, both 
in central and peripheral tissues.10 Therefore, blockade of the hCB1 has been explored for the 
treatment of obesity. With this in mind, rimonabant (SR141716A, Figure 1a), a hCB1 receptor inverse 
agonist, was developed by Sanofi-Aventis and introduced in Europe in 2006. However, it was quickly 
withdrawn from the market due to unacceptable psychiatric side effects.11-13 Many other hCB1 
receptor antagonists entered into clinical trials, such as taranabant (MK-0364, Figure 1b)14 and 
otenabant (CP945598, Figure 1c).15 However, they were not developed further due to similar 
psychiatric side effects, despite their diverse chemical structures. 
In order to avoid the CNS side effects, peripherally acting hCB1 receptor antagonists with 
physicochemical features that reduce brain penetration have been developed.16 Another approach 
has been the development of hCB1 receptor neutral antagonists, because it has been postulated that 
the CNS side effects of rimonabant were due to its inverse agonism.17-19  
Drug target binding kinetic parameters are receiving increasing attention, alongside classical affinity 
(Ki) and potency (IC50) values, as has been discussed for several other class A GPCR. In particular the 
receptor-ligand residence time (RT) is emerging as an additional parameter to assess the therapeutic 
potential of drug candidates with respect to drug efficacy and safety.20-22 In the research field of 
GPCR, a number of structure-kinetic relationship (SKR) studies have been published, and the results 
suggest that the strategic combination of SKR with classic structure-affinity relationships (SAR) can 
improve the resulting decision process.23-26 By doing so, ligand-receptor interactions can be better 
understood, as together they not only comprise the equilibrium state of a ligand-receptor 





driven drug discovery approach for the hCB1 receptor has been validated in some aspects already by 
its application in the development of allosteric modulators of the hCB1 receptor.28, 29  
In the current study we report the synthesis and evaluation of 1,2-diarylimidazol-4-carboxamide 
derivatives (Figure 1d), as human CB1 receptor antagonists with more polar characteristics than 
rimonabant.30, 31 Together with rimonabant they were evaluated in a radioligand displacement assay, 
a [35S]GTPγS binding assay, and a dual-point competition association assay that enables the relatively 
fast kinetic screening of compounds.32 Selected compounds were progressed to a full competition 
association assay. The compounds show high affinities and a diverse range of kinetic profiles at the 
hCB1 receptor, which allowed their structure-kinetic relationships (SKR) to be established. Their 
putative binding mode was analyzed using the recently resolved crystal structures of the hCB1 
receptor,33,34 shedding light on key structural features of the receptor binding site that are involved 
in ligand recognition and dissociation. Thus we provide evidence that, in additional to affinity, 
knowledge of binding kinetics is useful for selecting new hCB1 receptor antagonists in the early 
phases of drug discovery. 
 
Results and discussion 
Chemistry.  
The synthesis of the 1,2-diarylimidazol-4-carboxamide scaffold commenced from commercially 
available 4-(benzyloxy)aniline 1, which was converted to the 2,4-dichlorobenzamidine 2 (Scheme 1). 
After a one-pot condensation and cyclization sequence, the core-imidazole 3 was obtained. 
Afterwards, either saponification of the ethyl ester or acidic hydrolysis of the benzyl ether of 3 led to 
intermediates 4 and 5, respectively. Subsequently, Mitsunobu reaction on intermediate 5 yielded 
mono- and tri-fluoropropyl ether derivatives 6a and 6b. After saponification of the ethyl esters of 6a 





reacted with piperidin-1-amine to yield the corresponding amides (8a and 8b). Alternatively, the rest 
of the series was produced from intermediate 4 by first introducing the piperidin-1-amide. Lewis 
acid-catalyzed cleavage of benzyl ether 9 followed by substitution of the released alcohol 10 with 
various alkyl halides gave the corresponding ethers 11a-11h, completing the “left arm” series of 
antagonists (Table 1). 




Reagents and conditions: a) EtMgBr, 2,4-diClPhCN, THF, r.t., 20 h, 98%; b) i. EtO2CC(O)CH(Br)CH3, K2CO3, THF, 
r.t. 66 h, ii. AcOH, reflux, 1 h, 65%; c)  HBr, AcOH, r.t., 15 h, 63%; d) R1-OH, DEAD, Ph3P, THF, Toluene,  r.t., 15h, 
77%; e) KOH, EtOH:THF:H2O 2:2:1, 50 °C, 3.5 h, 95%; f) i. (COCl)2, DMF cat., CH2Cl2, r.t., 90 min, ii. Piperidin-1-
amine.HCl, pyridine, CH2Cl2, r.t., 2 h, 55% (2 steps); g) KOH, MeOH:H2O 3:1, reflux, 2 h, 99%; h) i. (COCl)2, DMF 
cat., CH2Cl2, reflux, 2 h, ii. Piperidin-1-amine, NEt3, CH2Cl2, 0 °C to r.t., 2 h, 74%; i) BBr3, CH2Cl2, r.t., 1 h, 58%; j) 
R1-X, base, CH2Cl2. 56-90% Corresponding R1 substitutions are listed in Table 1. 
The synthesis of the “right arm” series of antagonists was started from intermediate 4 (Scheme 2). 





amides 12a-12h were obtained, as well as racemic (±) 20. Deprotection of the aromatic alcohol on 
12a-12h and subsequent sulfonylation using 3,3,3-trifluoropropane-1-sulfonylchloride gave 
compounds 14a-14h.  
Scheme 2. Synthesis of antagonists 14a-h, 19, (±)22, (±)25 and 28. 
 
14a-h, 19, (±) 22, (±) 25, 28








(±) 23 R = Bn
(±) 24 R = H
b
12a-h, (±) 20 R = Bn
13a-h, (±) 21 R = H
b
15 R = Bn
16 R = H
b
26 R = Bn











Reagents and conditions: a) i. SOCl2, reflux; or (COCl)2, DMF cat., CH2Cl2, r.t.; ii. R2-NH2, NEt3, CH2Cl2, 17-98 % (2 
steps); or 2-amino-5-trifluoromethylpyridine, Me3Al, CH2Cl2, r.t. to 45 oC, 16 h, 64%; b) BF3.OEt2, Me2S, CH2Cl2, 
r.t.; or HBr, AcOH, r.t. 20-97 %; c) Et3N, F3CCH2CH2SO2Cl, CH2Cl2, -78 oC, 25-97 %; d) i. TBDMSCl, Et3N, CH2Cl2, 
r.t., 22 h; ii. Boc2O, THF, r.t., 4 h, 70% (4 steps, a, b, d i. & ii.); iii. TBAF, THF, r.t., 90 min; iv. F3CCH2CH2SO2Cl, 
Et3N, CH2Cl2, -78 oC, 3 h; v. SOCl2, MeOH, 0 oC to r.t., 1 h, 56% (3 steps, d iii.,  iv. & v.); e) i. (COCl)2, DMF cat., 
CH2Cl2, r.t., 2 h, ii. Cl3CCH2OH, NEt3, CH2Cl2, r.t., 3 h, 95% (2 steps, e, b); f) Zn, AcOH, 3 h; g) i. (COCl)2, DMF cat., 
CH2Cl2, r.t., 2 h, ii. 4-aminocyclohexanol, NaOH, H2O:CH2Cl2 2:1, r.t., 2 h, 54% (2 steps, f, g);  h) CH2O, NaBH4, 
NaBH3CN, CH3CN, H2O, AcOH, r.t., 48 h, 32%; . Corresponding R2 substitutions are listed in Table 2. 
 
After deprotection of racemic (±) 20 however, it was found that direct substitution was not possible, 
therefore a series of protecting group manipulations was executed on (±) 21 to end up with (±) 22. 





giving (±) 25. Exploring alternative synthesis routes, compound 19 was synthesized, with a few extra 
steps, by first esterifying 4 with 2,2,2-trichloroethanol, followed by deprotection of the aromatic 
alcohol. Sulfonylation of the released alcohol, saponification of the trichloroethylester, acid chloride 
formation and subsequent amide formation gave 19. To obtain trifluoromethylpyridine derivative 28, 
conventional methods as described for the industrial production of rimonabant were applied,35 
starting with the direct amidation of ethyl ether 3 followed by debenzylation and sulfonylation. 
 
Biology.  
All 1,2-diarylimidazol-4-carboxamide derivatives were evaluated as antagonists in an in vitro 
[35S]GTPγS binding assay on HEK-293 cells membrane fractions overexpressing the human CB1 
receptor. We also determined the functional activity of nine representative antagonists on the 
human CB2 receptor. The data in Table 1 and S1 shows that all compounds tested had higher 
functional activity for the human CB1 receptor over the human CB2 receptor, with approximately 110 
to 570-fold selectivity.  
Likewise they were also tested in a [3H]CP55940 radioligand displacement assay on membrane 
fractions of CHO cells overexpressing the recombinant human CB1 receptor. These results are 
reported in Tables 1 and 2. We found that, although using different cellular background and assay 
systems, there is a significant correlation (r2 = 0.49, P = 0.0001)  between the affinity (pKi) values 
from the radioligand binding assay and the potencies (pIC50) determined in the [35S]GTPγS binding 
assay (Figure 2). We subsequently determined the binding kinetics of the 1,2-diarylimidazol-4-







Figure 2: The correlation between the affinities/potencies of the CB1 receptor antagonists measured in a 
radioligand binding assay (X-axis) and in a GTPγS binding assay (Y-axis) (r2 = 0.49, P = 0.0001). Data taken from 
Tables 1 and 2. 
 
 
Figure 3: Association and dissociation profile of [3H]CP55940 (2.9 nM) at recombinant hCB1 receptors stably 
expressed on CHO cell membranes at 30 °C. After 120 min of association, unlabeled rimonabant (10 µM) was 
added to initiate the dissociation. Association data was fitted in Prism 6 using one-phase exponential 
association (n=3, combined and normalized). Dissociation data was fitted using one-phase exponential decay 
(n=4, combined and normalized). Data are shown as mean ± SEM from at least three separate experiments 






Table 1. In vitro pharmacology data, including conventional antagonism, binding affinities and KRI 





R1 [35S]GTPγS binding 
pIC50± SD or SEM  
(mean IC50 in nM) a 
pKi b 
± SEM  















F 8.2 ± 0.01 (6.0) d  10 ± 0.2 (0.34) 1.09 (1.34;0.84) 
9 -CH
2
















































































 8.7 ± 0.1 (2.4) 9.3 ± 0.1 (0.60)  0.73 (0.68;0.78) 
 
a pIC50 ± SD (n=2) or SEM (n ≥ 3), obtained from [35S]GTPγS binding on recombinant human CB1 receptors stably 
expressed on HEK-293 cell membranes.   
b pKi ± SEM (n=3), obtained from radioligand binding assays with [3H]CP55940 on recombinant human CB1 
receptors stably expressed on CHO cell membranes. 
c KRI ± SEM (n = 3) or KRI (n1, n2) (n = 2), obtained from dual-point competition association assays with 
[3H]CP55940 on recombinant human CB1 receptors stably expressed on CHO cell membranes. 






 Table 2. In vitro pharmacology data, including conventional antagonism, binding affinity and KRI 






SD or SEM  
(mean IC50 in 
nM) a 
pKi b 
± SEM  




9.0 ± 0.03 
(1.1) 




8.6 ± 0.1 
(2.7) d 
9.6 ± 0.1 (0.27)  0.71 ± 0.17 
14b (±) trans 
 
8.9 ± 0.04 
(1.1)  
10 ± 0.04 
(0.10)  
0.89 ± 0.12 
14c (-) trans 
 
8.8 ± 0.2 
(1.7) d  
9.7 ± 0.2 (0.30)  0.74 ± 0.15 
14d (+) cis 
 
8.8 ± 0.03 
(1.8)  




19 cis : trans 
(0.3:1) 
 
8.4 ± 0.01 
(3.8) d 
9.4 ± 0.1 (0.37)  0.88 ± 0.17 
22 (±) cis 
 
8.2 ± 0.1 
(7.1) 




7.1 ± 0.1 (83) 
d 










9.2 ± 0.1 
(0.66) d 
9.3 ± 0.4  
(0.22)  
1.29 ± 0.35 
14f 
 
8.9 ± 0.01 
(1.2) d 






8.7 ± 0.1 
(2.2) d 
9.5 ± 0.2  
(0.31)  
1.12 ± 0.35 
14h 
 
8.8 ± 0.03 
(1.7) 
9.9 ± 0.1  
(0.14)  
0.92 ±  0.16 
28 
 
9.2 ± 0.06 
(0.61) 
9.9 ± 0.1  
(0.19)  
1.39 ± 0.34 
 
a pIC50 ± SD (n=2) or SEM (n ≥ 3), obtained from [35S]GTPγS binding on recombinant human CB1 receptors stably 
expressed on HEK-293 cell membranes.   
b pKi ± SEM (n=3), obtained from radioligand binding assays with [3H]CP55940 on recombinant human CB1 
receptors stably expressed on CHO cell membranes. 
c KRI ± SEM (n = 3) or KRI (n1, n2) (n = 2), obtained from dual-point competition association assays with [3H] 
CP55940 on recombinant human CB1 receptors stably expressed on CHO cell membranes. 
d n = 2. 
 
 [3H]CP55940 binding kinetic assay.  
Receptor association and dissociation rate constants of [3H]CP55940 were directly determined in 
classic radioligand association and dissociation experiments at 30 oC. The binding of [3H]CP55940 
approached equilibrium after approximately 25 min (Figure 3), yielding a kon (k1) value of (1.4 ± 0.08) 
x 106 M-1s-1. Binding of the radioligand was reversible after the addition of rimonabant (10 μM), 
although the dissociation was rather slow. Even 240 min after the addition of rimonabant residual 
receptor binding (~15%) of [3H]CP55940 was observed. The dissociation rate constant, koff (k2), of 
[3H]CP55940 from the hCB1 receptor was (1.5 ± 0.2) x 10-4 s-1. The kinetic KD value (koff/kon) of 
[3H]CP55940 was 0.12 ± 0.03 nM (Table 3). The residence time (RT) of [3H]CP55940 was calculated as 








Table 3. Comparison of equilibrium binding and kinetic parameters of CP55940 determined using 
different methodsa). 
 





Displacement b) 0.56 ± 0.04 N.A.c) N.A. 
Association & 
Dissociation d) 
0.12 ± 0.03 (1.4 ± 0.08) x 106 (1.5 ± 0.2) x 10-4 
Competition association 
e) 
0.54 ± 0.10 (1.2 ± 0.1) x 106 (6.5 ± 1.0) x 10-4 
 
a: Data are presented as means ± standard error of the mean (SEM) of at least three independent experiments 
performed in duplicate. 
b: Equilibrium displacement of [3H]CP55940 from hCB1 receptor at 30 °C. 
c: Not applicable.  
d: Classic association and dissociation parameters of [3H]CP55940 measured in standard kinetic assays at 30 °C. 
e: Association and dissociation parameters of CP55940 measured in competition association assays at 30 °C.
Validation of the [3H]CP55940 competition association assay for human CB1 receptor.  
With the kon (k1) and koff (k2) values of [3H]CP55940 binding established from classical association and 
dissociation experiments, kon (k3) and koff (k4) of unlabeled CP55940 were determined by fitting the 
values based on the mathematical model as described in the experimental.36 In this validation 
experiment we tested three different concentrations of unlabeled CP55940, corresponding to IC25, 
IC50 and IC75 (Figure 4A). Values for kon and koff determined by this competition association method 






agreement with the kon (k1) value determined in the classical association experiment (Table 3). The 
koff value obtained by this method was also similar to that found in the classical kinetic dissociation 
experiments with [3H]CP55940, with just a four-fold difference between the values (Table 3). In 
order to confirm the robustness of the assay with unlabeled human CB1 receptor antagonists, an 
experiment was performed using rimonabant (Figure 4B, Table 4). The kon and koff values determined 
by this competition association method were (2.3 ± 0.3) x 105 M-1·s-1 and (1.4 ± 0.2) x 10-3 s-1, 
respectively, demonstrating that rimonabant behaves as a short residence time antagonist (14 ± 2.0 
min), in good agreement with findings reported earlier.37, 38  
Screening of hCB1 receptor antagonists using the dual-point competition association assay.  
The competition association assay described above is quite laborious and time-consuming. 
Therefore, a so-called “dual-point competition association assay” for the hCB1 receptor was 
developed, according to the concept that we had previously established for the adenosine A1 
receptor.32 To this end, [3H]CP55940 and unlabeled antagonists were co-incubated at concentrations 
equal to, or 2 to 3-fold higher than, their Ki/IC50 values which had been determined in the 
[3H]CP55940 displacement assay. The so-called kinetic rate index (KRI) was calculated by dividing the 
specific radioligand binding at 30 min (t1) by the binding at 240 min (t2). Antagonists with a KRI value 
larger than 1 indicate a slower dissociation rate, and thus a longer RT, than [3H]CP55940, and vice 
versa. Furthermore, it was observed that the KRI values of the hCB1 receptor antagonists had no 


















Figure 4: A) Competition association experiments with [3H]CP55940 binding to recombinant hCB1 receptors 
stably expressed on CHO cell membranes (30 °C) in the absence or presence of 3.5, 11, and 35 nM of unlabeled 
CP55940 (n=3, combined and normalized);  B) Competition association experiments with [3H]CP55940 binding 
to recombinant hCB1 receptors stably expressed on CHO cell membranes (30 °C) in the absence or presence of 
120 nM of unlabeled rimonabant (n=6, representative graph). t1 is the radioligand binding at 30 min, while t2 is 
the radioligand binding at 240 min. 
Table 4. Kinetic parameters (kon, koff and RT) of selected human CB1 receptor antagonists. 






11b (3.0 ± 0.5)x105 (2.2 ± 0.2) x 10-4 78 ± 5 
14f (7.2 ± 3.2)x105 (2.7 ± 0.5) x 10-4 62 ± 10 
28 (3.5 ± 0.7)x105 (7.8 ± 0.3) x 10-5 260 ± 56 
rimonabant (2.3 ± 0.3)x105 (1.4 ± 0.2) x 10-3 14 ± 2.0 
 
a kon ± SEM (n = 3), obtained from competition association assays with [3H]CP55940 on recombinant human 
CB1 receptors stably expressed on CHO cell membranes. 
b koff ± SEM (n = 3), obtained from competition association assays with [3H]CP55940 on recombinant human 
CB1 receptors stably expressed on CHO cell membranes. 




















Figure 5: A) The negative logarithm of the affinities of the hCB1 receptor antagonists used in this 
study had no obvious linear correlation with their KRI values (r2 = 0.04, P = 0.33); B) The negative 
logarithm of [35S]GTPγS IC50 values of the hCB1 receptor antagonists in this study had no obvious 
linear correlation with their KRI values (r2 = 0.12, P = 0.10). 
 
Structure−Affinity Relationships (SAR) versus Structure−Kinetic Relationships (SKR).  
The 1,2-diarylimidazol-4-carboxamide derivatives are rimonabant bioisosteres, in which the 2,4-
dichlorophenyl, amide, aryl, and methyl moieties are maintained on an alternative heterocyclic diazo 
core (Figure 1a and 1d). The derivatives included in this study differ in their substituents at the R1 
and R2 positions, which are at the “left” and “right” arms of the scaffold, respectively (Figure 1d). 
We were conscious that compound polarity may influence the activity parameters being studied, so 






included Polar Surface Area (PSA),39 ACDlogD7.4 with pKa correction40 and AZlogD7.4,41 which were 
supplemented with experimentally determined LogD values. A PSA of 90 Å2 has been described as a 
threshold value below which penetration of the blood–brain barrier is more likely, and thus serves as 
an indicator for potential to have CNS activity.42 The calculated PSA values (Tables S2 and S3) of 
most of the compounds in this study were above 90 Å2, suggesting that they would have low blood-
brain barrier penetration, and be better suited for peripheral antagonism of the hCB1 receptor. We 
observed that neither affinities nor KRI values of the CB1 receptor antagonists in this study had any 
obvious linear correlation with their lipophilicity or PSA values (Figures S1 and S2).  
“Left arm” optimization.  
Fixing the right arm as a piperidine moiety, as in rimonabant, various ethers with different carbon 
chain lengths were introduced on the left arm (Table 1). Extension of the trifluoromethylalkyl chain 
from three carbons (8a, 1.26 nM) to four atoms (11a, 0.32 nM) increased affinity by about four-fold. 
Reducing the level of fluorination on the terminal carbon of the linear ether side-chain from three 
atoms (8a, 1.26 nM) to one atom (8b, 0.34 nM) also increased the affinity. By contrast, the analogue 
possessing a benzyl substituent on the left arm (9, 6.28 nM) displayed the weakest affinity of the 
analogues studied. The aforementioned modifications did not seem to have a drastic effect on KRI, 
with all compounds giving values around unity (0.80 to 1.09). As part of a strategy to increase PSA a 
sulfonyl-containing side-chain was introduced. The ligand bearing an n-propyl-sulfonyl moiety (11b) 
displayed a good affinity of 0.28 nM and a rather low KRI value of 0.59. Mono-fluorinating the 
terminal position led to no change in affinity (11c, 0.32 nM).  In contrast to the ether substituents, 
trifluorination resulted in an almost three-fold increase (11d, 0.11 nM) relative to the mono-fluoro 
analogue. A slight increase in affinity was observed when the linear sulfonyl side-chain was extended 
from three carbon atoms (11b, 0.28 nM) to four (11e, 0.18 nM). Combination of this chain length 
with trifluoro-substitution, to give the side chain found in the CB1 receptor agonist (-)-(R)-3-(2-






potent antagonist of the human CB1 receptor (11f, 62 pM). Branching the chain from n-butyl to i-
pentyl did not change the affinity (11g vs. 11e), while introducing an additional methyl group led to a 
decrease in affinity (11h, t-hex chain, 0.60 nM). None of these ligands had a KRI value higher than 1, 
indicating their dissociation from the hCB1 receptor was faster than CP55940. The analogue with the 
lowest KRI value (11b, 0.59) was selected for full-curve measurement (Figure 6, Table 4). As 
expected, its residence time (78 min) was shorter than that of CP55940 (114 min, see above) (Table 
4). This result also serves as evidence that a KRI value seems to reliably reflect the corresponding 
dissociation rate constant. 
 
Figure 6: Competition association experiments with [3H]CP55940 binding to recombinant hCB1 receptors stably 
expressed on CHO cell membranes (30 °C) in the absence or presence of unlabeled long residence time 
compound 28 (8.22 nM, red, representative curve) or short residence time compound 11b (12.72 nM, blue, 
representative curve). Data are shown as mean values from one representative experiment. At least three 
separate experiments each performed in duplicate. 
 
All the linear side-chain antagonists had high affinities in the nanomolar to sub-nanomolar range, 
with 11f (60 pM) as the most potent derivative. However, from the perspective of drug-target kinetic 
studies, despite giving a range of KRIs (0.59-1.09), none of these antagonists showed a KRI value 






“Right arm” optimization.  
To explore the “right arm” of the 1,2-diarylimidazol-4-carboxamides, we chose to fix the “left arm” 
as a trifluoropropyl sulfonyl moiety (11d), since this group delivered high affinity (0.11 nM) and 
demonstrated a residence time similar to CP55940 (KRI = 1.02, Table 1).  Introducing a hydroxyl at 
the 3-position of the piperidine ring yielded a ligand with lower affinity and KRI value (14a, Ki = 0.27 
nM, KRI = 0.71) than 11d (Table 2).  
Efforts then focused on a series of ligands bearing cyclohexyl substituents instead of a piperidine. A 
carbocyclic analogue of 14a, bearing a trans-hydroxyl on the 3-position of the cyclohexyl ring 14b 
(racemic), delivered an approximately three-fold improvement in affinity and a slightly larger KRI 
value relative to the piperidine 14a (Table 2).  Moving the hydroxyl to the 4-position gave 4-
hydroxycyclohexyl analogue (19), as a mixture of cis and trans diastereoisomers in a ratio of 0.3:1, 
and resulted in an approximately four-fold reduction in affinity (0.37 nM), whilst the KRI was 
unchanged (0.88); having a mixture does not allow any further conclusions, though. Interestingly, 
the cis- and trans-2-hydroxycyclohexyl antagonists (14d and 14c, respectively) showed a substantial 
10-fold difference in affinity, while their KRI values were quite similar.  The more potent cis-isomer 
(14d, (+)) displayed an affinity of 27 pM and a KRI value close to unity.  Switching the 2-substituent 
of the cyclohexane ring to an amine was detrimental, resulting in ligands with lower affinities. 
However, it is of note that the unsubstituted cis-amino group (22, (±), 0.52 nM) was less detrimental 
to affinity than a cis-dimethylamino substituent (25, (±), 3.3 nM), whilst the dissociation rates were 
very similar, as judged by their KRI values (Table 2). At this stage, on the basis of affinity alone, 14d 
with an affinity of 27 pM seems an even better lead than 11f with an affinity of 62 pM. 
Last but not least, we found that by introducing an aromatic moiety, the compounds retain affinity in 
the sub-nanomolar range and, more importantly, their kinetic profiles were rather diverse. The 
analogue which bears a 4-trifluoromethoxyphenyl substituent (14e) showed high affinity (0.22 nM) 






then studied. The 3-pyridyl analogues 14f and 14g, bearing a 6-fluoro or trifluoromethyl group, 
respectively, showed similar affinities (0.13 nM vs. 0.31 nM, respectively), although the latter had a 
much higher KRI value (1.12 vs. 0.70, respectively). This effect on KRI was increased further when the 
position of the nitrogen atom in the ring was switched to give the 5-substituted 2-pyridyl analogue 
(28, KRI = 1.39), which displayed the highest KRI value of all the compounds presented in this study. 
Finally, defluorinating this latter compound did not change the affinity, but gave rise to a marked 
reduction in KRI (14h, Ki = 0.14 nM, KRI = 0.92).  
The compounds with high (28) and low (11b and 14f) KRI values were tested in a full competition 
association assay to determine their association and dissociation rate constants (Figure 6 and Table 
4). According to the full curves, the compound with KRI > 1 (28) displayed an “overshoot” in the 
competition association curve, indicating its slow dissociation and yielding the longer residence time 
of 260 min, as compared to 114 min of the radioligand. By contrast, the compounds with KRI < 1 
produced gradually ascending curves, suggesting faster dissociation and consequently shorter 
residence times of 78 min (11b) and 62 min (14f) (Figure 6, Table 4).  Additionally, we determined 
their affinities on the human CB2 receptor. From Table 1 and S1 it shows that they all had higher 
affinity for the human CB1 receptor, where approximately 12 to 125-fold selectivity over human CB2 
receptors was observed. 
 
Functional assays.  
As mentioned above, the antagonism in the [35S]GTPγS binding assay compares quite well with the 
affinities derived from the [3H]CP55940 displacement studies (Figure 2), while the KRI values of the 
compounds did not show any meaningful correlation with the pIC50 values from the GTPγS binding 
assay (Figure 5B). Since 28 showed slow dissociation, we decided to study this compound further in 






CP55940 action was characterized and compared with rimonabant. Pretreatment of CHOK1 hCB1 
receptor membranes with rimonabant for 1h, prior to stimulation by the CB1 receptor agonist 
CP55940 for 30 min, induced surmountable antagonism (a rightward shift of the agonist curve with 
little suppression of the maximum effect) as reported before.45 In the case of 28 insurmountable 
antagonism was observed; the agonist concentration-effect curve was shifted to the right with a 
concomitant decrease (~50%) in its maximal response (Figure 7). In both cases inverse agonism by 
the compounds alone (in the absence of CP55940) was also apparent (negative values at Y-axis in 
Figure 7). 
 
Figure 7: CP55940-stimulated [35S]GTPγS binding to recombinant hCB1 receptors stably expressed on CHO cell 
membranes (25 °C) in the absence (black, representative curve) or presence of long-residence-time compound 
28 (red, representative curve) or rimonabant (blue, representative curve). Compound 28 or rimonabant was 
pre-incubated with the membranes for 1h prior to the challenge of agonist. [35S]GTPγS was subsequently 
added and incubated for another 0.5 h. Plates were then filtered and the radioactivity counted. Curves were 
fitted to a four parameter logistic dose-response equation.  Data were normalized according to the maximal 
response (100%) produced by CP55940. At least three separate experiments each performed in duplicate. 
 
Computational studies.  
Finally, we investigated the ligand-receptor interactions using the recently disclosed X-ray crystal 
structure of hCB1 in complex with 29 [4-(4-(1-(2,4-dichlorophenyl)-4-methyl-3-(piperidin-1-






PDB:5TGZ).32 By docking 28 into the hCB1 receptor it can be seen that, like 29, it lies quite deep in the 
binding pocket of hCB1 in the docked pose, immediately above the conserved Trp3566.48 (Figures 8A 
and B). The main scaffold of the imidazole core and the 2,4-dichlorophenyl ring form a π-π 
interaction with the side chains of Phe102N-term and Phe1702.57 respectively  (Figure 8B). 
Unsurprisingly, and consistent with the SAR reported in Table 1, the “left arm” of our ligand docks 
into the same place as “Arm 2” of 29 in the crystal structure. This “left arm” extends into a long, 
narrow, and highly lipophilic channel formed by helices III, V, VI and ECL2 (Figure 8A). By contrast, 
the “right arm” of our ligands, which resemble “Arm 3” of 29 dock into an open cavity formed by 
various hydrophobic amino acid residues,33 irrespective of whether a cyclohexyl, piperidine, or 
pyridine moiety is present. In the case of a pyridine moiety (14e-14h and 28), the crystal structure 
suggests that there may be a π-π stacking interaction with His1782.65. Further support for the docked 
pose of 28 comes from the higher resolution x-ray structure of taranabant bound to hCB1 (PDB: 
5U09),34 since both compounds share a trifluoromethylpyridine moiety on their “right arm”.  
 











Figure 8: A) Docking of antagonist 28 into the binding site of the crystal structure of the CB1 receptor (PDB: 
5TGZ)33 co-crystalized with 29 (not shown). Compound 28 is represented by black sticks, and residues within 5 
Å of 28 are visualized as green sticks. The protein is represented by green ribbons, and relevant binding site 
confinements are indicated by white-grey (hydrophobic), red (electronegative), and blue (electropositive) 
layers. Ligand and residues atoms color code: yellow = sulfur, red = oxygen, blue = nitrogen, cyan = fluorine, 
white = hydrogen. B) 2-D interaction map of 28 docking into the CB1 receptor co-crystalized with 29 (PDB: 
5TGZ),33 demonstrating π- π stacking between imidazole core of 28 and Phe102N-term, 2,4-dichlorophenyl ring 






the CB1 receptor co-crystalized with 29 (PDB: 5TGZ)33 showing the overlay of numbered consecutively 
hydration sites of 14f (colored spheres; for color code, see below) calculated by WaterMap. Hydration sites 
shown as red and orange spheres represent “unstable” water molecules. White spheres symbolize “stable” 
water molecules, which should not be displaced by 14f or 28. For the key hydration sites (41, 69, 72, 81, 88) 
surrounding the –F atom of 14f, calculated ΔG values (in kcal/mol) with respect to bulk solvent are shown. 
    
Using the crystal structure of the hCB1-29 complex, we performed WaterMap calculations to try and 
understand the differences in residence times observed for the ligands studied, with the hypothesis 
that unfavorable hydration might provide an explanation.46-48 We focused on the pyridine ring 
substituents on the “right arm”, and ligands 14f and 28 in particular, because of their similar binding 
affinities but differing residence times. The smaller of the two ligands (14f, -F substitution, relatively 
short RT) was docked into the hCB1 receptor, and a WaterMap was calculated for the complex. 
Around the –F substituent we found unstable water molecules (41, 69, 72, 81 and 88 in Figure 8C ); 
these water molecules are coined unhappy waters.49 By contrast, ligand 28 was able to displace 
these water molecules with its larger -CF3 substituent, a process which might raise the energy of the 
transition state for dissociation. We postulate that this destabilization of the transition state may 
contribute to the prolonged residence time observed with this compound. 
 
Conclusions 
We have demonstrated that, in addition to affinity, knowledge of binding kinetics is useful for 
selecting and developing new hCB1 receptor antagonists in the early phases of drug discovery. In the 
specific case of the hCB1 receptor, a long residence time compound may be beneficial for a 
peripherally selective antagonist. We explored SAR and SKR parameters in a series of 1,2-
diarylimidazol-4-carboxamide derivatives by examining the influence of substitutions at both “arms” 






 By introducing more polar linear sulfonyl side chains on the “left arm”, affinity could be modulated, 
however the KRI values indicative for the compounds’ kinetic properties were less than or similar to 
CP55940. Substitution of the “right arm” maintained or increased affinity, and with the introduction 
of an aromatic ring system KRI values >1 were obtained. With a residence time of 260 min, which is 
substantially longer than CP55940 (114 min.) or rimonabant (14 min.), 4-(2-(2,4-dichlorophenyl)-5-
methyl-4-((5-(trifluoromethyl)pyridin-2-yl)carbamoyl)-1H-imidazol-1-yl)phenyl 3,3,3-
trifluoropropane-1-sulfonate (28) stood out from the ligands studied. This slowly dissociating hCB1 
receptor antagonist also showed insurmountability in a functional GTPγS binding assay. Using the 
recently resolved hCB1 crystal structures we analyzed the putative interactions of 28 with the 
receptor, from which we speculate that displacement of ‘unhappy’ water molecules may provide a 
plausible explanation for its slow dissociation. Therefore, compound 28, or derivatives with similar 
characteristics, may be a useful tool to test whether prolonged blockade of the (peripheral) hCB1 
receptor has a beneficial effect on CB 1 receptor related disorders, such as obesity.  
 
Experimental section 
Chemistry. All solvents and reagents were purchased from commercial sources and were of 
analytical grade. Demineralized water is simply referred to as water or H2O, as was used in all cases 
unless stated otherwise (i.e., brine). Thin-layer chromatography (TLC) was routinely consulted to 
monitor the progress of reactions, using aluminum-coated Merck silica gel F254 plates. Purification 
was performed on a semi-preparative high performance liquid chromatography (HPLC) with a mass 
triggered fraction collector, Shimadzu QP 8000 single quadrupole mass spectrometer equipped with 
19 x 100 mm C8 column. The mobile phase used was, if nothing else is stated, acetonitrile and buffer 
(aqueous NH4OAc (0.1 M) : acetonitrile 95 : 5). For isolation of isomers, a Kromasil CN E9344 (250 x 
20 mm i.d.) column was used. A mixture of heptane/ethyl acetate/diethylamine 95 : 5 : 0.1 was used 






purity of the final products was determined by Waters Acquity I-class ultra-performance liquid 
chromatography (UPLC) consisting of a binary solvent system, ultra-violet (UV) photo-diode array 
(PDA) detector, column temperature control manager and sample manager modules, coupled with 
in-line and mass spectrometry detection. The sample was injected onto, and separated by, a Waters 
Acquity BEH (C18) 1.7 mm (150x3 mm) UPLC column maintained at 40°C and eluted with 0.1% 
ammonium hydroxide in water (A) and acetonitrile (B) at a flow rate of 1 mL/min, using a linear 
gradient. Initial conditions started at 3% B, which was increased to 97% over 1.3 min, maintained for 
0.2 min before returning to initial conditions over 0.2 min  prior to the next injection. Eluent 
containing UPLC-separated analytes then flowed via the UV PDA detector scanning between 220-320 
nm wavelengths at a resolution of 1.2 nm sampling at 40 points/s, into a Waters SQD single 
quadrupole mass spectrometer (MS) fitted with an electrospray source. All MS analyses were 
acquired for a total run time of 2 min, with mass scanning from 100-1000 u in both positive and 
negative ion modes alternately, using electrospray ionization (ESI). Typical MS settings included 
capillary voltage - 1kV, cone voltage - 25V, source temperature - 150°C, and desolvation temperature 
- 350°C. The data were acquired via a PC running MassLynx v4.1 in open access mode and processed 
and reported via OpenLynx software application. For each sample the purity is determined by 
integration of the UV absorption chromatogram. All final compounds show a single peak and are at 
least 95% pure. 
1H NMR measurements were performed on either a Varian Mercury 300 or a Varian Inova 500, 
operating at 1H frequencies of 300 and 500 MHz respectively at ambient temperature. Chemical 
shifts are reported in parts per million (ppm), are designated by δ, and are downfield to the internal 
standard tetramethylsilane (TMS) in CDCl3. Coupling constants are reported in Hz and are designated 
as J. High-resolution mass spectra were recorded on either a Micromass ZQ single quadrupole or a 
Micromass LCZ single quadrupole mass spectrometer both equipped with a pneumatically assisted 
electrospray interface (LC-MS). Melting points were determined on a Reichert melting point 






N-(4-(Benzyloxy)phenyl)-2,4-dichlorobenzamidine (2). Compound 1 (5.0 g, 21.2 mmol) was added 
dropwise to a solution of ethyl magnesium bromide (44.5 mL, 1 M in THF, 44.5 mmol) in dry THF (25 
mL) under a nitrogen atmosphere. After stirring for 20 minutes a solution of 2,4-dichlorobenzonitrile 
(3.65 g, 21.2 mmol) in THF (25 mL) was added. The reaction mixture was stirred for 20 hours at r.t.. 
Water (50 mL) was carefully added. Extraction with EtOAc (2 x 100 mL), drying (Na2SO4), filtration 
and evaporation to dryness afforded the crude title compound (7.7 g, 98%). 
Ethyl 1-(4-(benzyloxy)phenyl)-2-(2,4-dichlorophenyl)-5-methyl-1H-imidazole-4-carboxylate (3). To a 
solution of compound 2 (6.88 g, 18.5 mmol) in THF (50 mL) was added potassium carbonate (2.56 g, 
18.5 mmol) and the suspension was stirred for 10 minutes. Ethyl-3-bromo-2-oxobutanoate (4.65 g, 
22.2 mmol) was added dropwise over 1 hour, and the mixture was stirred for 66 hours at r.t.. The 
solution was filtered and evaporated to dryness. The residue was dissolved in AcOH and refluxed for 
1 hour. The mixture was cooled to r.t., water (100 mL) added and the product extracted with EtOAc 
(2 x 200 mL). The combined organic phases were washed with saturated aqueous sodium hydrogen 
carbonate, dried (Na2SO4), filtered, and concentrated in vacuo. Flash chromatography (silica, 30-40% 
EtOAc in hexane) afforded the title compound (5.75 g, 65%) as a pale yellow solid. 1H NMR (CDCl3): δ 
7.50-7.20 (m, 8H), 7.10-6.90 (m, 4H), 5.10 (s, 2H), 4.50 (q, 2H), 2.5 (s, 3H), 1.5 (t, 3H). 
1-(4-(Benzyloxy)phenyl)-2-(2,4-dichlorophenyl)-5-methyl-1H-imidazole-4-carboxylic acid (4). To a 
suspension of compound 3 (3.62 g, 7.5 mmol) in MeOH (60 mL) was added potassium hydroxide 
(4.05 g, 72 mmol) in water (20 mL), and the reaction mixture heated to reflux.  After 2 h the mixture 
was cooled to r.t., acidified to pH~2 with HCl (1 M) and extracted with ethyl acetate (2 x 200 mL). 
The combined organic phases were dried (Na2SO4), filtered and concentrated in vacuo to give the 
crude title compound (3.38 g, 99%). 
Ethyl 2-(2,4-dichlorophenyl)-1-(4-hydroxyphenyl)-5-methyl-1H-imidazole-4-carboxylate (5). 
compound 3 (4.82 g, 10 mmol) was dissolved in HBr (33% in AcOH, 80 mL) and stirred overnight at r.t. 






residue was dissolved in EtOH, HCl (4 M in dioxane, 5 mL) and MgSO4 were added, and the resulting 
mixture heated under reflux for 2.5 h. The reaction mixture was cooled to r.t., filtered, and 
concentrated in vacuo. The residue was dissolved in EtOAc and washed with water basified with 
triethylamine and then brine. The organic layer was dried over Na2SO4 and concentrated in vacuo to 
give the crude title compound (4.74 g) as a brown, viscous oil of sufficient purity for the next step. 
Ethyl 2-(2,4-dichlorophenyl)-5-methyl-1-(4-(3,3,3-trifluoropropoxy)phenyl)-1H-imidazole-4-
carboxylate (6a).  A solution of compound 5 (978 mg, 2.5 mmol), 3,3,3-trifluoro-1-propanol (428 mg, 
3.75 mmol) and triphenylphosphine (984 mg, 3.75 mmol) in anhydrous THF (12 mL) were treated 
with DEAD (40% in toluene, 1.72 mL, 3.75 mmol). The resulting mixture was stirred at r.t. for 30 h, 
then heated to 50 °C overnight. After cooling to r.t., additional 3,3,3-trifluoro-1-propanol (428 mg, 
3.75 mmol) and triphenylphosphine (984 mg, 3.75 mmol) were added, followed by di-tert-
butylazodicarboxylate (863 mg, 3.75 mmol), and the resulting mixture stirred at r.t. overnight. Again, 
additional 3,3,3-trifluoro-1-propanol (428 mg, 3.75 mmol) and triphenylphosphine (984 mg, 3.75 
mmol) were added, followed by di-tert-butyl azodicarboxylate (863 mg, 3.75 mmol), and the 
resulting mixture stirred at r.t. overnight. The mixture was concentrated in vacuo and the residue 
purified by column chromatography (silica gel, 10-50% EtOAc in hexanes) to yield the title compound 
(880 mg, 68%) as a yellowish foam of sufficient purity for the next transformation. 1H NMR (500 MHz, 
CDCl3) δ 7.22-7.16 (m, 3H), 7.01 (d, J = 8.7 Hz, 2H), 6.83 (d, J = 8.7 Hz, 2H), 4.40 (q, J = 7.1 Hz, 2H), 
4.22-4.10 (m, 2H), 2.66-2.54 (m, 2H), 2.40 (s, 3H), 1.40 (t, J = 7.1 Hz, 3H). 
Ethyl 2-(2,4-dichlorophenyl)-1-(4-(3-fluoropropoxy)phenyl)-5-methyl-1H-imidazole-4-carboxylate (6b).  
A solution of compound 5 (978 mg, 2.5 mmol), 3-fluoropropan-1-ol (293 mg, 3.75 mmol) and 
triphenylphosphine (984 mg, 3.75 mmol) in anhydrous THF (9 mL) were treated with DEAD (40% 
solution in toluene, 1.72 mL, 3.75 mmol). The resulting mixture was stirred at r.t. overnight. The 
residue was purified by column chromatography (silica gel, 20-40% EtOAc in hexanes). The product 






then an equal amount of hexane was added. The resulting solid was filtered off, and the filtrate 
concentrated in vacuo to yield the title compound (1.07 g, 85%) as a colorless foam of ca. 90% purity 
which was used in the next transformation without further purification. 1H NMR (500 MHz, CDCl3) δ 
7.35-7.20 (m, 3H), 7.03 (d, J = 8.7 Hz, 2H), 6.87 (d, J = 8.7 Hz, 2H), 4.73-4.60 (m, 2H), 4.44 (q, J = 7.1 
Hz, 2H), 4.11-4.07 (m, 2H), 2.44 (s, 3H), 2.24-2.13 (m, 2H), 1.44 (t, J = 7.1 Hz, 3H). 
2-(2,4-Dichlorophenyl)-5-methyl-1-(4-(3,3,3-trifluoropropoxy)phenyl)-1H-imidazole-4-carboxylic acid 
(7a). A stirred solution of compound 6a (880 mg, 1.72 mmol), in a mixture of THF (15 mL) and EtOH 
(15 mL), was treated with KOH (1.07 g, 19 mmol) dissolved in water (10 mL) and the resulting 
mixture stirred at 50 °C. After 3 h 30 min the reaction mixture was cooled to r.t. then concentrated 
in vacuo. The residue was partitioned between CH2Cl2 and HCl (1 M) and, after phase separation, the 
aqueous layer was extracted two more times with CH2Cl2. The combined organic extracts were dried 
over MgSO4 and concentrated in vacuo to give the title compound (714 mg, 90%) as a yellowish 
foam. 1H NMR (500 MHz, CDCl3) δ 7.32-7.18 (m, 3H), 7.00 (d, J = 8.7 Hz, 2H), 6.85 (d, J = 8.7 Hz, 2H), 
4.18-4.14 (m, 2H), 2.66-2.55 (m, 2H), 2.42 (s, 3H). 
2-(2,4-Dichlorophenyl)-1-(4-(3-fluoropropoxy)phenyl)-5-methyl-1H-imidazole-4-carboxylic acid (7b). A 
solution of compound 6b (1.07 g, 2.13 mmol, ca. 90% pure), in a mixture of THF (20 mL) and EtOH 
(20 mL), was treated with KOH (1.40 g, 25 mmol) dissolved in water (10 mL) and the resulting 
mixture stirred at 50 °C. After 3 h 30 min the reaction mixture was cooled to r.t. then concentrated 
in vacuo. The residue was partitioned between CH2Cl2 and HCl (1 M) and, after phase separation, the 
aqueous layer extracted with CH2Cl2 and twice with EtOAc. The combined organic extracts were 
dried over MgSO4 and concentrated in vacuo to give the title compound (856 mg, 95%) as a 
yellowish foam which was sufficiently pure for the next step. 1H NMR (500 MHz, CDCl3) δ 7.35-7.22 
(m, 3H), 7.04 (d, J = 8.7 Hz, 2H), 6.88 (d, J = 8.7 Hz, 2H), 4.72-4.60 (m, 2H), 4.12-4.09 (m, 2H), 2.46 (s, 







4-carboxamide (8a). A solution of compound 7a (643 mg, 1.4 mmol) in CH2Cl2 (10 mL) was treated 
with oxalyl chloride  (200 µL, 2.36 mmol), followed by 10 µL DMF. The resulting mixture was stirred 
for 90 min at r.t., then concentrated in vacuo. The residue was dried under vacuum as a yellowish 
foam which was used without further purification. Subsequently, to a mixture of piperidin-1-amine 
hydrochloride (0.3 mmol) and pyridine (100 µL) in CH2Cl2 (1 mL) was added a portion of crude 
intermediate (2-(2,4-dichlorophenyl)-5-methyl-1-(4-(3,3,3-trifluoropropoxy)phenyl)-1H-imidazole-4-
carbonyl chloride (96 mg, 0.2 mmol)) in CH2Cl2 (1 mL) and the resulting mixture stirred at r.t. for 2 h 
30 min. The reaction mixture was washed with saturated aqueous NaHCO3 (2 mL) and, after phase 
separation, filtered through a phase separator. The solvents were evaporated and the residue 
purified by preparative HPLC eluting on a reverse-phase column (5-100% acetonitrile in aqueous 
NH4OAc (0.1 M)) to give the title compound (45 mg, 41%) as a colorless solid. 1H NMR (500 MHz, 
CDCl3) δ 7.90 (s, 1H), 7.35 (d, J = 1.9 Hz, 3H), 7.29 (d, J = 8.3 Hz, 1H), 7.23 (dd, J = 1.9, 8.3 Hz, 1H), 7.03 
(d, J = 8.9 Hz, 2H), 6.87 (d, J = 8.9 Hz, 2H), 4.19 (t, J = 6.6 Hz, 2H), 2.94-2.81 (m, 4H), 2.69-2.60 (m, 2H), 
2.47 (s, 3H), 1.82-1.73 (m, 4H), 1.49-1.41 (m, 2H); HRMS Calcd for [C25H25Cl2F3N4O2+H]: 541.1385. 
Found: 541.1366. HPLC: 100%.   
2-(2,4-Dichlorophenyl)-1-(4-(3-fluoropropoxy)phenyl)-5-methyl-N-(piperidin-1-yl)-1H-imidazole-4-
carboxamide (8b). A solution of compound 7b (732 mg, 1.55 mmol) in CH2Cl2 (20 mL) was treated 
with oxalyl chloride (200 µL, 2.36 mmol), followed by DMF (10 µL). The resulting mixture was stirred 
for 90 min at r.t., then concentrated in vacuo.  The residue was dried under vacuum as a yellowish 
foam which was used without further purification. Subsequently, to a mixture of piperidin-1-amine 
hydrochloride (0.39 mmol) and pyridine (100 µL) in CH2Cl2 (2 mL) was added a portion of crude 2-
(2,4-dichlorophenyl)-1-(4-(3-fluoropropoxy)phenyl)-5-methyl-1H-imidazole-4-carbonyl chloride (115 
mg, 0.26 mmol) in CH2Cl2 (2 mL) and the resulting mixture was stirred at r.t. for 2 h. The reaction 
mixture was washed with saturated aqueous NaHCO3 (2 mL) and, after phase separation, filtered 






HPLC eluting on a reverse-phase column (5-100% CH3CN in aqueous NH4OAc (0.1 M)) to give the title 
compound (74 mg, 56%) as a colorless solid. 1H NMR (500 MHz, CDCl3) δ 7.90 (s, 1H), 7.35 (d, J = 2.0 
Hz, 1H), 7.28 (d, J = 8.2 Hz, 1H), 7.23 (dd, J = 2.0, 8.2 Hz, 1H), 7.01 (d, J = 8.9 Hz, 2H), 6.86 (d, J = 8.9 
Hz, 2H), 4.66 (dt, J = 5.7, 47.0 Hz, 2H), 4.09 (t, J = 6.1 Hz, 2H), 2.95-2.82 (m, 4H), 2.47 (s, 3H), 2.25-
2.13 (m, 2H), 1.81-1.73 (m, 4H), 1.49-1.40 (m, 2H); HRMS Calcd for [C25H27Cl2FN4O2+H]: 505.1573. 
Found: 505.1572. HPLC: 100%.   
1-(4-(Benzyloxy)phenyl)-2-(2,4-dichlorophenyl)-5-methyl-N-(piperidin-1-yl)-1H-imidazole-4-
carboxamide (9). To a solution of compound 4 (3.38 g, 7.5 mmol) in CH2Cl2 (60 mL) were added 3 
drops of DMF, followed by oxalyl chloride (1.3 mL, 14.9 mmol). The mixture was refluxed for 2 hours, 
then cooled to r.t. and evaporated to dryness. The residue was dissolved in CH2Cl2 (50 mL) and 
cooled to 0 °C. Triethylamine (2.1 mL, 14.9 mmol) was added, followed by piperidin-1-amine (0.9 mL, 
8.2 mmol), and the mixture stirred at r.t. for 2 hours. Water (300 mL) was added and the mixture 
extracted with CH2Cl2 (3 x 100 mL).  The organic extracts were dried (Na2SO4), filtered, and 
concentrated in vacuo. Flash chromatography (silica, 66-100% EtOAc in hexane) afforded the title 
compound (2.94 g, 74%) as a white solid. 1H NMR (400 MHz, CDCl3) δ 7.71 (d, J = 8.3 Hz, 1H), 7.42-
7.32 (m, 7H), 7.29 (dd, J = 1.9, 8.3 Hz, 1H), 7.24 (d, J = 9.0 Hz, 2H), 6.98 (d, J = 9.0 Hz, 2H), 5.04 (s, 2H), 
4.05-3.52 (m, 4H), 2.54 (s, 3H), 2.29-2.16 (m, 4H), 1.78-1.57 (m, 2H); HRMS Calcd for 
[C29H28Cl2N4O2+H]: 535.1667. Found: 535.1667. HPLC: 96.9%. 
2-(2,4-Dichlorophenyl)-1-(4-hydroxyphenyl)-5-methyl- N-(piperidin-1-yl)-1H-imidazole-4-carboxamide 
(10). A solution of compound 9 (2.78 g, 5.2 mmol) in CH2Cl2 (80 mL) was cooled to 0 °C then treated 
dropwise with boron tribromide (1 M in CH2Cl2, 10.4 mL, 10.4 mmol).  The reaction mixture was 
stirred at r.t. for 1 hour then treated with water (200 mL).  The mixture was extracted with EtOAc (3 
x 200 mL). The combined organic phases were dried (Na2SO4), filtered, and concentrated in vacuo. 
Flash chromatography (silica, 75-100% EtOAc in hexane) afforded the title compound (1.34 g, 58%) 






7.23 (d, J = 8.3 Hz, 1H), 7.18 (dd, J = 1.9, 8.3 Hz, 1H), 6.92-6.85 (m, 4H), 2.90-2.67 (m, 4H), 2.43 (s, 3H), 
1.69-1.56 (m, 4H), 1.43-1.30 (m, 2H). 
2-(2,4-Dichlorophenyl)-5-methyl-N-(piperidin-1-yl)-1-( 4-(4,4,4-trifluorobutoxy)-phenyl)-1H-imidazole-
4-carboxamide (11a). A suspension of compound 10 (351 mg, 0.79 mmol) and K2CO3 (218 mg, 1.58 
mmol) in acetone (50 mL) was treated dropwise with 1-iodo-4,4,4-trifluorobutane (376 mg, 1.58 
mmol). The reaction mixture was refluxed overnight then cooled, filtered, and concentrated in vacuo. 
Flash chromatography (silica, hexane : EtOAc 1:2) afforded the title compound (200 mg, 46%) as a 
white solid. 1H NMR (400 MHz, CDCl3) δ 7.91 (br s, 1H), 7.32 (d, J = 1.9 Hz, 1H), 7.27 (d, J = 8.3 Hz, 1H), 
7.21 (dd, J = 2.0, 8.3 Hz, 1H), 7.00 (d, J = 8.9 Hz, 2H), 6.83 (d, J = 8.9 Hz, 2H), 3.99 (t, J = 6.0 Hz, 2H), 
3.13-2.67 (m, 4H), 2.45 (s, 3H), 2.38-2.23 (m, 2H), 2.10-2.00 (m, 2H), 1.84-1.71 (m, 4H), 1.50-1.38 (m, 
2H); MS m/z 578 (M+Na); HRMS Calcd for [C26H27Cl2F3N4O2+H]: 555.1541. Found: 555.1504. HPLC: 
100%. 
4-(2-(2,4-Dichlorophenyl)-5-methyl-4-(piperidin-1-ylcarbamoyl)-1H-imidazol-1-yl)phenyl propane-1-
sulfonate (11b). A solution of compound 10 (320 mg, 0.72 mmol) in CH2Cl2 (10 mL) was cooled to 
0 °C. Et3N (100 µL, 0.72 mmol) was added followed by 1-propanesulfonyl chloride (81 µL, 0.72 mmol) 
and the reaction mixture was stirred at room temperature overnight. Water was added, the mixture 
extracted with CH2Cl2 (3 x 20 mL), dried (Na2SO4), filtered and concentrated. Flash chromatography 
(silica, hexane : EtOAc 1 : 2) afforded the title compound (220 mg, 56%) as a white solid. 1H NMR 
(400 MHz, CDCl3) δ 7.82 (br s, 1H), 7.29-7.15 (m, 5H), 7.10-7.03 (m, 2H), 3.23-3.14 (m, 2H), 2.90-2.70 
(m, 4H), 2.42 (s, 3H), 2.01-1.88 (m, 2H), 1.75-1.65 (m, 4H), 1.41-1.31 (m, 2H), 1.06 (t, J = 7.5 Hz, 3H);  
13C NMR (126 MHz, CDCl3) δ 160.8, 149.0, 142.3, 136.8, 135.3, 135.0, 133.8, 133.4, 130.6, 129.9, 
129.1, 128.2, 127.4, 123.1, 57.2, 52.9, 25.4, 23.3, 17.5, 13.0, 10.9; HRMS Calcd for [C25H28Cl2N4O4S+H]: 
551.1287. Found: 551.1313. HPLC: 100%. 
4-(2-(2,4-Dichlorophenyl)-5-methyl-4-(piperidin-1-ylcarbamoyl)-1H-imidazol-1-yl)phenyl 3-






mL) was treated with Et3N (45 mg, 0.45 mmol) at r.t.. The resulting mixture was cooled to -78 °C and 
3-fluoropropane-1-sulfonyl chloride (72 mg, 0.45 mmol) in dry CH2Cl2 (0.5 mL) was added dropwise. 
After 1 h 40 min at -78 °C was added 3-fluoropropane-1-sulfonyl chloride (72 mg, 0.45 mmol) and 
after a total of 4 h 40 min was added Et3N (55 mg, 0.54 mmol). The reaction was allowed to reach r.t. 
overnight. It was then cooled to 0 °C and Et3N (55 mg, 0.54 mmol) was added, followed by 3-
fluoropropane-1-sulfonyl chloride (72 mg, 0.45 mmol) after a total of 19 h. After 1 h the reaction 
mixture was washed with water and concentrated in vacuo. The product was purified by HPLC (30-
100% CH3CN in aqueous NH4OAc (0.1 M) over 40 min) to yield the title compound as a white solid 
(160 mg, 63%). 1H NMR (400 MHz, CDCl3) δ 7.88 (br s, 1H), 7.39-7.17 (m, 5H), 7.11 (d, J = 8.8 Hz, 2H), 
4.58 (dt, J = 5.5, 46.8 Hz, 2H), 3.53-3.33 (m, 2H), 2.92-2.71 (m, 4H), 2.45 (s, 3H), 2.40-2.23 (m, 2H), 
1.83-1.62 (m, 4H), 1.46-1.33 (m, 2H). HRMS Calcd for [C25H27Cl2FN4O4S+H]: 569.119. Found: 569.1192. 
HPLC: 100%. 
4-(2-(2,4-Dichlorophenyl)-5-methyl-4-(piperidin-1-ylcarbamoyl)-1H-imidazol-1-yl)phenyl 3,3,3-
trifluoropropane-1-sulfonate methanesulfonic acid salt (11d). A solution of compound 10 (0.89 g, 
2.00 mmol) in CH2Cl2 (20 mL) was cooled to 0 °C then treated with Et3N (0.35 mL, 2.4 mmol), 
followed by 3,3,3-trifluoropropanesulfonyl chloride (prepared by an analogous method to that 
described in WO00/010968 for the butyl homologue) (0.35 mL, 2.40 mmol). The reaction mixture 
was stirred at r.t. overnight. TLC showed remaining starting material and so another portion of Et3N 
and 3,3,3-trifluoropropanesulfonyl chloride was added and the reaction mixture stirred for 
additional 2 h. Water was added and the product was extracted with CH2Cl2, dried (Na2SO4), filtered, 
and concentrated in vacuo. Flash chromatography (33-100% EtOAc in hexane) followed by 
recrystallisation (hexane : EtOAc) afforded the title compound (700 mg, 59%) as a colorless solid. 1H 
NMR (400 MHz, CDCl3) δ 7.92 (s, 1H), 7.34-7.24 (m, 5H), 7.20-7.13 (m, 2H), 3.54-3.48 (m, 2H), 3.00-
2.82 (m, 4H), 2.84-2.73 (m, 2H), 2.50 (s, 3 H), 1.83-1.72 (m, 4 H), 1.49-1.39 (m, 2H); HRMS Calcd for 







sulfonate (11e). A solution of compound 10 (320 mg, 0.72 mmol) in CH2Cl2 (10 mL) was cooled to 0 °C. 
Et3N (100 µL, 0.72 mmol) was added followed by 1-butanesulfonyl chloride (93 µL, 0.72 mmol) and 
the reaction mixture was stirred at r.t. overnight. Water was added and the mixture extracted with 
CH2Cl2 (3 x 20 mL), dried (Na2SO4), filtered, and concentrated in vacuo. Flash chromatography (silica, 
hexane : EtOAc 1:2) afforded  the title compound (230 mg, 57%)  as a white solid. 1H NMR (400 MHz, 
CDCl3) δ 7.82 (br s, 1H), 7.27-7.16 (m, 5H),  7.09-7.04 (m, 2H), 3.23-3.17 (m, 2H), 2.92-2.68 (m, 4H), 
2.42 (s, 3H), 1.93-1.84 (m, 2H), 1.74-1.66 (m, 4H), 1.50-1.40 (m, 2H), 1.40-1.33 (m, 2H), 0.91 (t, J = 7.4 
Hz, 3H) ; MS m/z 588 (M+Na); HRMS Calcd for [C26H30Cl2N4O4S+H]: 565.1443. Found: 565.1450. HPLC: 
100%. 
4-(2-(2,4-Dichlorophenyl)-5-methyl-4-(piperidin-1-ylcarbamoyl)-1H-imidazol-1-yl)-phenyl 4,4,4-
trifluorobutane-1-sulfonate (11f). A solution of compound 10 (0.49 g, 1.20 mmol) in CH2Cl2 (20 mL) 
was cooled to 0 °C and treated with Et3N (0.67 mL, 4.8 mmol), followed by 4,4,4-trifluorobutane-1-
sulfonyl chloride (prepared as described in WO00/010968) (0.38 g, 1.80 mmol). The reaction mixture 
was stirred at r.t. for 3 h. TLC showed remaining starting material so another portion of Et3N and 
4,4,4-trifluorobutane-1-sulfonyl chloride was added and the reaction mixture stirred overnight. 
Water was added, then the mixture was extracted with CH2Cl2.  The organic extracts were dried 
(Na2SO4), filtered, and concentrated in vacuo. Flash chromatography (33-100% EtOAc in hexane) 
followed by recrystallisation (hexane : EtOAc) afforded the title compound (0.45 g, 61%) as a 
colorless solid. 1H NMR (400 MHz, CDCl3) δ 7.92 (br s, 1H), 7.34-7.22 (m, 5H), 7.15 (d, J = 8.7 Hz, 2H), 
3.38 (t, J = 7.3 Hz, 2H), 3.12-2.74 (m, 4H), 2.49 (s, 3H), 2.43-2.32 (m, 2H), 2.32-2.22 (m, 2H), 1.82-1.74 
(m, 4H), 1.50-1.40 (m, 2H); HRMS Calcd for [C26H27Cl2F3N4O4S+H]: 619.1160. Found: 619.1148. HPLC: 
96.9%.   
4-(2-(2,4-Dichlorophenyl)-5-methyl-4-(piperidin-1-ylcarbamoyl)-1H-imidazol-1-yl)phenyl 3-






cooled to 0 °C then treated with Et3N (20 µL, 0.13 mmol). The resulting mixture was cooled to -78 °C, 
then 3-methylbutane-1-sulfonyl chloride (23 mg, 0.13 mmol) carefully added. The reaction was 
stirred at -78 °C for 1.5 h. Water was added, then the mixture was extracted with CH2Cl2. The organic 
extracts were dried, filtered, and concentrated in vacuo to give a residue which was purified by HPLC 
to deliver the title compound (46 mg, 71%) as a solid. 1H NMR (400 MHz, CDCl3) δ 7.86 (s, 1H), 7.31-
7.20 (m, 5H), 7.14-7.08 (m, 2H), 3.27-3.20 (m, 2H), 2.89-2.76 (m, 4H), 2.46 (s, 3H), 1.87-1.79 (m, 2H), 
1.78-1.68 (m, 5H), 1.44-1.36 (m, 2H), 0.93 (d, J = 6.5 Hz, 6H); HRMS Calcd for [C26H27Cl2F3N4O4S+H]: 
579.1600. Found: 579.1584. HPLC: 100%. 
4-(2-(2,4-Dichlorophenyl)-5-methyl-4-(piperidin-1-ylcarbamoyl)-1H-imidazol-1-yl)phenyl 3,3-
dimethylbutane-1-sulfonate (11h). A solution of compound 10 (50 mg, 0.11 mmol) in CH2Cl2 (3 mL) 
was cooled to 0 oC and treated with Et3N (20 µL, 0.13 mmol). The resulting mixture was cooled to -
78 °C and 3,3-dimethylbutane-1-sulfonyl chloride (25 mg, 0.13 mmol) was carefully added. The 
reaction was stirred at -78 °C for 2 h. Water was added, then the mixture extracted with CH2Cl2. The 
organic extracts were dried, filtered, and concentrated in vacuo to give a residue which was purified 
by preparative HPLC to deliver the title compound (46 mg, 69%) as a solid. 1H NMR (400 MHz, CDCl3) 
δ 7.85 (s, 1H), 7.32-7.17 (m, 5H), 7.11-7.09 (d, J = 8.7 Hz, 2H), 3.26-3.15 (m, 2H), 2.92-2.74 (m, 4H), 
2.46 (s, 3H), 1.87-1.78 (m, 2H), 1.77-1.68 (m, 5H), 1.46-1.34 (m, 2H), 0.92 (s, 9H); HRMS Calcd for 
[C28H34Cl2N4O4S+H]: 593.1756. Found: 593.1755. HPLC: 100%. 
racemic 1-(4-(Benzyloxy)phenyl)-2-(2,4-dichlorophenyl)-N-(3-hydroxypiperidin-1-yl)-5-methyl-1H-
imidazole-4-carboxamide (12a). Compound 4 (752 mg, 1.66 mmol) and SOCl2 (33.2 mmol) were 
mixed and the resulting mixture was refluxed for 1.5 h. Excess SOCl2 was removed under reduced 
pressure and the residue was azeotroped with toluene. 3-Hydroxy-1-aminopiperidine (6.64 mmol) 
was mixed with CH2Cl2 (15 mL) and THF (2 mL) and Et3N (13.28 mmol). The mixture was cooled to -
20 °C under a nitrogen atmosphere. A THF (5 mL) mixture of the acid chloride from above was added 






overnight. Aqueous NaOH (1 M, 5 mL) and EtOH (15 mL) were added and the mixture was heated to 
40 °C for 15 minutes. The reaction mixture was then diluted to 50 mL with CH2Cl2 and washed with 
water (2 x 20 mL) and brine (20 mL). The organic layer was dried (MgSO4), filtered, and concentrated 
in vacuo. The residue was purified by flash chromatography (8% EtOH in CH2Cl2) and then by reverse 
phase HPLC (Kromasil C8, 60% CH3CN in aqueous NH4OAc (0.1 M)). The product fraction was 
concentrated in vacuo and then dissolved in CH2Cl2 and washed with water several times and then 
brine. The organic layer was dried (MgSO4), filtered and concentrated in vacuo to give the title 
compound (160 mg, 17% yield). 1H NMR (400 MHz, CDCl3) δ 7.99 (s, 1H), 7.33-7.19 (m, 6H), 7.18-7.07 
(m, 2H), 6.90 (d, J = 8.8 Hz, 2H), 6.81 (d, J = 8.8 Hz, 2H), 5.18 (s, 1H), 4.92 (s, 2H), 3.94-3.85 (m, 1H), 
3.06-2.97 (m, 1H), 2.85-2.66 (m, 3H), 2.34 (s, 3H), 1.87-1.77 (m, 1H), 1.63-1.50 (m, 2H), 1.46-1.34 (m, 
1H); MS m/z 551 (M+H). 
racemic 1-(4-(Benzyloxy)phenyl)-2-(2,4-dichlorophenyl)-N-(3-hydroxycyclohexyl)-5-methyl-1H-
imidazole-4-carboxamide (12b). A suspension of compound 4 (2.00 g, 4.41 mmol) in CH2Cl2 (50 mL) 
was treated with oxalyl chloride (2.80 g, 22.1 mmol) at r.t., followed by one drop of DMF. The 
mixture was stirred at r.t. for 15 min after which the solvent was removed in vacuo. The acid 
chloride was suspended in CH2Cl2 (10 mL) and added dropwise to a mixture of 3-aminocyclohexanol 
(610 mg, 5.29 mmol), aqueous NaOH (1 M, 30 mL) and CH2Cl2 (30 mL). After stirring at r.t. for 2 h, 
adding more 3-aminocyclohexanol after 1 h 25 min (67 mg, 0.58 mmol) and 1 h 45 min (58 mg, 0.50 
mmol), water and CH2Cl2 were added and the phases separated. The organic phase was washed with 
aqueous HCl (10%) and brine, then dried (MgSO4), filtered, and concentrated in vacuo to yield the 
crude title compound (2.79 g). 1H NMR (400 MHz, CDCl3) δ 7.40-7.16 (m, 8H), 7.03-6.88 (m, 4H), 5.01 
(s, 2H), 4.44-4.32 (m, 0.5H), 4.18-4.11 (m, 0.5 H), 4.06-3.94 (m, 0.5 H), 3.76-3.66 (m, 0.5 H), 2.46 (s, 
3H), 2.03-1.10 (m, 8H); MS m/z 550 (M+H). 
racemic 1-(4-(Benzyloxy)phenyl)-2-(2,4-dichlorophenyl)-N-((trans)-2-hydroxycyclohexyl)-5-methyl-1H-






was treated with oxalyl chloride (2.80 g, 22.1 mmol) at r.t., followed by one drop of DMF. The 
mixture was stirred at r.t. for 35 min after which the mixture was concentrated in vacuo. The acid 
chloride was suspended in CH2Cl2 (10 mL) and added dropwise to a mixture of trans-2-
aminocyclohexanol hydrochloride (802 mg, 5.29 mmol), aqueous NaOH (1 M, 30 mL) and CH2Cl2 (30 
mL). After stirring at r.t. for 2 h, water/CH2Cl2 were added and the phases were separated. The 
organic phase was washed with aqueous HCl (10%) and brine, dried (MgSO4), filtered, and 
concentrated in vacuo to yield the crude title compound (2.69 g). 1H NMR (400 MHz, CDCl3) δ 7.94 (s, 
1H), 7.37-7.25 (m, 6H), 7.23-7.17 (m, 2H), 6.97 (d, J = 8.6 Hz, 2H), 6.89 (d, J = 8.6 Hz, 2H), 5.23 (s, 1H), 
4.98 (s, 2H), 3.80-3.62 (m, 1H), 3.59-3.42 (m, 1H), 2.42 (s, 3H), 2.14-1.93 (m, 2H), 1.75-1.59 (m, 2H), 
1.39-1.14 (m, 4H); MS m/z 550 (M+H). 
 racemic 1-(4-(Benzyloxy)phenyl)-2-(2,4-dichlorophenyl)-N-((cis)-2-hydroxycyclohexyl)-5-methyl-1H-
imidazole-4-carboxamide (12d). A suspension of compound 4 (2.00 g, 4.41 mmol) in CH2Cl2 (100 mL) 
was treated with oxalyl chloride (2.85 g, 22.5 mmol) at r.t., followed by one drop of DMF. The 
mixture was stirred at r.t. for 20 min after which the solvents were evaporated under reduced 
pressure. The acid chloride was suspended in CH2Cl2 (10 mL) and added dropwise to a mixture of cis-
2-aminocyclohexanol hydrochloride (816 mg, 5.38 mmol), aqueous  NaOH (1M, 30 mL) and CH2Cl2 
(30 mL). After stirring at r.t. for 2 h water was added and the phases were separated. The organic 
phase was washed with aqueous HCl (0.1 M) and brine, dried (MgSO4), filtered, and concentrated in 
vacuo to yield the title compound (2.40 g, 99%). 1HNMR (400 MHz, CDCl3) δ 7.45 (d, J = 7.8 Hz, 1H), 
7.41-7.16 (m, 8H), 6.98 (d, J = 8.8 Hz, 2H), 6.90 (d, J = 8.8 Hz, 2H), 5.01 (s, 2H), 4.16-4.08 (m, 1H), 
4.03-3.96 (m, 1H), 2.89 (br s, 1H), 2.43 (s, 3H), 1.83-1.54 (m, 6H), 1.47-1.32 (m, 2H); MS m/z 550 
(M+H). 
1-(4-(Benzyloxy)phenyl)-2-(2,4-dichlorophenyl)-5-methyl-N-(4-(trifluoromethoxy)phenyl)-1H-
imidazole-4-carboxamide (12e). A suspension of compound 4 (1.00 g, 2.21 mmol) in CH2Cl2 (15 mL) 






mixture was stirred at r.t. for 15 min after which the solvents were evaporated under reduced 
pressure. A mixture of 4-trifluoromethoxy-phenylamine (469 mg, 2.65 mmol), Et3N (313 mg, 3.09 
mmol) and CH2Cl2 (5 mL) was added dropwise to the acid chloride suspended in CH2Cl2 (15 mL). The 
reaction mixture was stirred at r.t. for 2 h and 10 min. CH2Cl2 was added and the resulting mixture 
was washed with aqueous HCl (10%) and brine, dried (MgSO4), filtered, and evaporated to yield the 
crude title compound (1.42 g). 1H NMR (400 MHz, CDCl3) δ 9.37 (br s, 1H), 7.76-7.74 (m, 2H), 7.39-
7.16 (m, 10H), 7.05-6.93 (m, 4H), 5.03 (s, 2H), 2.50 (s, 3H); MS m/z 612 (M+H). 
1-(4-(Benzyloxy)phenyl)-2-(2,4-dichlorophenyl)-N-(6-fluoropyridin-3-yl)-5-methyl-1H-imidazole-4-
carboxamide (12f). A suspension of compound 4 (1.00 g, 2.21 mmol) in CH2Cl2 (15 mL) was treated 
with oxalyl chloride (1.40 g, 11.0 mmol) at r.t., followed by one drop of DMF. The mixture was stirred 
at r.t. for 5 min after which the solvents were removed in vacuo. The acid chloride was suspended in 
CH2Cl2 (8 mL) then treated dropwise with a mixture of 6-fluoro-pyridin-3-ylamine (297 mg, 2.65 
mmol), Et3N (313 mg, 3.09 mmol) and CH2Cl2 (7 mL). Stirring was continued at r.t. for 75 min, after 
which CH2Cl2 was added and the resulting mixture washed with aqueous HCl (10%) and brine.  The 
organic extracts were dried (MgSO4), filtered, and concentrated in vacuo to yield the crude title 
compound (1.19 g). 1H NMR (400 MHz, CDCl3) δ 9.24 (s, 1H), 8.39-8.33 (m, 2H), 7.39-6.89 (m, 3H), 
5.02 (s, 2H), 2.49 (s, 3H); MS m/z 547 (M+H). 
1-(4-(Benzyloxy)phenyl)-2-(2,4-dichlorophenyl)-5-methyl-N-(6-(trifluoromethyl)pyridin-3-yl)-1H-
imidazole-4-carboxamide (12g). A suspension of compound 4 (1.00 g, 2.21 mmol) in CH2Cl2 (15 mL) 
was treated with oxalyl chloride (1.40 g, 11.03 mmol) at r.t., followed by one drop of DMF. The 
mixture was stirred at r.t. for 5 min after which the solvents were removed in vacuo. The acid 
chloride was suspended in CH2Cl2 (8 mL) then treated dropwise with a solution of 6-trifluoromethyl-
pyridin-3-ylamine (407 mg, 2.51 mmol) and Et3N (360 mg, 3.56 mmol) in CH2Cl2 (7 mL). The reaction 
mixture was stirred at r.t. for 1.5 h then diluted with CH2Cl2 and washed with aqueous HCl (10% w/w) 






crude title product (1.32 g). 1H NMR (400 MHz, CDCl3) δ 9.50 (s, 1H), 8.82 (d, J = 2.0 Hz, 1H), 8.55 (dd, 
J = 2.0, 8.6 Hz, 1H), 7.65 (d, J = 8.6 Hz, 1H), 7.40-7.21 (m, 7H), 7.06-6.89 (m, 5H), 5.03 (s, 2H), 2.50 (s, 
3H); MS m/z 597 (M+H). 
1-(4-(Benzyloxy)phenyl)-2-(2,4-dichlorophenyl)-5-methyl-N-(5-methylpyridin-2-yl)-1H-imidazole-4-
carboxamide (12h). A suspension of compound 4 (3.00 g, 6.62 mmol) in CH2Cl2 (70 mL) was treated 
with oxalyl chloride (4.20 g, 33.1 mmol) at r.t., followed by one drop of DMF. The mixture was stirred 
at r.t. for 5 min after which the solvents were evaporated under reduced pressure. A mixture of 5-
methyl-pyridin-2-ylamine (816 mg, 7.54 mmol), Et3N (890 mg, 8.80 mmol) and CH2Cl2 (20 mL) was 
added dropwise to the acid chloride suspended in CH2Cl2 (20 mL). The reaction mixture was stirred 
at r.t. for 30 min. CH2Cl2 was added and the resulting mixture was washed with aqueous HCl (10%) 
and brine, dried (MgSO4), filtered and evaporated. The residue was purified by flash chromatography 
(20-30% EtOAc in heptane) to yield the title compound as a white solid (980 mg, 27%). 1H NMR (400 
MHz, Pyridine-d5) δ 10.11 (s, 1H), 8.52 (s, 1H), 8.04 (s, 1H), 7.40-6.88 (m, 3H), 4.80 (s, 2H), 2.39 (s, 
3H), 1.88 (s, 3H); MS m/z 543 (M+H). 
racemic 2-(2,4-Dichlorophenyl)-1-(4-hydroxyphenyl)-N-(3-hydroxypiperidin-1-yl)-5-methyl-1H-
imidazole-4-carboxamide (13a). A mixture of racemic 1-(4-(benzyloxy)phenyl)-2-(2,4-
dichlorophenyl)-N-(3-hydroxypiperidin-1-yl)-5-methyl-1H-imidazole-4-carboxamide (160 mg, 0.29 
mmol) and dimethyl sulfide (1.45 mmol) in CH2Cl2 under nitrogen atmosphere were treated 
dropwise with BF3·OEt2 (1.45 mmol). The resulting mixture was stirred for 4 days at ambient 
temperature while continuously adding small volumes of CH2Cl2 and 1,4-dioxane. EtOH was added 
and the mixture was stirred for 30 mins and then concentrated in vacuo. The residue was dissolved 
in EtOAc (50 mL) and washed with water (2 x 20 mL) and brine (20 mL). The organic layer was dried 
(Na2SO4), filtered and concentrated in vacuo to give the title compound (127 mg, 95%) as a white 







4-carboxamide (13b). A suspension of crude 1-(4-(benzyloxy)phenyl)-2-(2,4-dichlorophenyl)-N-(3-
hydroxycyclohexyl)-5-methyl-1H-imidazole-4-carboxamide (2.79 g, 5.07 mmol) in CH2Cl2 (50 mL) and 
dimethyl sulfide (3.15 g, 50.7 mmol) was treated with boron trifluoride diethyl etherate (5.77 g, 50.7 
mmol). The reaction mixture was stirred at r.t. for 36 h (dark), adding more dimethyl sulfide (3.15 g, 
50.7 mmol) and boron trifluoride (5.77 g, 50.7 mmol) after 16 h. The solvent was evaporated and the 
residue dissolved in EtOAc/water. The phases were separated and the organic phase dried (MgSO4), 
filtered, and concentrated in vacuo to yield the crude title compound (2.54 g). MS m/z 460 (M+H). 
 racemic 2-(2,4-Dichlorophenyl)-N-((trans)-2-hydroxycyclohexyl)-1-(4-hydroxyphenyl)-5-methyl-1H-
imidazole-4-carboxamide (13c). Crude racemic 1-(4-(benzyloxy)phenyl)-2-(2,4-dichlorophenyl)-N-
((trans)-2-hydroxycyclohexyl)-5-methyl-1H-imidazole-4-carboxamide (2.68 g, 4.87 mmol) was 
suspended in HBr (33% in AcOH, 60 mL). The mixture was stirred at r.t., in the dark, for 1 h 20 min. 
EtOH was added and the mixture concentrated in vacuo. The residue was dissolved in MeOH and 
neutralized with NaHCO3 (1 M, aq). One spoon of K2CO3 was added and the mixture was stirred at r.t. 
for 1 h. The solvent was evaporated and the resulting mixture extracted with toluene followed by 
THF. The combined organic phases were washed with aqueous HCl (10%) and brine, dried (MgSO4), 
filtered and evaporated. The product was purified by HPLC (30-100% CH3CN in aqueous NH4OAc (0.1 
M) over 40 min) to yield the title compound as a white solid (829 mg, yield over 2 steps 41%). 1H 
NMR (400 MHz, CDCl3) δ 7.36-7.18 (m, 4H), 6.86-6.66 (m, 4H), 5.28 (s, 1H), 4.60 (br s, 1H), 3.85-3.74 
(m, 1H), 3.52-3.41 (m, 1H), 2.37 (s, 3H), 2.13-1.97 (m, 2H), 1.78-1.67 (m, 2H), 1.44-1.15 (m, 4H); MS 
m/z 460 (M+H). 
racemic 2-(2,4-Dichlorophenyl)-N-((cis)-2-hydroxycyclohexyl)-1-(4-hydroxyphenyl)-5-methyl-1H-
imidazole-4-carboxamide (13d). A suspension of racemic 1-(4-(benzyloxy)phenyl)-2-(2,4-
dichlorophenyl)-N-((cis)-2-hydroxycyclohexyl)-5-methyl-1H-imidazole-4-carboxamide (2.38 g, 4.33 






EtOH was added and the solvents were evaporated under reduced pressure. The residue was 
dissolved in MeOH and neutralized with aqueous NaHCO3 (1 M). The solvent was evaporated and the 
mixture dissolved in water/CH2Cl2. The phases were separated and the organic phase was washed 
with brine, dried (MgSO4), filtered and evaporated. The residue was dissolved in MeOH and one 
spoon of K2CO3 was added, and the resulting mixture was stirred at r.t. for 1 h before the solvent 
was evaporated. The residue was resuspended in CH2Cl2 and washed with aqueous HCl (10%), and 
the solvents were evaporated. The residue was dissolved in THF, dried (MgSO4), filtered and 
evaporated to yield the crude title compound (2.10 g). 1H NMR (400 MHz, THF-d8) δ 8.65 (d, J = 7.3 
Hz, 1H), 7.66 (d, J = 8.3 Hz, 1H), 7.55 (d, J = 1.7 Hz, 1H), 7.25 (dd, J = 1.7, 8.3, 1H), 7.18 (d, J = 8.6 Hz, 
2H), 6.79 (d, J = 8.6 Hz, 2H), 3.99-3.91 (m, 1H), 3.91-3.82 (m, 1H), 3.64-3.55 (m, 1H), 2.47 (s, 3H), 
1.86-1.63 (m, 5H), 1.58-1.44 (m, 1H), 1.38-1.28 (m, 2H); MS m/z 460 (M+H). 
2-(2,4-Dichlorophenyl)-1-(4-hydroxyphenyl)-5-methyl-N-(4-(trifluoromethoxy)pheny1)-1H-imidazole-
4-carboxamide (13e). Crude 12e (1.35 g, 2.20 mmol) was suspended in HBr (33% in AcOH, 25 mL). 
The reaction mixture was stirred at r.t., in the dark, for 1 h. EtOH was added and the solvents were 
evaporated at reduced pressure. The residue was dissolved in MeOH and neutralized with aqueous 
NaHCO3 (1 M). The solvent was evaporated and the mixture dissolved in water/CH2Cl2. The phases 
were separated and the organic phase was washed with brine, dried (MgSO4), filtered, and 
concentrated in vacuo to yield the crude title compound (1.10 g). 1H NMR (400 MHz, CDCl3) δ 7.73-
7.71 (m, 2H), 7.39-7.16 (m, 5H), 6.94-6.76 (m, 4H), 2.45 (s, 3H); MS m/z 522 (M+H). 
2-(2,4-Dichlorophenyl)-N-(6-fluoropyridin-3-yl)-1-(4-hydroxyphenyl)-5-methyl-1H-imidazole-4-
carboxamide (13f). Compound 12f (1.15 g, 2.10 mmol) was suspended in HBr (33% in AcOH, 25 mL). 
The reaction mixture was stirred at r.t., in the dark, for 2 h 30 min. EtOH was added and the solvents 
were evaporated under reduced pressure. The residue was dissolved in MeOH and neutralized with 
aqueous NaHCO3 (1 M). The solvent was evaporated and the mixture dissolved in water/CH2Cl2. The 






concentrated in vacuo to give a residue which was purified by HPLC (30-60% CH3CN in NH4OAc (0.1 
M) over 40 min, then 100% CH3CN) to yield the title compound as a white solid (519 mg, yield over 2 
steps 53%). 1H NMR (400 MHz, CDCl3) δ 9.14 (s, 1H), 8.37-8.30 (m, 2H), 7.34 (s, 1H), 7.25-7.20 (m, 2H), 
6.96-6.90 (m, 3H), 6.79-6.77 (m, 2H), 2.48 (s, 3H); MS m/z 457 (M+H). 
2-(2,4-Dichlorophenyl)-1-(4-hydroxyphenyl)-5-methyl-N-(6-(trifluoromethyl)pyridin-3-yl)-1H-
imidazole-4-carboxamide (13g). A suspension of crude 12g (1.17 g, 1.96 mmol) in CH2Cl2 (6 mL) and 
dimethyl sulfide (1.22 g, 19.6 mmol) was treated with boron trifluoride (2.78 g, 19.6 mmol). The 
reaction mixture was stirred at r.t. for 31 h (dark). Water and CH2Cl2 were added and the phases 
separated. The organic phase was washed with water (x4) and concentrated in vacuo. The residue 
was dissolved in MeOH and stirred at r.t. for 20 h before water was added and the MeOH removed 
in vacuo. The resulting mixture was extracted with Et2O (x 2) and the combined organic phases were 
washed with brine, dried (MgSO4), filtered, and concentrated in vacuo to yield the crude title 
compound (776 mg). 1H NMR (400 MHz, CDCl3) δ 9.29 (s, 1H), 8.75 (d, J = 2.1 Hz,  1H), 8.54 (dd, J = 
2.1, 8.6 Hz, 1H), 7.64 (d, J = 8.6 Hz, 1H), 7.33 (d, J = 1.7 Hz, 1H), 7.27-7.19 (m, 2H), 6.96 (d, J = 8.7 Hz, 
2H), 6.78 (d, J = 8.7 Hz, 1H), 5.51 (br s, 1H), 2.48 (s, 3H); MS m/z 507 (M+H). 
2-(2,4-Dichlorophenyl)-1-(4-hydroxyphenyl)-5-methyl-N-(5-methylpyridin-2-yl)-1H-imidazole-4-
carboxamide (13h). Compound 12h (958 mg, 1.76 mmol) was suspended in HBr (33% in AcOH, 25 
mL). The reaction mixture was stirred at r.t., in the dark, for 1 h. EtOH was added and the solvents 
were evaporated under reduced pressure. The residue was dissolved in MeOH and neutralized with 
aqueous NaHCO3 (1 M). The solvent was evaporated and the mixture dissolved in water/CH2Cl2. The 
phases were separated and the organic phase was washed with brine, dried (MgSO4), filtered and 
evaporated to yield the title compound (772 mg, 97%). 1H NMR (400 MHz, Pyridine-d5) δ 10.12 (s, 
1H), 8.52 (s, 1H), 8.03 (s, 1H), 7.40-6.89 (m, 8H), 2.42 (s, 3H), 1.88 (s, 3H); MS m/z 453 (M+H). 
racemic 4-(2-(2,4-Dichlorophenyl)-4-(3-hydroxypiperidin-1-ylcarbamoyl)-5-methyl-1H-imidazol-1-






hydroxyphenyl)-N-(3-hydroxypiperidin-1-yl)-5-methyl-1H-imidazole-4-carboxamide (118 mg, 0.25 
mmol) in CH2Cl2 (1 mL), and THF (1 mL) was treated with Et3N (0.25 mmol) under a nitrogen 
atmosphere. The solution was cooled to -78 °C and a solution of 3,3,3-trifluoropropane-1-sulfonyl 
chloride in CH2Cl2 (1 mL) was added slowly while monitoring the progress with LC-MS. The reaction 
mixture was quenched by addition of EtOH. The reaction mixture was concentrated in vacuo and the 
residue was purified by reverse phase HPLC (Kromasil C8, 5-100% CH3CN in aqueous NH4OAc (0.1 M)) 
and by flash chromatography (8% EtOH in CH2Cl2). The product was freeze-dried to give the title 
compound (40 mg, 25%) as a white powder. 1H NMR (CD3OD) δ 7.52-7.44 (m, 2H), 7.44-7.34 (m, 5H), 
3.91-3.82 (m, 1H), 3.77-3.69 (m, 2H), 3.11 (dd, J = 3.0, 10.1 Hz, 1H), 2.95-2.80 (m, 3H), 2.74-2.58 (m, 
2H), 2.46 (s, 3H), 1.95-1.75 (m, 2H), 1.73-1.62 (m, 1H), 1.44-1.31 (m, 1H); MS m/z 621 (M+H); HRMS 
Calcd for [C25H25Cl2F3N4O5S+H]: 621.0954. Found: 621.0919. HPLC: 100%. 
racemic 4-(2-(2,4-Dichlorophenyl)-4-((trans)-3-hydroxycyclohexylcarbamoyl)-5-methyl-1H-imidazol-1-
yl)phenyl 3,3,3-trifluoropropane-1-sulfonate (14b). A suspension of crude 2-(2,4-dichlorophenyl)-N-
(3-hydroxycyclohexyl)-1-(4-hydroxyphenyl)-5-methyl-1H-imidazole-4-carboxamide (2.53 mg, 5.49 
mmol) in dry CH2Cl2 (20 mL) was treated with Et3N (667 mg, 6.59 mmol) at r.t.. The resulting mixture 
was cooled to -78 °C and 3,3,3-trifluoropropane-1-sulfonyl chloride (1.30 mg, 6.59 mmol) was added 
dropwise. After stirring at -78 °C for 2 h 45 min, the reaction mixture was allowed to reach r.t., upon 
which it was washed with water and evaporated. The stereoisomers were separated by HPLC (30-
100% CH3CN in aqueous NH4OAc (0.1 M)) to yield the trans-hydroxycyclohexyl product (205 mg, 7.5% 
over 3 steps) as a white solid. 1H NMR (400 MHz, CDCl3) δ 7.34-7.23 (m, 5H), 7.20-7.10 (m, 3H), 4.45-
4.33 (m, 1H), 4.17-4.10 (m, 1H), 3.55-3.47 (m, 2H), 2.87-2.73 (m, 2H), 2.49 (s, 3H), 2.05-1.51 (m, 8H), 
1.48-1.36 (m, 1H); HRMS Calcd for [C26H26Cl2F3N3O5S+H]: 620.1001. Found: 620.1028. HPLC: 100%. 
(-) 4-(2-(2,4-Dichlorophenyl)-4-((trans)-2-hydroxycyclohexylcarbamoyl)-5-methyl-1H-imidazol-1-
yl)phenyl 3,3,3-trifluoropropane-1-sulfonate (14c). A suspension of racemic 2-(2,4-dichlorophenyl)-N-






1.80 mmol) in dry CH2Cl2 (10 mL) was treated with Et3N (182 mg, 1.80 mmol) at r.t.. The resulting 
mixture was cooled to -78 °C and 3,3,3-trifluoropropane-1-sulfonyl chloride (354 mg, 1.80 mmol) dry 
CH2Cl2 (1 mL) was added dropwise. After stirring at -78 °C for 1 h the reaction mixture was washed 
with water and evaporated. The racemic product was purified by HPLC (30-100% CH3CN in aqueous 
NH4OAc (0.1 M) over 40 min) to yield the title compound as a white solid (710 mg, 64 %). 1H NMR 
(400 MHz, CDCl3) δ 7.29-7.06 (m, 8H), 3.82-3.62 (m, 2H), 3.50-3.41 (m, 2H), 3.41-3.31 (m, 1H), 2.81-
2.65 (m, 2H), 2.43 (s, 3H), 2.09-1.90 (m, 2H), 1.75-1.61 (m, 2H), 1.34-1.12 (m, 4H); HRMS Calcd for 
[C26H26Cl2F3N3O5S+H): 620.1001. Found: 620.1011. The (-)-enantiomer was separated from the 
racemate (535 mg, 0.86 mmol) by chiral chromatography (Chiralpak AD, heptane : iPrOH 85 : 15) to 
afford the title compound (220 mg) (95.6% ee) as white solid after freeze drying. [α]D = -2.9 (c 1.04, 
CH3CN); 1H NMR (400 MHz, CDCl3) δ 7.29-7.06 (m, 8H), 3.82-3.62 (m, 2H), 3.50-3.41 (m, 2H), 3.41-
3.31 (m, 1H), 2.81-2.65 (m, 2H), 2.43 (s, 3H), 2.09-1.90 (m, 2H), 1.75-1.61 (m, 2H), 1.34-1.12 (m, 4H); 
HRMS Calcd for [C26H26Cl2F3N3O5S+H]: 620.1001. Found: 620.0956. HPLC: 100%. Vibrational Circular 
Dichroism experiments were unable to unambiguously assign the absolute stereochemistry of the (+) 
and (-) enantiomers.  
(+) 4-[2-(2,4-Dichlorophenyl)-4-({[cis-2-hydroxycyclohexyl] amino}carbonyl)-5-methyl-1H-imidazol-1-
yl]phenyl-3,3,3-trifluoropropane-1-sulfonate (14d). A suspension of crude racemic 2-(2,4-
dichlorophenyl)-N-((cis)-2-hydroxycyclohexyl)-1-(4-hydroxyphenyl)-5-methyl-1H-imidazole-4-
carboxamide (2.00 g, 4.34 mmol) in dry CH2Cl2 (30 mL) was treated with Et3N (440 mg, 4.34 mmol) at 
r.t.. The resulting mixture was cooled to -78 °C and 3,3,3-trifluoropropane-1-sulfonyl chloride (854 
mg, 4.34 mmol) was added dropwise. After stirring at -78 °C for 2 h 20 min, more Et3N (2 x (73 mg, 
0.72 mmol)) and 3,3,3-trifluoropropane-1-sulfonyl chloride (2 x (110 mg, 0.56 mmol)) were added 
(2nd addition after 1 h). After 2 h the reaction mixture was washed with water and evaporated. The 
racemic product was purified by HPLC (30-100% CH3CN in aqueous NH4OAc (0.1 M) over 40 min) to 
yield the title compounds as a white solid (1.31 g, yield over 2 steps 51%). 1H NMR (400 MHz, CDCl3) 






1H), 3.49-3.38 (m, 2H), 2.80-2.65 (m, 2H), 2.42 (s, 3H), 1.78-1.47 (m, 6H), 1.44-1.28 (m, 2H); HRMS 
Calcd for [C26H26Cl2F3N3O5S+H]: 620.1001. Found: 620.1025. The (+)-enantiomer was separated from 
the racemate (1.00 g, 1.61 mmol) by Chiral chromatography (Chiralpak AD, heptane/iPrOH 80/20) to 
yield the title compound (444 mg) (> 99.9% ee) as a white powder after freeze drying. [α]D = +9.9 (c 
1.02, CH3CN); 1H NMR (400 MHz, CDCl3) δ 7.38 (d, J = 7.7 Hz, 1H), 7.28-7.16 (m, 5H), 7.09 (d, J = 8.7 
Hz, 2H), 4.13-4.02 (m, 1H), 4.00-3.89 (m, 1H), 3.49-3.38 (m, 2H), 2.80-2.65 (m, 2H), 2.63-2.53 (m, 1H), 
2.42 (s, 3H), 1.78-1.47 (m, 6H), 1.44-1.28 (m, 2H); HRMS Calcd for [C26H26Cl2F3N3O5S+H] 620.1001. 
Found: 620.0945. HPLC: 100%. Vibrational Circular Dichroism experiments were unable to 
unambiguously assign the absolute stereochemistry of the (+) and (-) enantiomers. 
4-(2-(2,4-Dichloropheny1)-5-methy1-4-(4-(trifluoromethoxy)phenylcarbamoyl)-1H-imidazol-1-
yl)phenyl 3,3 ,3-trifluoropropane-1-sulfonate (14e). A suspension of 13e (150 mg, 0.29 mmol) in dry 
CH2Cl2 (2 mL) was treated with Et3N (38 mg, 0.37 mmol) at r.t.. The resulting mixture was cooled to -
78 °C and 3,3,3-trifluoropropane-1-sulfonyl chloride (79 mg, 0.40 mmol) in 0.5 mL dry CH2Cl2 was 
added dropwise. After stirring at -78 °C for 70 min, the reaction mixture was washed with water and 
evaporated. The product was purified by HPLC (30-100% CH3CN in aqueous NH4OAc (0.1 M) over 35 
min) to yield the title compound as a white solid (84 mg, yield over 3 steps 43%). 1H NMR (400 MHz, 
CDCl3) δ 9.10 (s, 1H), 7.71 (d, J = 9.0 Hz, 2H), 7.36-7.24 (m, 9H), 7.22-7.15 (m, 4H), 3.54-3.47 (m, 2H), 
2.86-2.72 (m, 2H), 2.53 (s, 3H); HRMS Calcd for [C27H19Cl2F6N3O5S+H]: 682.0405. Found: 682.0403. 
HPLC: 100%. 
4-(2-(2,4-Dichlorophenyl)-4-(6-fluoropyridin-3-ylcarbamoyl)-5-methyl-1H-imidazol-1-yl)phenyl 3,3,3-
trifluoropropane-1-sulfonate (14f). A suspension of 2-(2,4-dichlorophenyl)-N-(6-fluoropyridin-3-yl)-1-
(4-hydroxyphenyl)-5-methyl-1H-imidazole-4-carboxamide (150 mg, 0.33 mmol) in dry CH2Cl2 (2 mL) 
was treated with Et3N (43 mg, 0.43 mmol) at r.t.. The resulting mixture was cooled to -78°C and 
3,3,3-trifluoropropane-1-sulfonyl chloride (90 mg, 0.46 mmol) in dry CH2Cl2 (0.5 mL) was added 






mg, 0.07 mmol) was added and the mixture stirred for another 2 h. The reaction mixture was 
washed with water and evaporated. The product was purified by HPLC (30-100% CH3CN in aqueous 
NH4OAc (0.1 M) over 35 min) to yield the title compound as a white solid (133 mg, 66%). 1H NMR 
(400 MHz, CDCl3) δ 9.09 (s, 1H), 8.40-8.31 (m, 2H), 7.37-7.24 (m, 5H), 7.19 (d, J = 8.8 Hz, 2H), 6.95-
6.88 (m, 1H), 3.55-3-46 (m, 2H), 2.86-2.72 (m, 2H), 2.53 (s, 3H).  13C NMR (126 MHz, CDCl3) δ 161.5, 
160.7, 158.9, 148.7, 142.6, 138.4 (d, J = 15.1), 137.2, 135.5 (d, J = 38.6), 134.0, 133.3, 133.0 (d, J = 
4.5), 132.7 (d, J = 7.5), 130.8, 130.0, 129.4, 127.7, 127.6, 125.1 (q, J = 276.6), 123.2, 109.5 (d, J = 38.8), 
44.6 (q, J = 3.3), 29.3 (q, J = 31.9), 11.0.; HRMS Calcd for [C25H18Cl2F4N4O4S+H]: 617.0440. Found: 
617.0473. HPLC: 100%. 
4-(2-(2,4-Dichlorophenyl)-5-methyl-4-(6-(trifluoromethyl)pyridin-3-ylcarbamoyl)-1H-imidazol-1-
yl)phenyl 3,3,3-trifluoropropane-1-sulfonate (14g). A suspension of crude 13g (150 mg, 0.30 mmol) in 
dry CH2Cl2 (2 mL) was treated with Et3N (39 mg, 0.38 mmol) at r.t. then cooled to -78 °C. To this was 
added dropwise 3,3,3-trifluoropropane-1-sulfonyl chloride (91 mg, 0.46 mmol) in dry CH2Cl2 (0.5 mL). 
After stirring at -78 °C for 70 min, the mixture was washed with water and concentrated in vacuo to 
give a residue which was purified by HPLC (30-100% CH3CN in aqueous NH4OAc (0.1 M) over 40 min) 
to yield the title compound as a white solid (131 mg, yield over 3 steps 52%). 1H NMR (400 MHz, 
CDCl3) δ 9.29 (s, 1H), 8.77 (d, J = 2.1 Hz, 1H), 8.56 (dd, J = 2.1, 8.6 Hz, 1H), 7.66 (d, J = 8.6 Hz, 1H), 
7.37-7.16 (m, 7H), 3.55-3.46 (m, 2H), 2.86-2.72 (m, 2H), 2.53 (s, 3H); HRMS Calcd for 
[C26H18Cl2F6N4O4S+H]: 667.0408. Found: 667.0389. HPLC: 100%. 
4-(2-(2,4-Dichlorophenyl)-5-methyl-4-(5-methylpyridin-2-ylcarbamyl)-1H-imidazol-1-yl)phenyl 3,3,3-
trifluoropropane-1-sulfonate (14h). A suspension of 13h (150 mg, 0.33 mmol) in dry CH2Cl2 (2 mL) 
was treated with Et3N (44 mg, 0.43 mmol) at r.t.. The resulting mixture was cooled to -78 °C and 
3,3,3-trifluoropropane-1-sulfonyl chloride (94 mg, 0.48 mmol) in dry CH2Cl2 (0.5 mL) was added 
dropwise. After stirring at -78 °C for 80 min, the reaction mixture was washed with water and 






min) to yield the title compound as a white solid (132 mg, 65%). 1H NMR (400 MHz, CDCl3) δ 9.63 (s, 
1H), 8.23 (d, J = 8.4 Hz, 1H), 8.11 (d, J = 1.4 Hz, 1H), 7.51 (dd, J = 2.1, 8.4 Hz, 1H), 7.34-7.24 (m, 5H), 
7.18 (d, J = 8.9 Hz, 2H), 3.55-3.44 (m, 2H), 2.86-2.71 (m, 2H), 2.53 (s, 3H), 2.28 (s, 3H). HRMS Calcd 
for [C26H21Cl2F3N4O4S+H]: 613.0691. Found: 613.0702. HPLC: 100%. 
2,2,2-Trichloroethyl-1-(4-(benzyloxy)phenyl)-2-(2,4-dichlorophenyl)-5-methyl-1H-imidazole-4-
carboxylate (15). A solution of compound 4 (10.0 g, 22.1 mmol) in CH2Cl2 (210 mL) was treated with 
oxalyl chloride (18.5 g, 145 mmol), followed by a few drops of DMF. The mixture was stirred at r.t. 
for 2 h after which the solvents were evaporated. The residue was dissolved in CH2Cl2 (80 mL) and 
the mixture was cooled to 0 °C, upon which 2,2,2-trichloroethanol (3.63 g, 24.3 mmol) was added 
followed by DIPEA (3.42 g, 26.5 mmol). The ice bath was then removed and the reaction mixture was 
stirred at r.t. for 3 h, adding DMAP (279 mg, 2.28 mmol) after 1 h 40 min. The reaction mixture was 
diluted with CH2Cl2, washed with water, dried (MgSO4), filtered and concentrated in vacuo to yield 
the crude title compound (14.9 g). 1H NMR (400 MHz, CDCl3) δ 7.40-7.14 (m, 8H), 7.04-6.98 (m, 2H), 
6.94-6.88 (m, 2H), 5.01 (4H, s), 2.45 (s, 3H); MS m/z 583 (M+H). 
2,2,2-Trichloroethyl-2-(2,4-dichlorophenyl)-1-(4-hydroxyphenyl)-5-methyl-1H-imidazole-4-carboxylate 
(16). Crude 15 (14.77 g) was dissolved in HBr (33% in AcOH, 200 mL). After having stirred at r.t. for 
an additional hour the reaction mixture was cooled to 0 °C and EtOH was added. The mixture was 
stirred for 10 min before the solvents were evaporated. The residue was dissolved in MeOH and 
neutralized with aqueous NaHCO3 (1 M). The solvent was evaporated and the mixture dissolved in 
CH2Cl2. The organic phase was washed with brine and water, dried (MgSO4), filtered and 
concentrated in vacuo to yield the title compound (10.4 g, 95% over 2 steps). 1H NMR (400 MHz, 
CDCl3) δ 8.63 (br s, 1H), 7.25-7.08 (m, 3H), 6.86-6.68 (m, 4H), 4.95 (s, 2H), 2.43 (s, 3H); MS m/z 493 
(M+H). 
2,2,2-Trichloroethyl-2-(2,4-dichlorophenyl)-5-methyl-1-(4-(3,3,3- trifluoropropylsulfonyloxy)phenyl)-






under nitrogen was treated with Et3N (1.23 g, 12.2 mmol) at r.t.. The resulting mixture was cooled to 
-78 °C and 3,3,3-trifluoropropane-1-sulfonyl chloride (2.19 g, 11.1 mmol) was added dropwise. The 
reaction mixture was stirred at -78 °C for 3 h, adding more 3,3,3-trifluoropropane-1-sulfonyl chloride 
(0.28 g 1.43 mmol) after 2 h. Water was added and the phases were separated on a phase separator. 
The organic phase was concentrated in vacuo to yield the title compound (6.43 g, 97%). 1H NMR (400 
MHz, CDCl3) δ 7.37-7.15 (m, 7H), 5.01 (s, 2H), 3.53-3.45 (m, 2H), 2.84-2.70 (m, 2H), 2.48 (s, 3H); MS 
m/z 653 (M+H). 
2-(2,4-Dichlorophenyl)-5-methyl-1-(4-(3,3,3-trifluoropropylsulfonyloxy)phenyl)-1H-imidazole-4-
carboxylic acid (18). A solution of 17 (6.43 g, 9.82 mmol) in AcOH (100 mL) was treated with zinc dust 
(9.74 g, 148.91 mmol). The reaction mixture was stirred at r.t. for 3 h after which it was filtered 
through celite and evaporated. The residue was dissolved in CH2Cl2 and washed with aqueous HCl 
(0.1 M), dried, filtered, and concentrated in vacuo to yield the crude title compound (5.28 g). MS m/z 
523 (M+H). 
4-(2-(2,4-Dichlorophenyl)-4-(4-hydroxycyclohexylcarbamoyl)-5-methyl-1H-imidazol-1-yl)phenyl 3,3,3-
trifluoropropane-1-sulfonate (19). A solution of 18 (crude 528 mg) in CH2Cl2 (25 mL) was treated with 
oxalyl chloride (641 mg, 5.00 mmol). A precipitate formed immediately after the addition so more 
CH2Cl2 (15 mL) was added, followed by a few drops of DMF. The reaction mixture was stirred at r.t. 
for 2 h after which more oxalyl chloride (641 mg, 5.00 mmol) was added. After another 10 min the 
solvents were evaporated. Half of the crude material was suspended in CH2Cl2 (5 mL) and added 
dropwise to a mixture of 4-aminocyclohexanol (74 mg, 0.64 mmol), NaOH (1 M, 10 mL) and CH2Cl2 (5 
mL). The reaction mixture was stirred at r.t. for 2 h after which water/CH2Cl2 were added and the 
phases separated. The organic phase was washed with aqueous HCl (0.1 M) and concentrated in 
vacuo. The product was purified by HPLC to yield the title compound as a white solid after freeze 
drying (164 mg, 54% over 2 steps). Note that the title compound is a mixture of cis- and trans- 






J = 8.4 Hz, 0.6H), 4.07-3.99 (m, 0.3H), 3.99-3.86 (1H, m), 3.66-3.56 (m, 0.6H), 3.52-3.45 (m, 2H), 2.85-
2.71 (m, 2H), 2.48 and 2.47 (2 x s, 3H), 2.12-1.95 (m, 2.6H), 1.81-1.65 (m, 3.8H), 1.49-1.26 (m, 2.7H); 
HRMS Calcd for [C26H26Cl2F3N3O5S+H]: 620.1001. Found: 620.1002. HPLC: 100%. 
racemic N-((cis)-2-Aminocyclohexyl)-1-[4-(benzyloxy)phenyl)-2-(2,4-dichlorophenyl)-5-methyl-1H-
imidazole-4-carboxamide (20). A suspension of compound 4 (2.00 g, 4.41 mmol) in CH2Cl2 (50 mL) 
was treated with oxalyl chloride (2.80 mg, 22.1 mmol) at r.t., followed by one drop of DMF. The 
mixture was stirred at r.t. for 30 min after which the solvents were evaporated under reduced 
pressure. Half of the amount of the acid chloride (1.04 mg, 2.20 mmol) suspended in CH2Cl2 (250 mL) 
was added dropwise during 31 h to a mixture of (cis)-cyclohexane-1,2-diamine (5.00 mg, 43.79 
mmol), aqueous NaOH (1 M, 50 mL) and CH2Cl2 (50 mL). After the addition was complete water was 
added and the phases were separated. The organic phase was washed with aqueous HCl (10%) and 
brine, dried (MgSO4), filtered and evaporated to yield the crude title compound (1.31 mg). 1H NMR 
(400 MHz, CDCl3) δ 8.57 (br s, 2H), 7.69 (br s, 1H), 7.37-6.90 (m, 2H), 5.00 (s, 2H), 4.41 (br s, 1H), 3.72 
(br s, 1H), 2.42 (s, 3H), 2.18-1.40 (m, 8H); MS m/z 549 (M+H). 
racemic N-((cis)-2-Aminocyclohexyl)-2-(2,4-dichlorophenyl)-1-(4-hydroxyphenyl)-5-methyl-1H-
imidazole-4-carboxamide (21). A suspension of crude racemic 20 (791 mg, 1.44 mmol) in CH2Cl2 (5 
mL) and dimethyl sulfide (894 mg, 14.39 mmol) was treated with boron trifluoride (2.04 g, 14.4 
mmol). The reaction mixture was stirred at r.t. for 2.5 days (dark). Water and EtOAc were added and 
the phases separated. The organic phase was dried (MgSO4), filtered and evaporated to yield the 
crude title compound (715 mg). MS m/z 459 (M+H). 
racemic 4-(4-((cis)-2-Aminocyclohexylcarbamoyl-2-(2,4-dichlorophenyl)-5-methyl-1H-imidazol-1-
yl)phenyl 3,3,3-trifluoropropane-1-sulfonate (22). A suspension of crude racemic  21 (715 mg, 1.56 
mmol) in CH2Cl2 (15 mL) and Et3N (0.987 g, 9.76 mmol) was treated with TBDMSCl (0.985 g, 6.53 
mmol). The reaction mixture was stirred at r.t. for 22 h. CH2Cl2 and water were added and the phases 






intermediate an oil (1.14 g, 1.99 mmol). MS m/z 573 (M+H). A solution of the crude intermediate 
(1.14 g, 1.99 mmol) in THF (10 mL) was treated with (Boc)2O (444 mg, 2.03 mmol). The reaction 
mixture was stirred at r.t. for 4 h after which the solvent was evaporated at reduced pressure and 
the residue dissolved in CH2Cl2. The organic phase was washed with water, dried (MgSO4), filtered, 
and concentrated in vacuo. The residue was purified by flash chromatography (10-100% EtOAc in 
heptane) to yield the Boc-protected intermediate (620 mg, yield over 4 steps 70%). 1H NMR (400 
MHz, CDCl3) δ 7.37 (d, J = 8.2 Hz, 1H), 7.24-7.08 (m, 3H), 6.85 (d, J = 8.7 Hz, 2H), 6.70 (d, J = 8.7 Hz, 
2H), 5.12 (d, J = 4.5 Hz, 1H), 4.32-4.19 (m, 1H), 3.83-3.74 (m, 1H), 2.38 (s, 3H), 1.79-1.39 (m, 8H), 1.33 
(s, 9H), 0.87 (s, 9H), 0.11 (s, 6H); MS m/z 673 (M+H). A suspension of the fully protected 
intermediate (610 mg, 0.91 mmol) in dry THF (3 mL) was treated with TBAF (1.0 M THF, 237 mg, 0.91 
mmol). The reaction mixture was stirred at r.t. for 1 h 45 min. The solvent was evaporated and the 
residue dissolved in CH2Cl2, washed with water, dried (MgSO4), filtered and evaporated. The residue 
was dissolved in EtOAc and some silica gel was added. The suspension was filtered through a plug of 
silica gel and eluted with EtOAc. The solvent was evaporated to yield the crude desilylated 
intermediate (529 mg). 1H NMR (400 MHz, CDCl3) δ 7.36 (d, J = 8.1 Hz, 1H), 7.21 (d, J = 1.6 Hz, 1H), 
7.13 (d, J = 8.3 Hz, 1H), 7.09 (dd, J = 1.6, 8.3 Hz, 1H), 6.80 (d, J = 8.6 Hz, 2H), 6.68 (d, J = 8.6 Hz, 2H), 
5.07 (d, J = 6.6 Hz, 1H), 4.28-4.16 (m, 1H), 3.84-3.72 (m, 1H), 2.32 (s, 3H), 1.55-1.37 (m, 8H), 1.31 (9H, 
s); MS m/z 559 (M+H). A suspension of the crude intermediate (506 mg, 0.91 mmol) in dry CH2Cl2 (6 
mL) was treated with Et3N (110 mg, 1.09 mmol) at r.t.. The resulting mixture was cooled to -78 °C 
and 3,3,3-trifluoropropane-1-sulfonyl chloride (181 mg, 0.92 mmol) in dry CH2Cl2 (0.2 mL) was added 
dropwise. After stirring at -78 °C for 3 h (including extra additions of 3,3,3-trifluoro-propane-1-
sulfonyl chloride (2 x 43 mg, 0.22 mmol) after 1.5 h and 2.5 h), the reaction mixture was washed with 
water and evaporated to yield the crude intermediate (655 mg). MS m/z 719 (M+H). To a suspension 
of the Boc-protected intermediate (655 mg, 0.91 mmol) in MeOH (10 mL) at 0 °C was added 
dropwise a solution of thionyl chloride in MeOH (prepared by dropwise addition of thionyl chloride 






reaction mixture was stirred at r.t. for 1 h after which the solvents were evaporated. The product 
was purified by HPLC (30-100% CH3CN (with 0.1 % formic acid) in 0.1% formic acid (aq) during 40 
min). The CH3CN was evaporated and the resulting mixture extracted with CH2Cl2. The organic phase 
was washed with aqueous NaHCO3 (1 M), dried (MgSO4), filtered, and concentrated in vacuo to yield 
the title compound as a slightly yellow solid (315 mg yield over 3 steps 56%). 1H NMR (400 MHz, 
CDCl3) δ 7.51 (d, J = 8.7 Hz, 1H), 7.32-7.20 (m, 5H), 7.14 (d, J = 8.8 Hz, 2H), 4.20-4.09 (m, 1H), 3.52-
3.44 (m, 2H), 3.15-3.06 (m, 1H), 2.84-2.71 (m, 2H), 2.47 (s, 3H), 1.70-1.39 (m, 10H); HRMS Calcd for 
[C26H27Cl2F3N4O4S+H]: 619.1160. Found:  619.1216. HPLC: 95.4%. 
racemic 1-(4-(Benzyloxy)phenyl)-2-(2,4-dichlorophenyl)-N-((cis)-2-(dimethylamino)cyclohexyl)-5-
methyl-1H-imidazole-4-carboxamide (23). To a suspension of racemic 20 (493 mg, 0.90 mmol) in 
CH3CN (10 mL) was added formaldehyde, 36% (135 mg, 4.49 mmol) and sodium borohydride (75 mg, 
1.97 mmol) in portions. The suspension was stirred at r.t. for 2 days adding after 2.5 h sodium 
borohydride (77 mg, 2.04 mmol), 3.5 h formaldehyde (36% in H2O, 67 mg, 2.24 mmol), 18.5 h 
formaldehyde (36% in H2O, 67 mg, 2.24 mmol) and sodium borohydride (77 mg, 2.04 mmo1) (the 
temperature was increased to 40 °C for 4.5 h), 23 h AcOH (1.85 mL) at r.t., 28 h formaldehyde (36% 
in H2O, 135 mg, 4.49 mmol) followed by sodium cyanoborohydride (112 mg, 1.78 mmol), 42 h 
formaldehyde (36% in H2O, (135 mg, 4.49 mmol) followed by sodium cyano borohydride (126 mg, 
2.01 mmol). The reaction mixture was diluted with CH2Cl2, washed with NaOH (1 M) and brine, dried 
(MgSO4), filtered and evaporated. The residue was purified by HPLC (30-100% CH3CN in aqueous 
NH4OAc (0.1 M) over 30 min). The CH3CN was evaporated and the resulting mixture extracted with 
CH2Cl2, dried (MgSO4), filtered and evaporated to yield the title compound (163 mg, 32%). MS m/z 
577 (M+H). 
racemic 2-(2,4-Dichlorophenyl)-N-((cis)-2-(dimethylamino)cyclohexyl)-1-(4-hydroxyphenyl)-5-methyl-
1H-imidazole-4-carboxamide (24). A suspension of racemic 23 (163 mg, 0.28 mmol) in CH2Cl2 (2 mL) 






The reaction mixture was stirred at r.t. for 2 days (dark) adding more of dimethyl sulfide (176 mg, 
2.82 mmol) and boron trifluoride (401 mg, 2.82 mmol) after 17 h. Water and CH2Cl2 were added and 
the phases separated. The organic phase was washed with water, dried (MgSO4), filtered, and 
concentrated in vacuo to yield the crude title compound (104 mg). MS m/z 487 (M+H). 
racemic 4-(2-(2,4-Dichlorophenyl)-4-((cis)-2-(dimethylamino)cyclohexylcarbamoyl)-5-methyl-1H-
imidazol-1-yl]phenyl 3,3,3-trifluoropropane-1-sulfonate (25). A suspension of racemic 24 (104 mg, 
0.21 mmol) in dry CH2Cl2 (1.5 mL) was treated with Et3N (26 mg, 0.26 mmol) at r.t.. The resulting 
mixture was cooled to -78 °C and 3,3,3-trifluoropropane-1-sulfonyl chloride (50 mg, 0.26 mmol) in 
dry CH2Cl2 (0.5 mL) was added dropwise. After stirring at -78 °C for 6.5 h (and adding more 3,3,3-
trifluoropropane-1-sulfonyl chloride (2 x 50 mg, 0.26 mmol) after 2 h and 4 h, and Et3N (26 mg, 0.26 
mmol) after 4 h), the reaction mixture was washed with water and evaporated. The residue was 
purified by HPLC (30-100% CH3CN (with 0.1% formic acid) in 0.1% formic acid over 40 min) and 
freeze dried. The product was dissolved in CH2Cl2 and washed with NaHCO3 (1 M) and water, dried 
(MgSO4), filtered and concentrated in vacuo to yield the title compound as a slightly yellow oil (37 
mg yield over 2 steps 20%). 1H NMR (400 MHz, CDCl3) δ 7.54 (d, J = 7.6 Hz, 1H), 7.37 (d, J = 8.3 Hz, 
1H), 7.31 (d, J = 2.0 Hz, 1H), 7.29 (d, J = 8.9 Hz, 1H), 7.26 (dd, J = 2.0, 8.3 Hz, 1H), 7.17 (d, J = 8.9 Hz, 
1H), 4.59-4.51 (m, 1H), 3.56-3.48 (m, 2H), 2.86-2.76 (m, 2H), 2.51 (s, 3H), 2.31 (s, 6H), 2.26-2.19 (m, 
1H), 2.07 (dt, J = 3.8, 11.8 Hz, 1H), 2.04-1.96 (m, 2H), 1.85-1.77 (m, 1H), 1.54-1.25 (m, 5H); HRMS 
Calcd for [C28H31Cl2F3N4O4S+H]: 647.1473. Found: 647.1472. HPLC: 100%. 
1-(4-(Benzyloxy)phenyl)-2-(2,4-dichlorophenyl)-5-methyl-N-(5-(trifluoromethyl)pyridin-2-yl)-1H-
imidazole-4-carboxamide (26). A solution of 2-amino-5-(trifluoromethyl)pyridine (404 mg, 2.49 mmol) 
in CH2Cl2 (2.5 mL) under argon was carefully treated with trimethylaluminium (2.0 M in toluene, 1.25 
mL, 2.5 mmol) over 5 min. The solution was stirred at r.t. for 1.5 h to give a 0.66 M solution of the 
amidation reagent. A portion of this solution (3.75 mL, 2.5 mmol) was added to compound 3 (400 mg, 






(aq, 2 M, 7.5 mL). The mixture was diluted with dichloromethane and neutralized by addition of KOH 
(aq, 2 M). The organic phase was separated and the aqueous phase was extracted further with 
dichloromethane. The collected organic phases were washed with H2O, dried (Na2SO4), filtered, and 
concentrated in vacuo to give a residue which was purified by preparative HPLC to give the title 
compound (319 mg, 64%) as a solid. 1H NMR (400 MHz, CDCl3) δ 9.91 (s, 1H), 8.57 (s, 1H), 8.52 (d, J = 
8.8 Hz, 1H), 7.92 (dd, J = 2.1, 8.8 Hz, 1H), 7.44-7.32 (m, 6H), 7.30-7.21 (m, 2H), 7.04 (d, J = 8.9 Hz, 2H), 
6.95 (d, J = 8.9 Hz, 2H), 5.05 (s, 2H), 2.52 (s, 3H); MS m/z 597 (M+H). 
2-(2,4-Dichlorophenyl)-1-(4-hydroxyphenyl)-5-methyl-N-(5-(trifluoromethyl)pyridin-2-yl)-1H-
imidazole-4-carboxamide (27). Compound 26 (319 mg, 0.53 mmol) was dissolved in HBr (4.1 M in 
acetic acid, 7.5 mL, 30.8 mmol) and the mixture stirred at r.t. for 4 h. The acetic acid was co-
evaporated with EtOH, the residue neutralized with ammonia and dissolved in methanol. 
Purification by flash chromatography gave the title compound (266 mg, 98%). 1H NMR (400 MHz, 
DMF-d7) δ 10.36 (s, 1H), 10.09 (s, 1H), 8.89 (d, J = 1.0 Hz, 1H), 8.69 (d, J = 8.9 Hz, 1H), 8.45 (dd, J = 1.0, 
8.9 Hz, 1H), 7.85 (d, J = 8.3 Hz, 1H), 7.80 (s, 1H), 7.67 (d, J = 8.3 Hz, 1H), 7.40 (d, J = 8.4 Hz, 2H), 7.06 
(d, J = 8.4 Hz, 2H), 2.65 (s, 3H); MS m/z 507 (M+H). 
4-(2-(2,4-Dichlorophenyl)-5-methyl-4-(5-(trifluoromethyl)pyridin-2-ylcarbamoyl)-1H-imidazol-1-
yl)phenyl 3,3,3-trifluoropropane-1-sulfonate (28). A mixture of 27 (136 mg, 0.27 mmol) and Et3N (40 
µL, 0.32 mmol) in CH2Cl2 (4.0 mL) was cooled to -78 °C then carefully treated with 3,3,3-
trifluoropropane-1-sulfonyl chloride (63 mg, 0.32 mmol). The resulting mixture was stirred at -78 °C 
for 1 h, then allowed to reach room temperature. Water was added to the reaction, and the phases 
were separated. The organic phase was washed with NaHCO3, and brine, then dried (Na2SO4), 
filtered, and concentrated in vacuo to give a residue which was purified by preparative HPLC to give 
the title compound (88 mg, 49%) as a solid. 1H NMR (400 MHz, CDCl3) δ 9.87 (s, 1H), 8.55 (s, 1H), 
8.49 (d, J = 8.8 Hz, 1H), 7.91 (dd, J = 2.1, 8.8 Hz, 1H), 7.36-7.21 (m, 5H), 7.19 (d, J = 8.8 Hz, 2H), 3.55-






(q, J = 4.1), 142.7, 137.0, 136.2, 135.6 (q, J = 3.2), 135.2, 134.1, 133.4, 131.0, 130.0, 129.3, 127.9, 
127.5, 125.1 (q, J = 277.1), 123.8 (q, J = 271.3), 123.2, 122.1 (q, J = 32.7), 113.1, 44.5 (q, J = 3.3), 29.3 
(q, J = 31.5), 11.1. HRMS Calcd for [C26H18Cl2F6N4O4S +H]: 667.0408. Found: 667.0540. HPLC: 100%. 
Biology. Chemicals and Reagents. [3H]CP55940 (specific activity 141.2 Ci/mmol) was purchased from 
Perkin Elmer (Waltham, MA). Bicinchoninic acid (BCA) and BCA protein assay reagent were obtained 
from Pierce Chemical Company (Rochford, IL). Rimonabant was from Cayman Chemical Company 
(Ann Arbor, MI). CHOK1hCB1_bgal cells (catalog number 93-0959C2) were obtained from DiscoveRx 
(Fremont, CA). The membranes (catalog number RBHCB1M400UA) used for [35S]GTPγS antagonism 
experiment were purchased from Perkin Elmer (Waltham, MA).  All other chemicals were of 
analytical grade and obtained from standard commercial sources. 
Cell Culture and Membrane Preparation.  CHOK1hCB1_bgal cells were cultured in Ham’s F12 Nutrient 
Mixture supplemented with 10% fetal calf serum, 1 mM glutamine, 50 μg/mL penicillin, 50 μg/ml 
streptomycin, 300 mg/mL hygromycin and 800 μg/mL geneticin in a humidified atmosphere at 37 °C 
and 5% CO2. Cells were subcultured twice a week at a ratio of 1:10 on 10-cm ø plates by 
trypsinization. For membrane preparation the cells were subcultured 1:10 and transferred to large 
15-cm ø plates. Membrane fractions were prepared exactly as described before.50 
Equilibrium Radioligand Displacement Assays. [3H]CP55940 displacement assays on 96-well plate 
were used for the determination of affinity (IC50 and Ki) values of antagonists for the cannabinoid CB1 
receptors. The displacement experiments were performed using 6 concentrations of competing 
antagonists in 25 μL of assay buffer (50 mM Tris–HCl, 5 mM MgCl2, 0.1% BSA, pH 7.4) in the presence 
of another 25 μL of assay buffer with a final concentration of 3.5 nM [3H]CP55940. At this 
concentration, total radioligand binding did not exceed 10% of that added to prevent ligand 
depletion. Membrane aliquots containing 5 μg of CHOK1hCB1_bgal membrane in 100 μL assay buffer 
were incubated at 30 °C for 60 min. Nonspecific binding (NSB) was determined in the presence of 10 






plates (Perkin Elmer, Groningen, the Netherlands), presoaked for 30 min with 0.25% PEI 
(PolyEthyleneImine), using a PerkinElmer Filtermate-harvester (Perkin Elmer, Groningen, the 
Netherlands). After 30 min of dehydration of the filter plate at 50 oC, the filter-bound radioactivity 
was determined by scintillation spectrometry using the 2450 MicroBeta2 Plate Counter. The binding 
values were recorded in both counts per minute (CPM) and disintegrations per minute (DPM). Each 
antagonist was measured in duplicate and at least 3 individual experiments were performed.   
Classic Radioligand Kinetic Assays. Association experiments were performed by incubating 
membrane aliquots containing 5 μg of CHOK1hCB1_bgal membrane in a total volume of 100 μL of 
assay buffer at 30 °C with 3.5 nM [3H]CP55940. The amount of radioligand bound to the receptor 
was measured at different time intervals during a total incubation of 120 min. Dissociation 
experiments were performed by preincubating membrane aliquots containing 5 μg of protein in a 
total volume of 100 μL of assay buffer for 60 min. After the preincubation, radioligand dissociation 
was initiated by the addition of 10 μM unlabeled rimonabant. The amount of radioligand still bound 
to the receptor was measured at various time intervals for a total of 240 min. to ensure that full 
dissociation from cannabinoid CB1 receptor was reached. Incubation was terminated by rapid 
filtration performed on GF/C filters (Whatman International, Maidstone, UK), presoaked for 30 min 
with 0.25% PEI, using a Brandel harvester (Brandel, Gaithersburg, MD). Filter-bound radioactivity 
was determined by scintillation spectrometry using a Tri-Carb 2900 TR liquid scintillation counter 
(Perkin Elmer, Boston, MA).  
Competition Association Assays. Kinetic Rate Index (KRI) values are an average of at least two 
independent experiments, each consisting of two replicates. Kinetic rate constant values are an 
average of at least three independent experiments, each consisting of two replicates. The binding 
kinetics of unlabeled ligands was quantified using the competition association assay based on the 
theoretical framework by Motulsky and Mahan.36 A concentration of 1 to 3-fold of the IC50 value was 






association assay was initiated by adding membrane aliquots (5 μg/well) at different time points for 
a total of 240 min to a total volume of 100 μL of assay buffer at 30 °C with 3.5 nM [3H]CP55940 in the 
absence or presence of competing CB1 receptor antagonists (1 to 3-fold IC50). Incubations were 
terminated, and samples were obtained as described under Equilibrium Radioligand Displacement 
Assay. The “dual-point” competition association assays32 were run similarly, with only two time 
points, at 30 and 240 min, respectively. 
 [35S]GTPγS Binding Assays. Antagonism assay: The antagonism of all tested compounds was 
evaluated at 30 oC in a [35S]GTPγS binding assay as reported earlier.51 Insurmountability assay: 
Membrane homogenates containing the CB1 receptor (5 µg) were equilibrated in the assay buffer 
(50 mM Tris–HCl, 5 mM MgCl2, 1 mM EDTA, 100 mM NaCl, 0.05% BSA, pH7.4) supplemented with 1 
µM GDP, 1 mM DTT and 5 µg saponin. Membrane preparations were pre-incubated with or without 
antagonists (10-fold Ki values on the CB1 receptor) for 1 h prior to the challenge of a CB1 receptor 
agonist, CP55940 at 25 oC with concentrations ranging from 1 µM to 0.1 nM. Subsequently, 
[35S]GTPγS (final concentration 0.3 nM) was added and incubation continued for another 30 min at 
25 oC. Incubations were terminated and samples were obtained as described under Equilibrium 
Radioligand Displacement Assays.  
Data analysis. All experimental data were analyzed using the nonlinear regression curve fitting 
program GraphPad Prism 6.0 (GraphPad Software, Inc., San Diego, CA). From displacement assays, 
IC50 values were obtained by non-linear regression analysis of the displacement curves. The obtained 
IC50 values were converted into Ki values using the Cheng-Prusoff equation to determine the affinity 
of the ligands.52 The kon and koff values for radiolabeled and unlabeled ligands were fitted and 
calculated, and the kon and koff values were used to calculate residence times (in min) and kinetic 
dissociation binding constants (kinetic KD). Association and dissociation rates for unlabeled 
compounds were calculated by fitting the data into the competition association model using 














































































Where k1 is the kon of the radioligand (M-1s-1), k2 is the koff of the radioligand (s-1), L is the radioligand 
concentration (nM), I is the concentration of the unlabeled competitor (nM), X is the time (min) and 
Y is the specific binding of the radioligand (DPM). During a competition association these parameters 
are set, obtaining k1 from the control curve without competitor and k2 from previously performed 
dissociation assays described under Traditional Radioligand Kinetic Assays. With that the k3, k4 and 
Bmax can be calculated, where k3 represents the kon (M-1s-1) of the unlabeled ligand, k4 stands for the 
koff (s-1) of the unlabeled ligand and Bmax equals the total binding (DPM). All competition association 
data were globally fitted. Residence times (RT, expressed in min) were calculated as RT = 1/(60*koff). 
Computational studies. All computational studies were performed in the Schrödinger suite,53 and 
based on the crystal structure of the CB1 receptor co-crystalized with 29 (PDB: 5TGZ).33 The crystal 
structure was prepared with the protein preparation wizard.53 Ligands were docked using induced fit 
docking,54 with core constraints on the 2,4-dichlorophenyl ring  of  29 (all ligands share this moiety). 
To study whether the difference in RTs among 11d, 14f and 28 could be explained by unfavorable 
hydration, we generated a WaterMap around 14f.47, 48 Figures were rendered using PyMol.55 
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Determination of target selectivity between human CB1 and CB2 receptors and physicochemical 
properties for human CB1 receptor antagonists Contents. 
1. Selectivity data for representative human CB1 receptor antagonists at human CB2 receptor 
Method: The antagonism of all tested compounds was evaluated at 30 oC in a [35S]GTPγS binding 
assay as reported earlier.51 




pIC50 ± SD or SEM 
(mean IC50 in nM)  a 
pKi  
± SEM 
(mean Ki in nM) b 
11b N. D. c 7.5 ± 0.01 (35) 
11d 6.6 ± 0.05 (288) N. D. c 
11f 6.5 (320) N. D. c 
11g 6.6 ± 0.01 (271) d N. D. c 
11h 5.9 ± 0.03 (1358) N. D. c 
14b (±) trans 6.4 ± 0.1 (425) d N. D. c 
14d (+) cis 6.4 ± 0.2 (440) d N. D. c 
22 (±) cis 6.1 ± 0.03 (805) d N. D. c 
14f N. D. c 8.9 ± 0.1 (1.4) 
14h 6.4 ± 0.05 (400) d N. D. c 
28 6.9 ± 0.04 (133)  d  8.3 ± 0.1 (4.9) 
 
a pIC50 ± SD (n=2) or SEM (n ≥ 3), except 11f was n=1, obtained from [35S]GTPγS binding on recombinant human 
CB2 receptors stably expressed on HEK-293 cell membranes.   
b pKi ± SEM (n=3), obtained from radioligand binding assays with [3H]CP55940 on recombinant human CB2 
receptors stably expressed on CHO cell membranes. 







2. Calculating Polar Surface Area (PSA) 
Method: PSA is an in-house implementation (AstraZeneca, Vladimir Sherbukin) of a literature 
model.39 In brief, Van der Waals surface area around polar atoms (N, O and H attached either to N or 
O), all other atoms are treated as non-polar. The algorithm sums up atomic contributions and 
subtracts buried surfaces where two atomic spheres intersect making a bond. Parameters for the 
following elements are available: H, C, N, O, S, F and Cl. If any other element occurs in the molecule, 
the value will be missing. 
3. Calculating ACDlogD7.4 with pKa correction 
Method: the values of ACDLogD7.4 with pKa correction were calculated using the ACD software, 
version 12 (www.acdlabs.com) with utilization of in house pKa data (AstraZeneca) as a pKa 
correction library. 
4. Calculating AZlogD7.4 
Method: the values of AZlogD7.4 were obtained from AstraZeneca’s Auto-QSAR method.41 
5. LogD determination 
Method: measurement of LogDO/W is based on the traditional shake flask technique, but with the 
modification of measuring compounds in mixtures of ten at a time using UPLC with quantitative 
mass spectrometry (MS) as a method to measure the relative octanol and aqueous concentrations. 
Two quality control (QC) samples (Cyclobenzaprine with moderate LogD, and Nicardipine with high 
LogD) are used in all pools to ensure good quality. Caffeine, with low LogD, is used as an additional 
QC sample and is randomly placed in all runs. The method has been thoroughly validated against the 
previous shake flask methodologies. The range of LogD values that can be determined by this 
method is dependent on the solubility of the compound in octanol and buffer, as well as the MS 







Robot, samples: Hamilton Star 
Robot, optimization:  BRAVO Velocity11, Biomek FX 
Mass spectrometer:  Waters Micromass TQS with MassLynx 4.1 
LC-system:   Waters Acquity Ultra Performance LC 
Column:  Acquity UPLC HSS T3 1.8 µm, 2.1∙50 mm or Acquity UPLC BEH C18 
1.7 µm, 2.1∙50 mm 
Vortexer:   IKA-VIBRAX-VXR 
Shaker:   Edmund Bühler SM25 
Centrifuge:   Eppendorf Centrifuge 5810 R 
Plates:  2 ml U96 deep well plate PP (Nunc Cat No 278752) 
1.3 ml U96 deep well plate PP (Nunc Cat No 260252)  
Nunc microtiter plate 96-well V-bottom PP (Nunc Cat No 249944). 
Phosphate buffer: 
Na2HPO4x2H2O (p.a grade) and NaH2PO4xH2O (p.a grade) purchased from Merck or other vendor. A 
stock solution of 100 mM (pH approximately 7.2) is prepared by dissolving 12.731 g Na2HPO4x2H2O 
and 3.929 g NaH2PO4xH2O in 1 L of water. This stock solution can be stored in room temperature for 
at least one year. 
The stock solution is diluted ten times and pH adjusted to 7.4. Thereafter, equal parts of buffer and 
1-octanol are vigorously mixed in a separation funnel three times (at least 15 minutes between each 
mixing) to saturate the solutions. The mixture is left overnight to separate the upper octanol phase 
from the lower buffer phase before being used in experiments. 
All the physicochemical properties are summarized in Table S2 and S3. Their correlations with 
affinities and KRI values are summarized in Figure S1 and S2.  
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 94.14 6.327 4.56 > 5.80 
 
















94.14 5.039 4.07 4.90 
14a (±) 
 
116.7 3.844 3.42 3.80 
14b (±) trans  112.2 4.303 4.64 4.60 
14c (-) trans  112.2 4.557 4.74 > 4.40 
14d (+) cis  112.2 4.557 4.74 > 4.30 
19 cis : trans 
(0.3:1) 
 112.2 4.395 4.38 4.20 
22 (±) cis  117.7 2.416 3.67 3.35 
25 (±)cis  90.87 3.001 4.23 3.80 








 99.63 3.33 4.78 > 4.30 
 
14g 
 99.63 3.745 5.45 > 4.90 
14h  99.63 4.914 5.37 5.80 
28  99.63 4.256 5.52 > 5.00 
 
 
Figure S1: Absence of correlation between physicochemical parameters and affinities a) The calculated PSA 
values (X-axis) had no obvious linear correlation with the negative logarithm of affinity values (pK i, Y-axis) of 
the hCB1 receptor antagonists (r2 = 0.14, P = 0.068); b) The calculated LogD values (X-axis, ACDlogD7.4 with pKa 
correction) had no obvious linear correlation with the negative logarithm of affinity values (pKi, Y-axis) of the 
hCB1 receptor antagonists (r2 = 0.012, P = 0.62); c) The calculated LogD values (X-axis, AZ logD74) had no 
obvious linear correlation with the negative logarithm of affinity values (pKi, Y-axis) of the CB1 receptor 
antagonists (r2 = 8.2e-006; P = 0.99); d) The experimentally determined LogD values (X-axis, LogD) had no 
obvious linear correlation with the negative logarithm of affinity values (pKi, Y-axis) of the hCB1 receptor 










Figure S2: Absence of correlation between physicochemical parameters and KRI values a) The calculated PSA 
values (X-axis) had no obvious linear correlation with the KRI values (Y-axis) of the hCB1 receptor antagonists 
(r2 = 0.0044, P = 0.76); b) The calculated LogD values (X-axis, ACDlogD7.4 with pKa correction) had no obvious 
linear correlation with the KRI values (Y-axis) of the hCB1 receptor antagonists (r2 = 0.045, P = 0.32); c) The 
calculated LogD values (X-axis, AZ logD74) had no obvious linear correlation with the KRI values (Y-axis) of the 
hCB1 receptor antagonists (r2 = 0.38; P = 0.0029); d) The experimentally determined LogD values (X-axis,LogD) 
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Kinetics of human Cannabinoid 1 (CB1) receptor 
antagonists: structure-kinetics relationships 
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About this chapter 
While equilibrium binding affinities and in vitro functional antagonism of human CB1 receptor 
antagonists have been studied in detail, little is known on the kinetics of their receptor interaction. 
In this study, we therefore conducted kinetic assays for nine 1-(4,5-diarylthiophene-2-carbonyl)-4-
phenylpiperidine-4-carboxamide derivatives and included the CB1 antagonist rimonabant as a 
comparison. For this we newly developed a dual-point competition association assay with 
[3H]CP55940 as the radioligand. This assay yielded Kinetic Rate Index (KRI) values from which 
structure-kinetics relationships (SKR) of hCB1 receptor antagonists could be established. The fast 
dissociating antagonist 6 had a similar receptor residence time (RT) as rimonabant, i.e. 19 and 14 
min, respectively, while the slowest dissociating antagonist (9) had a very long RT of 2222 min, i.e. 
pseudo-irreversible dissociation kinetics. In functional assays, 9 displayed insurmountable 
antagonism, while the effects of the shortest RT antagonist 6 and rimonabant were surmountable. 
Taken together, this study shows that hCB1 receptor antagonists can have very divergent RTs, which 
are not correlated to their equilibrium affinities. Furthermore, their RTs appear to define their mode 
of functional antagonism, i.e. surmountable vs. insurmountable. Finally, based on  the recently 
resolved hCB1 receptor crystal structure, we propose that the differences in RT can be explained by a 
different binding mode of antagonist 9 from short RT antagonists that is able to displace unfavorable 
water molecules. Taken together, these findings are of importance for future design and evaluation 








The human cannabinoid 1 (hCB1)  receptor is categorized as a “lipid G protein-coupled receptor 
(GPCR)” due to its hydrophobic endogenous ligands, such as anandamide (AEA) and 2-
arachidonoylglycerol (2-AG), which are crucial components of the endocannabinoid system (ECS).1, 2 
The CB1 receptor  belongs to the class A GPCR family, and has been shown to signal through 
inhibitory Gαi/o heterotrimeric G proteins,3 and to interact with β-arrestin.4 Nowadays, it is widely 
acknowledged that the hCB1 receptor is not only present in the central nervous system (CNS), but 
also widely distributed in the peripheral nervous system (PNS) and peripheral tissues,5 including the 
heart, lung, liver, gastrointestinal tract, pancreas and adipose tissue.6, 7 The ECS, including the hCB1 
receptor, has been shown to be overactive in metabolic disorders where increased endocannabinoid 
levels are found in plasma, in central and peripheral tissues.8 Therefore, blockade of the hCB1 
receptor is seen as a potential approach for the treatment of metabolic disorders such as obese 
dyslipidemia, liver disease and diabetes.9  
Rimonabant, as an anti-obesity drug, was the first hCB1 receptor antagonist to reach the market in 
Europe, but was withdrawn in 2008 by the manufacturer because of the risk of serious psychiatric 
adverse effects, such as depression.10-13 As a result, many research programs in this field were 
terminated. Afterwards, the development of peripherally-restricted hCB1 antagonists gained 
attention, as they may not have CNS-related side-effects. The general strategy was to introduce 
more polar or even ionic functional groups to a ligand’s scaffold. However, some recent clinical and 
pre-clinical reports on this type of compounds either show no antiobesity effect at all 14 or no 
improved effect in comparison to rimonabant.14-17 
Most recently, the concept of drug target binding kinetics is receiving increased attention. In 
particular the receptor-ligand residence time (RT) is emerging as an additional parameter to assess 
the therapeutic potential of drug candidates with respect to drug efficacy and safety.18-20 The 






relationship (SAR) analyses results in a better understanding of a ligand-receptor interaction, as 
together this not only comprises the equilibrium state of a ligand-receptor interaction but also its 
metastable intermediates and/or transition states. Recently, a number of structure-kinetic 
relationship (SKR) studies have been published in the field of GPCR.21-24 These suggest that including 
binding kinetic data when triaging compounds can change, and hopefully improve, the resulting 
decision process as a compound’s target affinity and residence time are not always correlated. 
In the current study, a series of 9 previously reported peripherally-selective 1-(4,5-diarylthiophene-
2-carbonyl)-4-phenylpiperidine-4-carboxamide derivatives were selected for a structure-kinetics 
relationships (SKR) study, next to structure-affinity relationships (SAR). These compounds arose from 
so-called scaffold hopping, where the pyrazole ring of rimonabant was replaced by a five-membered 
thiophene ring.25, 26 In addition, some polar substituents were introduced on the thiophene and 
phenyl rings, as well as a carboxamide moiety; all to increase the ligands’ polar surface area, and 
thus to reduce brain penetration (Table 1). Together with rimonabant as a reference, they were 
evaluated in equilibrium and kinetic radioligand binding assays yielding affinity values and kinetic 
binding parameters, which resulted in traditional SAR and novel SKR, respectively. All compounds 
had high affinities, but possessed diverse kinetic profiles at the hCB1 receptor. This “kinetic screening 
campaign” led to the identification of a very long (9, 2222 min) and short RT hCB1 receptor 
antagonist (6, 19 min), while rimonabant was determined to have a RT of 14 min. Subsequently, we 
applied two other radioligand binding experiments (i.e. “two-step incubation” and “wash-out” 
equilibrium displacement experiments) to characterize the pseudo-irreversible binding kinetics of 
antagonist 9, compared to the reversible binding kinetics of antagonist 6 and rimonabant. With such 
large differences in RT (~185 fold), we decided to further investigate their concomitant functional 
effects in both G protein-dependent and -independent (i.e. β-arrestin recruitment) signaling. Their 
putative binding mode was analyzed using the recently resolved crystal structures of the hCB1 
receptor,27 shedding light on key structural features of the receptor binding site that are involved in 






additional knowledge of a compound’s binding kinetics is useful for selecting and developing new 
and, potentially, improved hCB1 receptor antagonists in the early phases of drug discovery. 
 
Method 
Chemicals and reagents. The syntheses of antagonists 1-9 have been described previously.25, 26 All 
compounds were fully characterized by HPLC and 1H NMR. For compounds 1, 2, 3, 4, 8 and 9, purity 
was analyzed by a Symmetry C18 column (50 x 2.1 mm ; 3.5 µm), with a 15 minute gradient of 
acetonitrile/water (0 % -> 90 % CH3CN). For compound 5, purity was analyzed by an XTerra MS C18 
column (50 x 2.1 mm ; 3.5 µm), with a 15 minute gradient of acetonitrile/10mM ammonium acetate 
with 3% CH3CN (0 % -> 90 % CH3CN). For compound 6 and 7, purity was analyzed by an Acquity BEH 
C18 column (50 x 2.1 mm ; 1.7 µm), with a 3 minute gradient of acetonitrile/water with 3% CH3CN (1 % 
-> 95 % CH3CN). All antagonists were found to have a purity of 95% or higher. The compound 
characterization details for the nine antagonists are shown below. 
1-[[5-(2,4-Dichlorophenyl)-4-[4-(2-hydroxyethoxy)phenyl]-2-thienyl]carbonyl]-4-phenyl-4-
piperidinecarboxamide (1). 1H NMR (600 MHz, DMSO-d6) δ 7.72 (s, 1H), 7.59 (s, 1H), 7.48 (s, 2H), 7.43 
(d, J = 7.6 Hz, 2H), 7.35 (t, J = 7.7 Hz, 2H), 7.28 – 7.22 (m, 2H), 7.14 – 7.08 (m, 3H), 6.85 (d, J = 8.8 Hz, 
2H), 4.83 (t, J = 5.5 Hz, 1H), 4.15 (d, J = 12.5 Hz, 2H), 3.94 (t, J = 4.9 Hz, 2H), 3.68 (q, J = 5.2 Hz, 2H), 
2.54 (d, J = 8.7 Hz, 2H), 1.89 (t, J = 10.7 Hz, 2H). Purity: 99%. Retention Time: 9.26 min. 
1-[[4-[4-[(2-Aminoethyl)thio]phenyl]-5-(2,4-dichlorophenyl)-2-thienyl]carbonyl]-4-phenyl-4-
piperidinecarboxamide (2). 1H NMR (600 MHz, DMSO-d6) δ 7.88 (bs, 3H), 7.75 (d, J = 1.8 Hz, 1H), 7.64 
(s, 1H), 7.54 – 7.48 (m, 2H), 7.42 (d, J = 7.4 Hz, 2H), 7.36 (t, J = 7.8 Hz, 2H), 7.30 (d, J = 8.5 Hz, 2H), 
7.25 (t, J = 7.3 Hz, 2H), 7.19 (d, J = 8.4 Hz, 2H), 7.11 (s, 1H), 4.15 (d, J = 11.2 Hz, 2H), 3.17 (t, J = 7.3 Hz, 
2H), 2.95 (t, J = 7.3 Hz, 2H), 2.55 (d, J = 14.1 Hz, 2H), 1.96 – 1.83 (m, 2H). Purity: 99 %. Retention Time: 







phenyl-4-piperidinecarboxamide (3). 1H NMR (600 MHz, DMSO-d6) δ 7.74 (d, J = 1.3 Hz, 1H), 7.65 (s, 
1H), 7.54 – 7.47 (m, 2H), 7.43 (d, J = 7.4 Hz, 2H), 7.35 (t, J = 7.8 Hz, 2H), 7.27 (s, 1H), 7.25 (d, J = 4.5 Hz, 
4H), 7.16 (d, J = 8.5 Hz, 2H), 7.10 (s, 1H), 4.16 (d, J = 12.6 Hz, 2H), 3.15 – 3.10 (m, 2H), 3.10 – 3.03 (m, 
2H), 2.89 (s, 3H), 2.55 (d, J = 13.5 Hz, 2H), 1.89 (t, J = 10.6 Hz, 2H). Purity: 100 %. Retention Time: 
9.79 min. 
1-[[5-(2,4-Dichlorophenyl)-4-[4-[3-(methylsulfonyl)propoxy]phenyl]-2-thienyl]carbonyl]-4-phenyl-4-
piperidinecarboxamide (4). 1H NMR (600 MHz, DMSO-d6) δ 7.73 (s, 1H), 7.60 (s, 1H), 7.48 (d, J = 1.0 
Hz, 2H), 7.42 (d, J = 7.4 Hz, 2H), 7.35 (t, J = 7.8 Hz, 2H), 7.28 – 7.22 (m, 2H), 7.13 (d, J = 8.8 Hz, 2H), 
7.10 (s, 1H), 6.86 (d, J = 8.8 Hz, 2H), 4.16 (d, J = 14.0 Hz, 2H), 4.05 (t, J = 6.2 Hz, 2H), 3.26 – 3.22 (m, 
2H), 3.00 (sz, 3H), 2.55 (d, J = 13.6 Hz, 2H), 2.16 – 2.07 (m, 2H), 1.89 (t, J = 11.2 Hz, 2H). Purity: 95 %. 
Retention Time: 9.64 min. 
1-[[5-(2,4-Dichlorophenyl)-4-[4-[(3-hydroxypropyl)thio]phenyl]-2-thienyl]carbonyl]-4-phenyl-4-
piperidinecarboxamide (5). 1H NMR (600 MHz, DMSO-d6) δ 7.73 (d, J = 0.9 Hz, 1H), 7.63 (s, 1H), 7.49 
(d, J = 1.7 Hz, 2H), 7.42 (d, J = 7.4 Hz, 2H), 7.36 (t, J = 7.8 Hz, 2H), 7.25 (t, J = 7.2 Hz, 2H), 7.21 (d, J = 
8.5 Hz, 2H), 7.14 (d, J = 8.5 Hz, 2H), 7.10 (s, 1H), 4.55 (t, J = 5.2 Hz, 1H), 4.15 (d, J = 13.4 Hz, 2H), 3.47 
(q, J = 6.0 Hz, 2H), 2.98 (t, J = 7.3 Hz, 2H), 2.57 – 2.52 (m, 2H), 1.89 (t, J = 12.4 Hz, 2H), 1.69 (p, J = 6.6 
Hz, 2H). Purity: 100 %. Retention Time: 9.28 min. 
1-[[5-(2,4-Dichlorophenyl)-4-[4-[(3-hydroxypropyl)sulfonyl]phenyl]-2-thienyl]carbonyl]-4-phenyl-4-
piperidinecarboxamide (6). 1H NMR (600 MHz, DMSO-d6) δ 7.81 (d, J = 8.4 Hz, 2H), 7.76 – 7.73 (m, 
2H), 7.55 (d, J = 8.3 Hz, 1H), 7.52 (dd, J = 8.3, 2.0 Hz, 1H), 7.48 (d, J = 8.5 Hz, 2H), 7.43 (d, J = 7.5 Hz, 
2H), 7.36 (t, J = 7.8 Hz, 2H), 7.25 (t, J = 7.2 Hz, 2H), 7.10 (s, 1H), 4.63 (t, J = 5.3 Hz, 1H), 4.17 (d, J = 
13.3 Hz, 2H), 3.40 (q, J = 6.0 Hz, 2H), 3.30 – 3.24 (m, 2H), 2.54 (d, J = 14.2 Hz, 2H), 1.90 (t, J = 12.3 Hz, 







piperidinecarboxamide (7). 1H NMR (600 MHz, DMSO-d6) δ 7.73 (d, J = 0.8 Hz, 1H), 7.64 (s, 1H), 7.52 – 
7.47 (m, 2H), 7.43 (d, J = 7.5 Hz, 2H), 7.36 (t, J = 7.8 Hz, 2H), 7.26 (t, J = 7.2 Hz, 2H), 7.21 (d, J = 8.4 Hz, 
2H), 7.14 (d, J = 8.4 Hz, 2H), 7.11 (s, 1H), 4.42 (t, J = 5.1 Hz, 1H), 4.16 (d, J = 13.3 Hz, 2H), 2.95 (t, J = 
7.2 Hz, 2H), 2.54 (d, J = 15.6 Hz, 2H), 1.90 (t, J = 12.6 Hz, 2H), 1.63 – 1.56 (m, 2H), 1.55 – 1.49 (m, 2H). 
Purity: 100 %. Retention Time: 1.79 min. 
4-[5-[(4-Carbamoyl-4-phenylpiperidin-1-yl)carbonyl]-2-(2,4-dichlorophenyl)thien-3-yl]phenyl 
propane-1-sulfonate (8). 1H NMR (600 MHz, DMSO-d6) δ  7.74 (d, J = 2.0 Hz, 1H), 7.68 (s, 1H), 7.51 (dt, 
J = 8.3, 5.2 Hz, 2H), 7.43 (d, J = 7.4 Hz, 2H), 7.36 (t, J = 7.8 Hz, 2H), 7.33 – 7.29 (m, 2H), 7.29 – 7.23 (m, 
4H), 7.11 (s, 1H), 4.16 (d, J = 13.3 Hz, 2H), 3.56 – 3.46 (m, 2H), 2.54 (d, J = 14.0 Hz, 2H), 1.90 (t, J = 
12.2 Hz, 2H), 1.86 – 1.78 (m, 2H), 1.02 (t, J = 7.4 Hz, 3H). Purity: 98 %. Retention Time: 10.62 min. 
1-[[5-(2,4-Dichlorophenyl)-4-[4-[3-(methylthio)propoxy]phenyl]-2-thienyl]carbonyl]-4-phenyl-4-
piperidinecarboxamide (9). 1H NMR (600 MHz, DMSO-d6) δ 7.72 (s, 1H), 7.59 (s, 1H), 7.48 (d, J = 1.0 
Hz, 2H), 7.43 (d, J = 7.4 Hz, 2H), 7.36 (t, J = 7.8 Hz, 2H), 7.25 (t, J = 7.2 Hz, 2H), 7.17 – 7.07 (m, 3H), 
6.85 (d, J = 8.8 Hz, 2H), 4.15 (d, J = 12.2 Hz, 2H), 4.01 (t, J = 6.1 Hz, 2H), 2.59 (t, J = 7.2 Hz, 2H), 2.54 (d, 
J = 13.1 Hz, 2H), 2.05 (s, 3H), 1.97 – 1.91 (m, 2H), 1.91 – 1.83 (m, 2H). Purity: 98 %. Retention Time: 
11.43 min. 
[3H]CP55940 (specific activity 141.2 Ci/mmol) and [35S]GTPγS (specific activity 1250 Ci/mmol) were 
purchased from Perkin Elmer (Waltham, MA). Bicinchoninic acid (BCA) and BCA protein assay 
reagent was obtained from Pierce Chemical Company (Rochford, IL). Rimonabant (SR141716A) was 
from Cayman Chemical Company (Ann Arbor, MI). CHOK1hCB1_bgal and CHOK1hCB2_bgal cells 
(catalog number 93-0959C2 and 93-0706C2) and the Pathhunter® detection kit (catalog number 93-
0001M) were obtained from DiscoveRx (Fremont, CA). All other chemicals were of analytical grade 






Cell culture and membrane preparation. CHOK1hCB1_bgal cells and CHOK1hCB2_bgal cells were 
cultured in Ham’s F12 Nutrient Mixture supplemented with 10% fetal calf serum (FCS), 1 mM 
glutamine, 50 μg/ml penicillin, 50 μg/ml streptomycin, 300 mg/ml hygromycin and 800 μg/ml 
geneticin in a humidified atmosphere at 37°C and 5% CO2. Cells were subcultured twice a week at a 
ratio of 1:10 on 10-cm ø plates by trypsinization. For membrane preparation the cells were 
subcultured 1:10 and transferred to large 15 cm ø plates. Membrane fractions were prepared as 
described before.28 
Radioligand equilibrium displacement assays. Membrane aliquots containing 5 μg (CHOK1hCB1_bgal) 
or 1.5 μg (CHOK1hCB2_bgal) protein were incubated in a total volume of 100 μL assay buffer (50 
mM Tris–HCl, 5 mM MgCl2, 0.1% BSA, pH 7.4) at 30°C for 60 min. Displacement experiments were 
performed using 6 concentrations of competing antagonist in the presence of a final concentration 
of ~3 nM [3H]CP55940 (CHOK1hCB1_bgal) or ~1.5 nM [3H]CP55940 (CHOK1hCB2_bgal). At this 
concentration, total radioligand binding did not exceed 10% of that added to prevent ligand 
depletion. Nonspecific binding (NSB) was determined in the presence of 10 μM rimonabant 
(CHOK1hCB1_bgal) or 10 μM AM630 (CHOK1hCB2_bgal). For the “two-step incubation” assays, 
antagonists were first pre-incubated with membrane aliquots at 30 oC for 3 h, then ~3 nM of 
[3H]CP55940 was added and coincubated for a further 60 min. For all experiments, incubation was 
terminated by rapid filtration performed on 96-well GF/C filter plates (Perkin Elmer, Groningen, the 
Netherlands), presoaked for 30 min with 0.25% PEI (PolyethyleneImine), using a PerkinElmer 
Filtermate-harvester (Perkin Elmer, Groningen, the Netherlands). After drying the filter plate at 50 oC 
for 30 min, the filter-bound radioactivity was determined by scintillation spectrometry using the 
2450 MicroBeta2 Plate Counter (Perkin Elmer, Boston, MA).  
“Wash-out” assays. For washout experiments, 100 μl assay buffer containing either 1% DMSO (as 
blank control for total binding and non-specific binding) or antagonist (9, 6 or rimonabant, final 






CHOK1hCB1_bgal protein. This mixture was brought to a total volume of 300 μL assay buffer, which 
was then incubated at 30 oC for 1 h. Subsequently, the mixture was centrifuged at 13,000 revolutions 
per minute (RPM) at 4 oC for 5 min to allow the removal of the supernatant containing unbound 
ligand. Then the membrane pellet was resuspended in 1 ml assay buffer by vortexing and spun at 
13,000 RPM at 4 oC for 10 min. After three washing cycles, the membrane pellets were resuspended 
in 300 μl assay buffer and placed on ice. Subsequently, 100 μl [3H] CP55940 (~3 nM) was added, 
followed by another incubation at 30 oC for 60 min. Incubation was terminated by rapid filtration 
performed on GF/C filters (Whatman International, Maidstone, UK), presoaked for 30 min with 0.25% 
PEI, using a Brandel harvester (Brandel, Gaithersburg, MD). Filter-bound radioactivity was 
determined by scintillation spectrometry using a Tri-Carb 2900 TR liquid scintillation counter (Perkin 
Elmer, Boston, MA). 
Radioligand association and dissociation assays. Association experiments were performed by 
incubating membrane aliquots containing 5 μg of CHOK1hCB1_bgal membrane in a total volume of 
100 μL of assay buffer at 30 °C with ~3 nM [3H]CP55940. The amount of radioligand bound to the 
receptor was measured at different time intervals during a total incubation of 120 min. Dissociation 
experiments were performed by preincubating membrane aliquots containing 5 μg of protein in a 
total volume of 100 μL of assay buffer for 60 min. After the preincubation, radioligand dissociation 
was initiated by the addition of 5 μl 10 μM unlabeled rimonabant. The amount of radioligand still 
bound to the receptor was measured at various time intervals for a total of 240 min to ensure that 
full dissociation from hCB1 receptor was reached. Incubations were terminated and samples were 
obtained as described under Radioligand equilibrium displacement assays. 
Radioligand competition association assays. The binding kinetics of unlabeled ligands were 
quantified using the competition association assay based on the theoretical framework by Motulsky 
and Mahan.29 The competition association assay was initiated by adding membrane aliquots (5 






30 °C with ~3 nM [3H]CP55940 in the absence or presence of a single concentration of competing 
hCB1 receptor antagonists (1 to 3-fold IC50). Incubations were terminated and samples were obtained 
as described under Radioligand equilibrium displacement assays. The “dual-point” competition 
association assays were designed as described previously,30 where in this case the two time points 
were selected at 30 (t1)  and 240 min (t2). 
[35S]GTPγS binding assays for selected long and short RT antagonists (9, 6, rimonabant). The assays 
were performed by incubating 5 µg of homogenized CHOK1CB1_bgal membranes in a total volume 
of 80 µl assay buffer (50 mM Tris-HCl buffer, 5 mM MgCl2, 150 mM NaCl, 1 mM EDTA, 0.05% BSA and 
1 mM DTT, pH 7.4) supplemented with 1 µM GDP and 5 µg saponin. The assays were performed in a 
96-well plate format, where DMSO stock solutions of the compounds were added using a HP D300 
Digital Dispenser (Tecan, Männedorf, Switserland). The final concentration of organic solvent per 
assay point was ≤0.1%. In all cases, the basal level of [35S]GTPγS binding was measured in untreated 
membrane samples, whereas the maximal level of [35S]GTPγS binding was measured by treatment of 
the membranes with 1 μM CP55940, unless stated otherwise. To determine the IC50 values (inverse 
agonism) of hCB1 receptor antagonists, as well as EC50 values of CP55940 (a reference CB1 receptor 
agonist), the membranes were incubated with increasing concentrations of ligand for 90 minutes at 
30°C. To determine the IC50 (antagonism) values of hCB1 receptor antagonists, membrane 
preparations were pre-incubated for 30 min at 30 oC with a range of concentrations of the 
antagonists prior to the addition of an EC80 concentration of CP55940 (3.8 nM) and 20 µL [35S]GTPγS 
(final concentration ~0.3 nM) after which incubation continued for another 90 min at 30 oC. For the 
insurmountability experiments, membrane preparations were pre-incubated with or without 
antagonists (10-, 30-, 100-fold Ki values) for 60 min at 30 oC, prior to the addition of CP55940 (1 µM 
to 0.1 nM) and 20 µl [35S]GTPγS (final concentration ~0.3 nM), after which incubation continued for 
another 30 min at 30 oC. For the surmountability (control) experiments, antagonists and CP55940 






terminated and samples were obtained as described under Radioligand equilibrium displacement 
assays, by using GF/B filters (Whatman International, Maidstone, UK). 
PathHunter® β-arrestin recruitment assays for selected long and short RT antagonists (9, 6, 
rimonabant). The PathHunter® protein complementation assay (Fremont, CA, USA) was performed 
according to the manufacturer’s protocol.31 CHOK1hCB1_bgal cells were seeded at a density of 5,000 
cells per well of solid black-walled 384-well plates (Catalogue number 3712, Corning, NY, USA) in 20 
μl cell culture medium and incubated overnight in a humidified atmosphere at 37 °C and 5% CO2. 
DMSO stock solutions of the compounds were added using a HP D300 Digital Dispenser (Tecan, 
Männedorf, Switzerland). The final concentration of organic solvent per assay point was ≤0.1 %. The 
basal level of β-arrestin recruitment was measured in untreated cells, and the maximal level of β-
arrestin recruitment was measured by treatment of cells with 1 μM CP55940, unless stated 
otherwise. To determine the IC50 values (inverse agonism) of hCB1 receptor antagonists, as well as 
EC50 values of CP55940, the cells were stimulated with increasing concentrations of ligand and 
incubated for 90 min (standard duration) or 6 h (extended duration) in a humidified atmosphere at 
37 °C and 5 % CO2. To determine the IC50 (inhibition) values of hCB1 receptor antagonists, the cells 
were exposed to increasing concentrations of each antagonist and preincubated for 30 min under 
the same condition, followed by the addition of an EC80 concentration of CP55940 (39 nM), after 
which the cells were incubated for 90 min in a humidified atmosphere at 37 °C and 5% CO2. For the 
insurmountability assays, the cells were pre-incubated with or without antagonists (10-, 30-, 100-
fold Ki values on the hCB1 receptor) for 60 min, after that CP55940 (1 µM to 0.1 nM) was added and 
incubated for another 30 min. For the surmountability (control) experiments, antagonists and 
CP55940 were co-incubated for 30 min at 37 °C and 5% CO2. For all the experiments, β-galactosidase 
enzyme activity was determined by using the PathHunter® detection mixture, according to the kit’s 
protocol.31 Detection mixture (12 μL per well) was added and the plate was incubated for 60 min in 
the dark at room temperature. Chemiluminescence, indicated as relative light units (RLU), was 






Computational studies on selected long and short RT antagonists (9, 6, rimonabant). The 
computational studies were based on the crystal structure of the hCB1 receptor co-crystalized with 
AM6538 (PDB: 5TGZ) 27 and prepared with the protein preparation wizard.32 Since the antagonists 9, 
6 and rimonabant were similar to the co-crystalized AM6538, induced fit docking 33 was used with 
core constraints on the 2,4-dichlorophenyl ring  of  AM6538. To study to the potential differences in 
hydration between ligands, an apo (without ligand present) WaterMap was generated.34, 35 Figures 
were rendered using PyMol,36 for clarity the “cartoon” representation of residues 362 to 375 was 
hidden. 
Data analysis. All experimental data were analyzed using the nonlinear regression curve fitting 
program GraphPad Prism 6.0 (GraphPad Software, Inc., San Diego, CA). From displacement assays, 
IC50 values were obtained by non-linear regression analysis of the displacement curves. The obtained 
IC50 values were converted into Ki values using the Cheng-Prusoff equation to determine the affinity 
of the ligands,37 using a KD value of 0.10 nM (CHOK1hCB1_bgal) and 0.33 nM (CHOK1hCB2_bgal).38 
The observed association rates (kobs) derived from both assays were obtained by fitting association 
data using ‘one phase exponential association’. The dissociation rate constants were obtained by 
fitting dissociation data to a ‘one phase exponential decay’ model. The kobs values were converted 
into association rate constants (kon) using the equation kon = (kobs – koff)/[L], where [L] is the amount 
of radioligand used for the association experiments. The association and dissociation rate constants 
were used to calculate the kinetic KD using the equation KD = koff/kon. The residence time (RT, in min) 
was calculated using the equation RT = 1/(60 * koff), as koff is in s-1. Association and dissociation rate 
constants for unlabeled compounds were calculated by fitting the data into the competition 














































































where k1 is the kon of the radioligand (M-1s-1), k2 is the koff  of the radioligand (s-1), L is the radioligand 
concentration (nM), I is the concentration of the unlabeled competitor (nM), X is the time (s) and Y is 
the specific binding of the radioligand (DPM). The control curve (without competitor) from 
competition association assays generated the k1 value, and the k2 value was obtained in previous 
experiments (data not shown). With that the k3, k4 and Bmax were calculated, where k3 represents the 
kon (M-1s-1) of the unlabeled ligand, k4 stands for the koff (s-1) of the unlabeled ligand and Bmax equals 
the total binding (DPM). All competition association data were globally fitted. [35S]GTPγS binding and 
β-arrestin recruitment curves were analyzed by nonlinear regression using “log (agonist or inhibitor) 
vs response-variable slope” to obtain potency, inhibitory potency or efficacy values of agonists and 
inverse agonists (EC50, IC50 or Emax, respectively). In the (in)surmountability assays, Gaddum/Schild 
EC50 shift equations were used to obtain Schild-slopes and pA2 values; statistical analysis with two-
way ANOVA with Tukey’s post-test was applied. All values obtained are means of at least three 
independent experiments performed in duplicate, unless stated otherwise. 
 
Results 
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pKi  ± SEM 
(Ki in nM )g 
Rimonabant N.A.h  8.8 ± 0.1  (1.8) 0.65 ± 0.03 
(2.3 ± 0.3)  
x 105  
(1.4 ± 0.2)  
x 10-3 





















 9.7 ± 0.03 (0.19) 1.39 (1.41; 1.36) 
(1.5 ± 0.2)  
x 105 
(3.0 ± 0.7) 
x 10-5 
556 ± 124 0.22 ± 0.07 



















OH 9.6 ± 0.1  (0.28) 1.02 ± 0.31 N.D. N.D. N.D. N.D. 8.2 ± 0.3 (9.7) 
6 -SO2CH2CH2CH2OH 7.9 ± 0.01  (14) 0.70 ± 0.17 
(5.2 ± 0.7) 
 x 104 
(8.8 ± 1.7) 
x 10-4 









OH 9.6 ± 0.1  (0.24) 1.32 ± 0.15 
(1.4 ± 0.2)  
x 105 
(4.7 ± 0.7)  
x 10-5 









   9.9 ± 0.03 (0.13) 1.51 ± 0.14 
(2.0 ± 0.2)  
x 105 
(3.8 ± 1.2) 
x 10-5 
435 ± 132 0.19 ±0.05 7.4 ± 0.02 (38) 
9 -OCH2CH2CH2SCH3 8.9 ± 0.1 (1.4) 1.57 ± 0.39 
(8.5 ± 0.8)  
x 104 
(7.5 ± 3.0) 
x 10-6 
2222 ± 888 0.084 ± 0.026 7.3 ± 0.1 (54) 
 
a pKi ± SEM (n = 3), obtained from radioligand binding assays with [3H] CP55940 on recombinant human CB1 
receptors stably expressed on CHO cell membranes. 
b KRI ± SEM (n = 3) or KRI (n1; n2) (n = 2), obtained from dual-point competition association assays with [
3H] 






c kon ± SEM (n = 3), obtained from competition association assays with [3H] CP55940 on recombinant human 
CB1 receptors stably expressed on CHO cell membranes. 
d  koff ± SEM (n = 3), obtained from competition association assays with [3H] CP55940 on recombinant human 
CB1 receptors stably expressed on CHO cell membranes. 
e RT = 1/(60 * koff); RT is expressed in min, whereas koff is expressed in s-1. 
f KD = koff/kon. 
g pKi ± SEM (n = 3), obtained from radioligand binding assays with [3H] CP55940 on recombinant human CB2 
receptors stably expressed on CHO cell membranes. 
h N.A. not applicable. 
i N.D. not determined. 
 
The binding affinities of nine hCB1 receptor antagonists were determined in equilibrium radioligand 
displacement studies. All antagonists were able to concentration-dependently inhibit specific 
[3H]CP55940 binding to the human CB1 receptor and their affinities are listed in Table 1. All 
antagonists had a high binding affinity, ranging from 0.13 nM for antagonist 8 to 14 nM for 
antagonist 6, while the reference antagonist, rimonabant, had an affinity of 1.8 nM. Moreover, we 
determined the affinity of all nine compounds on the hCB2 receptor. From Table 1 it follows that 
they all had higher affinity for the  hCB1 receptor, where approximately 5-292-fold selectivity over 
hCB2 receptors was observed. 
Kinetic Rate Index (KRI) values of hCB1 receptor antagonists.  
Subsequently, these hCB1 receptor antagonists were screened in the so-called “dual-point” 
competition association assay. The specific binding of [3H]CP55940 was measured after 30 and 240 
minutes in the absence and presence of a single concentration of unlabeled hCB1 receptor 
antagonists, which yielded their Kinetic Rate Index (KRI). The KRI values of the hCB1 receptor 
antagonists ranged from 0.65 to 1.57 (Table 1). Antagonists with a KRI value larger than 1.0 were 






[3H]CP55940, and vice versa. Four antagonists (3, 7, 8 and 9) had KRI values ≥ 1.3, whereas two 
antagonists (6 and rimonabant) had KRI values ≤ 0.7 (Table 1). 
Structure−Affinity Relationships (SAR) and Structure−Kinetics Relationships (SKR) of hCB1 receptor 
antagonists.  
The obtained affinities (Ki values) and kinetic profiles (kon, koff values and RTs) permitted us to derive 
SAR and SKR for this series of antagonists. Different sidechains were examined as the R group (Table 
1). On antagonist 1 the R1 substituent was a 2-hydroxyethoxy, which resulted in a high affinity of 
0.53 nM and a KRI-value of 0.81. When the side chain of antagonist 1 was replaced by a similar 2-
mercaptoethylamine (2), its affinity was unchanged and its KRI value was substantially increased to 
1.30. When the terminal amine of 2 was extended by methanesulfonyl (-SO2CH3) as in antagonist 3, 
it yielded an approximately 3-fold increased affinity (0.53 nM vs 0.19 nM) and slightly higher KRI 
value (1.39). The slightly less polar side chain of antagonist 4 did not improve affinity in comparison 
to 2  but slightly reduced  the KRI value (1.08). Next, a 3-mercapto-1-propanol side chain was 
introduced (5), which did not affect the affinity, but the compound’s KRI value was close to unity 
(1.02). When the thio-ether of 5 was oxidized to sulfonyl (6), the affinity was decreased by 50-fold to 
14 nM and the KRI value reduced to 0.70. When the propyl side chain of antagonist 5 was extended 
to a butyl (7), the affinity remained the same (0.28 nM vs. 0.24 nM), but its KRI value increased to 
1.32. Lastly, antagonists 8 and 9 were obtained by slight variations of the linear side chains from 
antagonists 6 and 7, respectively, which resulted in pronounced effects on both affinity and kinetics. 
From the 5-mercapto-1-pentanol side chain (7) to 3-(methylthio)propan-1-ol (9), the affinity dropped 
by approximately 6-fold (0.24 nM vs. 1.4 nM), while the KRI value increased from 1.32 to the highest 
of the series (1.57). From sulfonic 1-propanol (6) to alkyl sulfate (8), not only the affinity improved 
from 14 nM to 0.13 nM (107-fold), but also its KRI value increased from the lowest value of the 
series (0.70) to the second highest value (1.51, Table 1). 
















Figure 1. Competition association experiments with [3H]CP55940 binding to recombinant hCB1 receptors stably 
expressed on CHO cell membranes (30 °C) in the absence or presence of unlabeled long-residence-time 
antagonist 9 (A), short-residence-time antagonist 6 (A), or reference antagonist rimonabant (B). 
Representative graphs are shown from one experiment performed in duplicate. Note, t1,  t2 are indicated, 
which were the two time points used in KRI determinations. Data are summarized in Table 1. 
 
Next, the kinetic binding parameters of six antagonists that had either low or high KRI values (3, 6, 7, 
8, 9 and rimonabant) were determined using the competition association assay with [3H]CP55940. 
Association rate constants varied by merely 4.5-fold, ranging from (5.2 ± 0.7) x 104 M-1s-1 for 
compound 6 to (2.3 ± 0.3) x 105 M-1s-1 for rimonabant (Table 1). There was a 180-fold difference in 
dissociation rate constants, in line with the divergent KRI values. Rimonabant had the fastest 
dissociation rate constant of (1.4 ± 0.2) x 10-3 s-1 and thus the shortest RT of 14 min, while compound 
9 had the slowest dissociation rate constant of (7.5 ± 3.0) x 10-6 s-1 and thus the longest RT of 2222 
min (Table 1). Of note, the long RT antagonist 9 (Figure 1A) displayed a typical “overshoot” in the 






antagonists, both antagonist 6 (Figure 1A) and rimonabant (Figure 1B), presented gradually 
ascending curves. 
 
Figure 2. The correlations between the negative logarithm of the hCB1 receptor antagonists’ dissociation rate 
constants (pkoff) and their Kinetic Rate Index (KRI) (A), the CB1 receptor antagonists’ affinity (pKi) and their 
“kinetic KD” (pKD) (B), association rate constants (log kon) (C) and dissociation rate constants (pkoff) (D). The data 
point of the longest RT antagonist 9 is highlighted in red. Data used in these plots are detailed in Table 1. The 
central line corresponds to the linear regression of the data, the dotted lines represent the 95% confidence 
intervals for the regression. 
 
Notably, a good correlation between the negative logarithm of the antagonist’s dissociation rate 
constants and their KRI values derived from the kinetic assays was obtained (Figure 2A), which 
confirmed that a compound’s KRI value is a good predictor for its dissociation rate constant. A 
significant correlation was also observed between the antagonist affinities (pKi values) determined in 






experiments (Figure 2B). In contrast, the kinetic parameters (log kon or pkoff values) of the hCB1R 
antagonists did not show a significant correlation with their affinities (Figure 2C and 2D).
Binding kinetics of selected hCB1 receptor antagonists using (pseudo-)equilibrium binding assays.  
As another means to investigate differences in compound binding kinetics, “two-step incubation” 
equilibrium displacement experiments were performed for the long (9) and short RT antagonists (6 
and rimonabant), as shown in Figure 3A-C. When the displacement curves of the longest RT 
antagonist 9 were compared with the control and the two-step incubation, a significant one log-unit 
shift was observed (Figure 3A) resulting in a pKi of 8.9 ± 0.1 to 9.8 ± 0.1, respectively. In contrast, no 
such affinity-shift was observed for either short RT antagonist (Figure 3B and C, Table 2), indicative 
of quick equilibration kinetics.  
Table 2. Affinities of selected long (9) and short (6) RT hCB1 receptor antagonists determined by the “two-step 
incubation” assays, using rimonabant as a reference.  
a pKi ± SEM (n = 3), obtained from radioligand binding assays with [3H] CP55940 on recombinant human CB1 
receptors stably expressed on CHO cell membranes. 
b pKi ± SEM (n = 3), obtained from radioligand binding assays with [3H] CP55940 on recombinant human CB1 
receptors stably expressed on CHO cell membranes (taken from Table 1 for comparison). 
c Affinity shift = pKi (two-step incubation) - pKi (standard assay). 
Student’s t-test was applied for the comparison of “affinity” obtained from “two-step” incubation by standard 
affinity, * p < 0.05, ns for not significant. 
Antagonists “Two-step” incubationa 
(pKi ± SEM) 
Standard assay 
(Control)b 
(pKi ± SEM) 
“Affinity Shift” c 
(log unit) 
9 9.8 ± 0.1 * 8.9 ± 0.1  + 0.9 
6 7.9 ± 0.04  ns 7.9 ± 0.01   0 







Figure 3. The “two-step incubation” experiments with [3H]CP55940 binding to recombinant hCB1 receptors 
stably expressed on CHO cell membranes (30 °C) in the absence or presence of unlabeled long-residence-time 
antagonist 9 (A), short-residence-time antagonist 6 (B), or reference antagonist rimonabant (C). Combined 
graphs are shown from three experiments performed in duplicate. The “wash-out” experiment with 
[3H]CP55940 binding to recombinant hCB1 receptors stably expressed on CHO cell membranes (30 °C) in the 
absence (UTB and TB) or presence of 1 µM of the longest RT antagonist 9 , the short RT antagonist 6 or 
reference antagonist rimonabant (D). The percentage of the specific radioligand binding relative to the 
unwashed blank control (UTB, 100%) is 83 ± 6.2 % for washed blank control (TB), 3.8 ± 4.1   % for antagonist 9 , 
59 ± 2.2 % for antagonist 6 and 44 ± 4.4 % for rimonabant. Data are mean values ± SEM of three independent 






The observed affinity-shift of the long RT antagonist 9 was further investigated in a “wash-out” 
experiment. As shown in Figure 3D, once the long RT antagonist 9 saturated hCB1 receptors during 
pre-incubation, they could not be recovered by washing as indicated by a lack of [3H]CP55940 
binding, while for both short RT antagonists (6 and rimonabant) washing of pre-saturated hCB1 
receptors did result in significant restoration of [3H]CP55940 binding. Taken together, these two 
(pseudo-)equilibrium experiments yielded a qualitative indication that antagonist 9 had significantly 
slower dissociation kinetics from hCB1 receptors than rimonabant and antagonist 6. This was in 
agreement with the quantitative results obtained from the (dual-point) competition association 
experiments. 
Computational studies on selected long and short RT antagonists. 
 
Figure 4.  Docking of rimonabant (A), antagonist 9 (B) and antagonist 6 (C) into the binding site of the crystal 
structure of the hCB1 receptor (PDB: 5TGZ)27 co-crystalized with AM6538 (not shown), showing the overlay of 
numbered consecutively hydration sites of the apo-WaterMap. Hydration sites shown as red spheres represent 
“unstable” water molecules (>5 kcal/mol), whereas white spheres symbolize “stable” water molecules. For the 
unfavorable hydration centers (“unstable” water molecules) the ΔG is reported (A). Rimonabant is represented 
by black sticks, and residues within 5 Å of rimonabant are visualized as blue sticks. The protein is represented 
by blue ribbons (A). Antagonist 9 is represented by black sticks, and residues within 5 Å of 9 are visualized as 
green sticks. The protein is represented by green ribbons. The displaced unstable water molecule was covered 
with a cross (B). Antagonist 6 is represented by black sticks, and residues within 5 Å of 6 are visualized as 
yellow sticks. The displaced unstable water molecule was covered with a cross (C). The protein is represented 
by yellow ribbons.  Ligand and residues atoms color code: yellow = sulfur, red = oxygen, blue = nitrogen, white 
= hydrogen. 
 
In addition, to study differences between RT and binding modes, rimonabant, antagonist 6 and 9 






cavity, formed by W2795x43, I2805x44 and L3606x52, could be occupied by unfavorable water molecules 
(W11, W16 and W72 in Figure 4). W11 (ΔG = 8.69 kcal/mol) was one of the most unfavorable 
hydration centers in this WaterMap. This hydration center is neither displaced by rimonabant nor by 
the short RT antagonist 6 (Figure 4A and C). Interestingly, following from the proposed binding pose 
of the long RT antagonist 9, this hydration center can be displaced by this antagonist (Figure 4B) as 
the pocket formed by the aforementioned residues is being opened. 
Functional characterization of long and short RT antagonists. 
Subsequently, the short RT antagonists (6 and rimonabant) and long RT antagonist (9) were 
functionally characterized in hCB1 receptor agonist-induced [35S]GTPγS binding and G protein-
independent (β-arrestin recruitment) assays. Firstly, their antagonistic behavior was revealed on 
both G protein-dependent and –independent signaling (Table 3), as all antagonists caused a dose-
dependent decrease of agonist-induced signaling. The long RT antagonist 9 had the highest 
antagonistic potency in both [35S]GTPγS binding and β-arrestin recruitment assays (3.0 ± 0.3 nM and 
30 ± 2.7 nM, respectively), while potencies of the short RT antagonist 6 were the lowest (589 ± 96 
nM and 8261 ± 179 nM, respectively). Interestingly, the antagonist potencies were significantly 
lower in β-arrestin recruitment compared to [35S]GTPγS binding assays, where the potencies 
obtained from the latter were in closer agreement to the affinity values. Secondly, their mode of 
antagonism, i.e. surmountable or insurmountable, was investigated in both [35S]GTPγS binding and 
β-arrestin recruitment assays. Pretreatment of CHOK1hCB1 receptor membranes ([35S]GTPγS binding, 
Figure 5A) or cells (β-arrestin recruitment, Figure 6A) with increasing concentrations of the long RT 
antagonist 9 before stimulation by the CB1 receptor agonist CP55940 induced insurmountable 
antagonism (Figure 5A). In other words, the CP55940 concentration-effect curves were shifted to 
the right with a concomitant decrease in the maximal response. Conversely, the short RT antagonists 






without affecting its maximum effect ([35S]GTPγS binding, Figure 5C, E; and β-arrestin recruitment, 
Figure 6C, E). 
Table 3. Functional effects of selected long (9) and short (6) RT hCB1 receptor antagonists 
determined by [35S]GTPγS binding and β-arrestin recruitment assays, using rimonabant as a 
reference. 
 














 Preincubation Coincubation  
Antagonist 
pIC50 ± SEM 







pIC50 ± SEM 
(IC50 in nM) c 
9 
8.5 ± 0.0 
(3.0) 
N.A.d N.A. 8.9 ± 0.0 2.4 ± 0.2 
8.6 ± 0.1 
(2.7)  
6 
6.3 ± 0.1 
(589) 
8.5 ± 0.5 1.0 ± 0.2 9.1 ± 0.2 1.1 ± 0.0 
7.1 ± 0.1 
(84) 
Rimonabant 
8.0 ± 0.1 
(11) 
10 ± 0.2 1.3 ± 0.1 10 ± 0.3 1.2 ± 0.2 






7.5 ± 0.0 
(30) 
N.A. N.A. 8.1 ± 0.1 1.8 ± 0.0 
6.8 ± 0.2 
(165) 
6 
5.1 ± 0.0 
(8261) 
6.4 ± 0.0 1.2 ± 0.2 7.7 ± 0.1 0.7 ± 0.2 
6.8 ± 0.2 
(179) 
Rimonabant 
6.8 ± 0.1 
(184) 
8.0 ± 0.2 1.3 ± 0.3 8.2 ± 0.4 1.2 ± 0.3 
6.3 ± 0.2 
(627) 
  
a pIC50 ± SEM, obtained from either [35S]GTPγS binding (n = 4) or β-arrestin recruitment (n = 3) assays on 
recombinant human CB1 receptors stably expressed on CHO cell membranes or intact cell line. 
b Obtained from Schild analyses,  [35S]GTPγS binding assays (n = 3) or β-arrestin recruitment assays (n=3, 
except for pre-incubation assays with Rimonabant n = 5).  
c pIC50 ± SEM, obtained from either [35S]GTPγS binding (n = 3) or β-arrestin recruitment (n = 3) assays on 
recombinant human CB1 receptors stably expressed on CHO cell membranes or intact cell line. 










Figure 5. CP55940-stimulated [35S]GTPγS binding to recombinant hCB1 receptors stably expressed on CHO cell 
membranes (30 °C) in the absence or presence of long-residence-time antagonist 9 (A and B), short-residence-
time antagonist 6 (C and D) and reference antagonist rimonabant (E and F). Antagonist 9 (A), 6 (C) or 
rimonabant (E) were either incubated for 60 min prior to the challenge with the hCB1 receptor agonist 
CP55940 or coincubated with CP55940 (antagonist 9, B, antagonist 6, D or rimonabant, F). The agonist curves 
were generated in the presence of increasing concentrations of antagonist, namely 10-, 30-, 100-fold their 
respective Ki values. The shift in agonist EC50 was determined to perform Schild analyses. Two-way ANOVA with 
Tukey’s post-test was applied for the comparison of Emax by agonist control, **** p < 0.0001, ns for not 
significant. Data were normalized according to the maximal response (100%) produced by CP55940. Combined 













Figure 6. CP55940-stimulated β-arrestin recruitment to recombinant hCB1 receptors stably expressed on CHO 
cells (37 °C and 5 % CO2) in the absence or presence of long-residence-time antagonist 9 (A and B), short-
residence-time antagonist 6 (C and D) and reference antagonist rimonabant (E and F). Antagonist 9 (A), 6 (C) or 
rimonabant (E) were either incubated for 60 min prior to the challenge of the hCB1 receptor agonist CP55940 
or were coincubated with CP55940 (antagonist 9, B, antagonist 6, D or rimonabant, F). The agonist curves were 
generated in the presence of increasing concentrations of antagonist, namely 10-, 30-, 100-fold their 
respective Ki values. The shift in agonist EC50 was determined to perform Schild analyses. Two-way ANOVA with 
Tukey’s post-test was applied for the comparison of Emax by agonist control, **** p < 0.0001, ns for not 
significant. Data were normalized according to the maximal response (100%) produced by CP55940. Combined 
graphs are shown from at least three experiments performed in duplicate (n=3, except for pre-incubation 
assays with Rimonabant n=5). See Table 3 for pA2 and Schild-slope values. 
Under such experimental set-up, the obtained Schild-slopes of both 6 and rimonabant were close to 
unity in either [35S]GTPγS binding or β-arrestin recruitment assays (Table 3). Moreover, from 






0.01 from Table 2), while for rimonabant these were more divergent (10 ± 0.2 from Table 3 vs 8.8 ± 
0.1 from Table 2). In addition, pA2 values derived from β-arrestin recruitment assays for 6 and 
rimonabant  were less comparable with the corresponding pKi values. Next, we performed co-
incubation experiments with these antagonists in the presence of CP55940 ([35S]GTPγS binding, 
Figure 5B, D, F; and β-arrestin recruitment, Figure 6B, D, F). In this experimental set-up, all 
antagonists produced a rightward shift in the CP55940 concentration-effect curves without a 
suppression of the maximal response. Notably, the Schild-slopes of the short RT antagonists (6 and 
rimonabant) were close to unity in both [35S]GTPγS binding (1.1 ± 0.0 for 6, 1.2 ± 0.2 for rimonabant, 
Table 3) and β-arrestin recruitment assays (0.7 ± 0.2 for 6, 1.2 ± 0.3 for rimonabant, Table 3). In 
contrast, for the long RT antagonist 9 the Schild-slope derived from both assays was well above unity 
(Table 3). 
Inverse agonism of the selected CB1 antagonists.  
Finally, it became clear from the [35S]GTPγS binding assays that the antagonists behaved as inverse 
agonists (Figure 7A). It follows that all antagonists caused a dose-dependent decrease of basal 
[35S]GTPγS binding. The short RT antagonist 6 was 21-fold less potent as an inverse agonist than short 
RT rimonabant, while the latter was actually equally potent to the long RT antagonist 9 (Table 3). 
Furthermore, we decided to investigate the presence of inverse agonism in the β-arrestin 
recruitment assay. After adjusting the standard protocol (i.e. extending the incubation time from 90 
min to 6 h) inverse agonism was observed for all antagonists (Figure 7B and Table 3), as in the 
[35S]GTPγS binding assays. Rimonabant was the least potent inverse agonist in the β-arrestin 
recruitment assay (IC50 = 627 nM), while the short RT and long RT antagonist had a similar potency (6: 
IC50 = 179 nM and 9: IC50 = 165 nM, respectively). Overall, the inverse agonistic potencies in β-









Figure 7. Characterization of inverse agonism for long RT antagonist 9, short RT antagonist 6 and reference 
antagonist rimonabant. [35S]GTPγS binding to recombinant hCB1 receptors stably expressed on CHO cell 
membranes (A) or β-arrestin recruitment to recombinant hCB1 receptors stably expressed on CHO cells (B) with 
ligand concentrations ranging from 0.1 nM to 10 µM. Data were normalized according to the maximal response 
(100%) produced by CP55940. Combined graphs are shown from three experiments performed in duplicate in 




Ligand optimization based on Structure−Kinetics Relationships (SKR).  
Receptor binding kinetics is increasingly being recognized as an important parameter to understand a 
drug’s mechanism of action and ultimately improve its in vivo efficacy and safety. Here we focused 
on the substitutions at the thiophene’s 3-position (R group) in a series of rimonabant related 
antagonists (Table 1). Applying equilibrium and kinetic radioligand binding assays, we assayed the 
binding interactions of nine of such hCB1 receptor antagonists together with the reference 
compound rimonabant. As a result, diverse affinity and KRI values were determined and both long 
and short RT antagonists were identified. Interestingly, the recent hCB1 receptor crystal structures 
indicate that the aliphatic R-substitutions fit in the lipophilic “long and narrow channel” of the hCB1 






for the improvement of binding interactions at the hCB1 receptor. Specifically from antagonists 6 (RT 
= 19 min) and 9 (RT = 2222 min) it seems that a longer (6- vs 5-atom) tail with less polarity 
contributes significantly to slow receptor dissociation kinetics and better affinity (1.4 nM of 9 vs 14 
nM of 6).Interestingly, the more than 100-fold gain in residence time is not fully reflected in the 
increase in affinity. This may in part be due to the entropic cost of the aliphatic chain when it has to 
adapt to the steric requirements of the hydrophobic channel of the binding site, resulting in a slower 
association rate.40 Taken together, this limited SKR study proves that kinetic profiles should and can 
be taken into account during the lead optimization process in drug discovery.  
The computational insights of the binding modes.  
Using the crystal structure of the hCB1-AM6538 complex (PDB: 5TGZ),27 we performed WaterMap 
calculations to try and understand the differences in residence times observed for the hCB1 receptor 
antagonists studied, with the hypothesis that unfavorable hydration might provide an explanation.34, 
35, 41, 42 We focused on antagonist 9 and 6, and in particular the substitutions at the thiophene’s 3-
position (R- group) as this was the only structural difference (Figure 4). When the antagonist with the 
shorter and more hydrophilic side chain (6, -SO2CH2CH2CH2OH, short RT) was docked into the apo 
WaterMap, it was able to displace water molecules found in positions W16 and W72; while unstable 
water molecule W11 was still around its side chain (Figure 4C). We propose that the interaction with 
T1973x33 forces 6 in an orientation where its sulfonyl further stabilized water molecules found in 
position W11. By contrast, antagonist 9 was able to displace all these water molecules (W11, W16 
and W72) with its longer and more hydrophobic side chain, a process which might raise the energy of 
the transition state for dissociation (Figure 4B). We postulate that this destabilization of the 
transition state may contribute to the prolonged RT observed with this compound. In contrast, 
rimonabant cannot displace those unhappy water similarly to antagonist 6, due to its lack of the 
linear side chain reaching those energetically unfavorable or unhappy waters (Figure 4A). 






A so-called dual-point competition association assay for hCB1 receptor was applied for the “kinetic 
screening campaign” to increase throughput in comparison to the traditional competition association 
experiments as shown before.30 A good correlation between the antagonists’ KRI values and 
dissociation rate constants (koff, k4) corroborated the robustness of this assay (Figure 2A). In contrast, 
no significant correlations were found between the kinetic binding parameters, kon (k3) or koff (k4), and 
affinity values of these antagonists (Figure 2 C, D). Besides, the equilibrium Ki and kinetic KD values 
were significantly correlated (Figure 2B). Noteworthy, the extraordinary long RT antagonist 9 (Figure 
3, highlighted in red color) was observed as a significant “outlier” in the correlation plots involving 
the affinity values obtained from equilibrium assays (Figure 2B, D). This clearly indicates that 
equilibrium was not reached for this antagonist during the radioligand displacement assay where a 
relatively short incubation time is used. In general, equilibrium affinities of long RT antagonists might 
often be underestimated and this potentially results in ignoring such interesting compounds for 
further evaluation.   
Subsequently, we designed a “two-step incubation” experiment for further investigation of the 
affinity-shift of short and long RT antagonists. The displacement curve of the long RT antagonists 9 
was shifted leftward about 10-fold, compared to a standard affinity determination, which was then 
similar to its calculated kinetic KD (Table 1 and 2). In contrast, the affinity of short RT antagonists (6 
and rimonabant) determined in the “two-step incubation” and standard experiments showed no 
such shift (Table 2). These results once more indicate that during a longer period of incubation in the 
absence of a competing ligand a larger fraction of antagonist 9 forms a tight and slowly dissociating 
ligand-receptor complex. During preincubation the antagonist 9 enjoys a binding “monopoly” to hCB1 
receptors and the occupied hCB1 receptors are pseudo-irreversibly blocked, as antagonist 9 (with its 
extremely long RT) is unlikely to dissociate again. Such a potential two-step (or multi-step) 
bimolecular binding has also been reported for CCR5 antagonists, where a shift in the apparent 
affinity was also reported after pre-incubation.43  Moreover, the pseudo-irreversible binding of long 






was washing-resistant, while short RT antagonists 6 and rimonabant were washed away more easily 
(Figure 3D). A washing-resistant effect has been reported more often for covalently binding ligands 
to various targets.44-46 While the current study was mostly focused on developing methodologies for 
investigating whether the addition of SKR would result in a different triaging of CB1 antagonists, we 
are aware that the translation to native tissues should be made. For example, it is known that CB1 
receptors are the most highly expressed receptors in the brain, where they have been shown to form 
functional heteromers with other GPCR, such as adenosine A2A receptors47 and beta2 adrenergic 
receptors.48 Although this has yet to be investigated for CB1 receptors, a ligand’s binding kinetics is 
likely to be very different on a monomer than a (hetero)dimer as was recently shown for 
homodimers of adenosine A3 receptors.49, 50   
The functional effects of long or short RT human CB1 receptor antagonists.  
Diverging dissociation rate constants of antagonists have been linked to differentiation in functional 
effects (i.e. surmountable vs insurmountable antagonism) and concomitant physiological relevance, 
even before the concept of kinetic studies was gaining acceptance.51, 52 In our studies, the differences 
in binding interactions between long and short RT antagonists (9 vs 6 and rimonabant) prompted us 
to further investigate potential differences in functional effects. In both [35S]GTPγS binding and β-
arrestin recruitment assays, long RT antagonist 9 generated an insurmountable effect when 
preincubated before stimulation with the agonist CP55940 (Figure 5A and 6A). Importantly, when 
the preincubation was excluded, its effects became surmountable proving that (Figure 5B and 6B) 
the long RT antagonist 9 prevents the agonist CP55940 to activate receptors by competitive pseudo-
irreversible binding to hCB1 receptors, as opposed to allosterically inhibiting CP55940 activation.53, 54 
Since the short RT antagonists (6 and rimonabant) do not occupy hCB1 receptors for that long, 
CP55940 was able to activate hCB1 receptors in the presence of such antagonists under all 
experimental conditions, which resulted in surmountable antagonism (Figure 5C-F and 6C-F). 






Here for the short RT antagonists (6 and rimonabant) Schild-slopes close-to-unity were obtained, 
which indicated a one-to-one competition with the agonist CP55940 while equilibrium was reached. 
Interestingly, the Schild-slopes determined in the coincubation experiments of long RT antagonist 9 
were above 1, i.e. the EC50 shifts were greater than predicted by such analysis. This effect can again 
be explained by its pseudo-irreversible binding to the hCB1 receptor, where equilibrium was not 
reached at the chosen incubation times. Of note, in native systems (i.e. under non-equilibrium 
conditions) endocannabinoid exposure is high, but short due to metabolic degradation of the 
agonist.56, 57 However, long and short RT antagonists will still differentiate under these circumstances, 
as an insurmountable antagonist (i.e. with long RT) can cope with the high local concentrations of the 
endogenous agonist , while the short RT antagonist cannot. One last note is on the applicability 
domain of a Schild-plot analysis. Strictly speaking this analysis was derived for systems without 
constitutive activity, while its use for other systems, i.e. displaying constitutive activity like in our 
study, has been (re)considered.58 From Kenakin’s reasoning it appears that a small overestimation of 
the potency of inverse agonists is possible. 
Secondly, the selected long or short RT hCB1 receptor antagonists (9, 6 and rimonabant59) behaved as 
inverse agonists in the standard [35S]GTPγS binding assays (Table 3, Figure 7A). In the β-arrestin 
recruitment assay inverse agonism was only observed when the assay-kit manufacturer’s protocol 
was adjusted to contain a longer incubation time (i.e. 6-hour instead of 90 min) (Figure 7B).31 Of note, 
the cells tolerated this increased incubation time, since the potency of the reference agonist 
CP55940 did not change (data not shown). The inverse agonism at cannabinoid receptors (i.e. CB1 
and CB2) in the β-arrestin recruitment assay has been seldom reported.60 Importantly, although we 
have used a cell line that heterologously (and abundantly) expresses CB1 receptors which might raise 
the question that the level of constitutive activity is an artefact, it is known that this receptor is the 
highest expressed GPCR in the brain.61, 62 Moreover, the scientific community, including 






cause of adverse side effects seen with CB1 antagonists and is therefore in pursuit of ‘neutral’ 
antagonists.63, 64 Noteworthy, there was no correlation between inverse agonism and RTs.  
Lastly, the CB1 receptor is a class A GPCR and it has been reported that its down-stream signaling 
pathways involve both G protein-coupling and β-arrestin recruitment.65 When comparing the 
functional results from [35S]GTPγS binding and β-arrestin recruitment, we learned the antagonists 
were more potent in the former. Recently, it was reported that hCB1 receptor activation can trigger 3 
“waves” of signaling, G protein-coupling as the first, β-arrestin recruitment as the second, and a 
combination of the two as the last.66 The possible correlation between binding kinetics and signaling 
effects on the CB1 receptor merits further investigation.   
In conclusion, we have evaluated the binding kinetics of nine 1-(4,5-diarylthiophene-2-carbonyl)-4-
phenylpiperidine-4-carboxamide derivatives at the hCB1 receptor, and described structure-kinetics 
relationships (SKR) defined by their Kinetic Rate Index (KRI) values and dissociation rate constants. 
The antagonist 9 was found to be a pseudo-irreversible hCB1 receptor antagonist with a residence 
time of 2222 min at 30 oC. Moreover, the difference in receptor-ligand interaction (i.e. long vs short 
RT) was correlated with the mode of functional antagonism (insurmountable vs surmountable), as 
determined for both G protein-dependent and –independent signaling pathways. Following from 
docking studies and WaterMap calculations, we speculate that displacement of unfavorable water 
molecules may provide a plausible explanation for antagonist 9’s slow dissociation, or even pseudo-
irreversible binding at the hCB1 receptor. These findings could be highly valuable for the further 
development of potent and safe CB1 receptor antagonists for metabolic disorders such as obesity. 
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About this chapter 
We expanded on a series of pyrido[2,1-f]purine-2,4-dione derivatives as human adenosine A3 
receptor (hA3R) antagonists to determine their kinetic profiles and affinities. Many compounds 
showed high affinities and a diverse range of kinetic profiles. We found hA3R antagonists with very 
short residence time (RT) at the receptor (2.2 min for 5) and much longer RTs (e.g. 376 min for 27, or 
391 min for 31). Two representative antagonists (5 and 27) were tested in [35S]GTPγS binding assays, 
and their RTs appeared correlated to their (in)surmountable antagonism. From a kon-koff-KD kinetic 
map we divided the antagonists into three subgroups, providing a possible direction for the further 
development of hA3R antagonists. Additionally, we performed a computational modelling study that 
sheds light on the crucial receptor interactions dictating the compounds’ binding kinetics. Knowledge 
of target binding kinetics appears useful for developing and triaging new hA3R antagonists in the 








The adenosine A3 receptor is the youngest member discovered in the family of adenosine receptors,1 
all of which belong to class A G-protein coupled receptors (GPCR) and fall into four distinct subtypes 
(A1, A2A, A2B and A3). Although all subtypes are activated by the endogenous ligand adenosine, these 
purinergic receptors differ from each other in their distribution and to which G protein they are 
coupled. Following agonist activation, the A1 and A3 adenosine receptors cause a decrease in cAMP 
levels as they primarily couple to Gi proteins. The A2A and A2B adenosine receptors on the other hand, 
are primarily linked to Gs proteins and this leads to increased levels of cAMP upon receptor 
activation.2  
Although the pharmacological characterization of adenosine receptors has been well documented,3 
the human adenosine A3 receptor (hA3R) is less well characterized because of its “dichotomy” in 
different therapeutic applications.4 Moreover, certain ligands have been described as cytoprotective 
or cytotoxic merely depending on the concentration employed, highlighting the difficulties that arise 
when characterizing novel hA3R compounds.5 Nevertheless, there is no doubt that the hA3R has 
therapeutic potential in clinical indications (i.e. cardiovascular diseases,6, 7 cancer,7, 8 and respiratory 
diseases7, 9-11), due to its overexpression on cancer and inflammatory cells.3, 12-15    
Traditional drug screening methods, and those employed in previous hA3R drug discovery attempts, 
revolve around the use of a ligand’s affinity as the selection criterion for further optimization in a so-
called structure-affinity relationships (SAR) approach. In recent years, however, there has been 
emerging the realization that selecting ligands based on their affinity, an equilibrium parameter, does 
not necessarily predict in vivo efficacy. This is due to the dynamic conditions in vivo, that often are in 
contrast to the equilibrium conditions applied in in vitro assays.16 In fact a ligand’s kinetic properties 
may provide a better indication of how a ligand will perform in vivo.17 Specifically, the parameter of 






lifetime of the ligand-receptor complex and can be calculated as the reciprocal of the ligand’s 
dissociation constant (RT=1/koff).18, 19  





a pKi ± SEM (n ≥ 3, average Ki value in nM), obtained at 25 oC from radioligand binding assays with [3H]PSB-11 
([3H]34) on human Adenosine A3 receptors stably expressed on CHO cell membranes. 
b KRI (n = 2, individual estimates in parentheses), obtained at 10 oC from dual-point competition association 
assays with [3H]34 on human Adenosine A3 receptors stably expressed on CHO cell membranes. 
c kon ± SEM (n ≥ 3), obtained at 10 oC from competition association assays with [3H]34 on human Adenosine A3 
receptors stably expressed on CHO cell membranes. 
d koff ± SEM (n ≥ 3), obtained at 10 oC from competition association assays with [3H]34 on human Adenosine A3 
receptors stably expressed on CHO cell membranes. 
e RT (min) = 1/(60*koff). 
 
While the binding kinetics of some (labeled) hA3R agonists have been studied,20 this parameter has 
not been part of medicinal chemistry efforts for antagonists, i.e. yielding structure-kinetics 
relationships (SKR), next to SAR.21 Therefore, in order to provide the first SKR analysis on the hA3R, a 
highly potent and selective hA3R antagonist scaffold was chosen. The pyrido[2,1-f]purine-2,4-dione 
template has been previously characterized with respect to affinity alone. In a Topliss approach22 we 
had synthesized and characterized a number of highly potent and selective hA3R antagonists.23, 24 
One of the reference antagonists (1) with good affinity and selectivity over other adenosine 
receptors is represented in Table 1. Using this compound as the starting point, we further selected 
and synthesized compounds to add to the library of pyrido[2,1-f]purine-2,4-dione derivatives. Using 
Compound 
pKi a ± SEM 
(mean Ki in nM) 
KRIb kon c (M-1 s-1) koff d  (s-1) RT e (min) 






radioligand displacement assays and competition association assays, we obtained affinity (Ki) and 
kinetic parameters (kon, koff, and RTs). This allowed a full SKR study alongside a more traditional SAR 
analysis. The findings provide information on the structural requirements for a favorable kinetic 
profile at the hA3R and consequently may improve the in vitro to in vivo translation for hA3R 
antagonists.   
Results and discussion 
Chemistry. 
 The synthesis approach shown in Scheme 1 was adapted from Priego et al.23, 24 Starting from the 
commercially available materials benzylurea (3), ethyl cyanoacetate and sodium methoxide 1-benzyl-
6-amino-uracil (4) was synthesized in a 88% yield.25 In situ dibromination of uracil 4 at the C5 position 
by N-bromosuccinimide, followed by cyclisation with 4-methoxypyridine gave the pyrido[2,1-
f]purine-2,4-dione (5) in a one pot reaction. Final compounds 1, 2 and 6-22 (as depicted in Table 1) 
were obtained, with yields varying in the range of 3-86%, by alkylating the N3 position of 5 using a 
variety of alkyl, alkenyl and alkynyl bromides in acetonitrile and 1,8-diazabicyclo[5.4.0]undec-7-ene 
(DBU) as a base. Secondly, to be able to diversify on the N1 (R2) position, building block 23 had to be 
obtained. Full conversion of methylcyclopropyl compound 2 into the desired debenzylated 23 was 
realized by multiple additions of ammonium formate and Pd(OH)2 at 80 oC in ethanol overnight. Due 
to poor solubility 23 was extracted with hot DMF and Pd(OH)2 was removed by filtration, resulting in 
a quantitative yield. Finally various N1 substituted benzyl (24-32) and phenethyl (33) derivatives 
(Scheme 1) were made starting from the respective benzyl- or phenethyl bromides in DMF with 
K2CO3 used as base. 
Biological Evaluation.  
All binding affinities of the pyrido[2,1-f]purine-2,4-dione derivatives were determined at 25 oC in a 2 






[3H]8-Ethyl-4-methyl-2-phenyl-(8R)-4,5,7,8-tetrahydro-1H- imidazo[2,1-i]-purin-5-one26 ([3H]PSB-11, 
34) binding to the human adenosine A3 receptor and their affinities are listed in Tables 1, 2 and 3. All 
compounds had (sub)nanomolar binding affinities ranging from 0.38 nM for compound 27 to 108 nM 
for compound 5.  
Scheme 1. Synthesis of 1,3-disubstituted-1H,3H-pyrido[2,1-f]purine-2,4-dione derivatives. 
 
Reagents and conditions: a) ethyl cyanoacetate, NaOEt, EtOH, reflux, overnight; b) i) NBS, CH3CN, 80 oC, 1h ii) 
4-methoxypyridine, 80 oC, overnight; c) R1-Br, DBU, CH3CN, 80 oC, overnight; d) 20%  Pd(OH)2, ammonium 
formate, EtOH, reflux, overnight; e) R2-Br, K2CO3, DMF, 40 oC overnight. 
 
Subsequently, the human adenosine A3 receptor ligands were screened in a so-called “dual-point” 
competition association assay,27 allowing for the semi-quantitative estimation of the compounds’ 
dissociation rates and therefore the compounds’ RTs. The specific binding of [3H]34 was measured 
after 20 and 240 minutes in the absence and presence of a single concentration (i.e. 1 x IC50) of 
unlabeled human adenosine A3 receptor antagonists, which yielded their Kinetic Rate Index (KRI). A 
long RT compound shows a characteristic “overshoot” followed by a steady decrease in specific 
binding until a new equilibrium is reached; in such a case the KRI value is greater than unity. 
Conversely, a ligand with a fast dissociation rate is represented by a more shallow curve, yielding a 
KRI value smaller than one when dividing the binding at t1 by the binding at t2. The KRI values in the 






Table 2. Binding Affinities and Kinetic Parameters of Pyrido[2,1-f]purine-2,4-dione Derivatives with 







pKi a ± SEM 
(mean Ki in 
nM) 
KRIb 
kon c (M-1 s-
1) 




7.0 ± 0.02 
(108) 
0.38 ± 0.12 
(5.3 ± 1.5) 
x105 
(1.4 ± 0.5) x 
10-2 
2.2 ± 1.4 
6 CH3 
7.7 ± 0.1 
(20.8) 
0.54 
 (0.52; 0.55) 
n.d.f n.d. n.d. 
7 CH2CH3 




n.d. n.d. n.d. 
8 CH2CH2CH2CH3 




n.d. n.d. n .d. 
9 CH2CH2CH2CH2CH3 




(1.1 ± 0.1) x 
106 
(6.0 ± 0.5) x 
10-4 
28 ± 2.2 
10 CH2CH2CH2CH2CH2CH3 




(2.3 ± 1.0) x 
105 
(8.2 ± 1.3) x 
10-5 
213 ± 35 
11 CH2CH2CH2CH2CH2CH2CH3 




(4.2 ± 0.3) x 
105 
(6.2 ± 0.2) x 
10-5 
278 ± 45 
12 CH2CH=CH2 




n.d. n.d. n.d. 
13 CH2C≡CH 




n.d. n.d. n.d. 
14 CH2CH2CH=CH2 




n.d. n.d. n.d. 
15 CH2CH2OCH3 




(4.3 ± 0.8) x 
105 
(6.3 ± 0.7) x 
10-4 
27 ± 2.6 
16 CH2CH2CH2OH 
7.1 ± 0.1 
(81) 
1.04 ± 0.11 n.d. n.d. n.d. 
17 CH2CH(CH3)2 
8.9 ± 0.02 
(1.2) 
1.64 ± 0.24 
(7.8 ± 2.7) x 
105 





8.5 ± 0.1 
(3.5) 
1.73 ± 0.28 
(5.5 ± 1.3) x 
105 









n.d. n.d. n.d. 
20 CH2CH2C(CH3)3 




n.d. n.d. n.d. 
21 CH2Si(CH3)3 




n.d. n.d. n.d. 
2  CH2C3H5 
9.0 ± 0.02 
(1.0) 
2.68 ± 0.48 
(2.8 ± 0.5) x 
106 
















a pKi ± SEM (n ≥ 3, average Ki value in nM), obtained at 25 oC from radioligand binding assays with [3H]34 on 
human Adenosine A3 receptors stably expressed on CHO cell membranes. 
b  KRI ± SEM (n = 3) or KRI (n = 2, individual estimates in parentheses), obtained at 10 
oC from dual-point 
competition association assays with [3H]34 on human Adenosine A3 receptors stably expressed on CHO cell 
membranes. 
c  kon ± SEM (n ≥ 3), obtained at 10 oC from competition association assays with [3H]34 on human Adenosine A3 
receptors stably expressed on CHO cell membranes. 
d koff ± SEM (n ≥ 3), obtained at 10 oC from competition association assays with [3H]34 on human Adenosine A3 
receptors stably expressed on CHO cell membranes. 
e RT (min) = 1/(60*koff). 
f n.d. = not determined. 
 
Compounds with a KRI value less than 0.7 or greater than 1.5 were selected for complete kinetic 
characterization through the use of a competition association assay with [3H]34 (Figure 1A). In order 
to obtain extensive Structure-Kinetics Relationships (SKR), close structural analogs ( 9, 28, 29 and 30) 
of 1 were also tested to obtain their association (kon) and dissociation (koff) rate constants. 
Association rate constants varied by 30-fold, ranging from (1.0 ± 0.1) x 105  M-1s-1 for antagonist 31 to 
(3.0 ± 0.3) x 106 M-1s-1 for antagonist 30 (Table 3).  
Interestingly, there was an approximately 290-fold difference in dissociation rate constants, 
reflecting the divergent KRI values. Antagonist 5 had the fastest dissociation rate constant of (1.4 ± 
0.5) x 10-2 s-1 and thus the shortest RT of 2.2 min, while both antagonist 27 and 31 had the slowest 
dissociation rate constants of (4.7 ± 0.7) x 10-5 s-1 and (5.3 ± 1.5) x 10-5 s-1, respectively, and thus the 










Table 3. Binding Affinities and Kinetic Parameters of Pyrido[2,1-f]purine-2,4-dione Derivatives with 






pKi a ± SEM 
(mean Ki in nM) 
KRIb kon c (M-1 s-1) koff d  (s-1) RT e (min) 
2 benzyl 
9.0 ± 0.02 
(1.0) 
2.68 ± 0.48 (2.8 ± 0.5) x 106 (6.0 ± 1.7) x 10-5 315 ± 105 
24 3-CH3-benzyl 




n.d.f n.d. n.d. 
25 4-CH3-benzyl 




n.d. n.d. n.d. 
26 4-CH2CH3-benzyl 




n.d. n.d. n.d. 
27 3-OCH3-benzyl 




(4.8 ± 0.2) x 105 (4.7 ± 0.7)x 10-5 376 ± 58 
28 4-OCH3-benzyl 




(4.8 ± 0.1) x 105 (7.8 ± 2.0) x 10-5 250 ± 72 
29 3-Cl-benzyl 




(8.2 ± 1.3) x 105 (4.7 ± 0.7) x 10-4 36 ± 5.5 
30 4-Cl-benzyl 




(3.0 ± 0.3) x 106 (8.2 ± 0.2) x 10-4 20 ± 0.5 
31 3,4-dichlorobenzyl 




(1.0 ± 0.1) x 105 (5.3 ± 1.5) x 10-5 391 ± 137 
32 4-Br-benzyl 




n.d. n.d. n.d. 
33 phenethyl 




n.d. n.d. n.d. 
 
a pKi ± SEM (n ≥ 3, average Ki value in nM),  obtained at 25 oC from radioligand binding assays with [3H]34 on 
human Adenosine A3 receptors stably expressed on CHO cell membranes. 
b  KRI ± SEM (n = 3) or KRI (n = 2, individual estimates in parentheses), obtained at 10 
oC from dual-point 
competition association assays with [3H]34 on human Adenosine A3 receptors stably expressed on CHO cell 
membranes. 
c  kon ± SEM (n ≥ 3), obtained at 10 oC from competition association assays with [3H]34 on human Adenosine A3 
receptors stably expressed on CHO cell membranes. 
d koff ± SEM (n ≥ 3), obtained at 10 oC from competition association assays with [3H]34 on human Adenosine A3 
receptors stably expressed on CHO cell membranes. 
e RT (min) = 1/(60*koff) 





















Figure 1: (A) Representative competition association assay curves of [3H]34 in the absence (control) or 
presence of a long residence time compound 27 and a short residence time compound 5. Experiments were 
performed at 10 °C using the compound’s respective IC50 value at the hA3R. (B) Competition association curves 
of [3H]34 in the absence (control) or presence of long residence time compound 27. Experiments were 
performed at 25 °C using the compound’s respective IC50 value at the hA3R. t1 is the radioligand binding at 20 
min, while t2 is the radioligand binding at 240 min. 
 
displayed a typical “overshoot” in the competition association curve, indicative of a slower 
dissociation than the radiolabeled probe [3H]34, while the short RT antagonists, exemplified by 
antagonist 5 (Figure 1A) presented more shallow, gradually ascending curves. There was a good 
correlation between the negative logarithm of the antagonists’ dissociation rate constants and their 
KRI values derived from the kinetic screen (Figure 2A), which confirmed that a compound’s KRI value 
A. 
B. 
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is a good predictor for its dissociation rate constant. Notably, the experimental temperatures in the 
kinetic assays were lower than in the equilibrium displacement assays (25 oC vs 10 oC), because 
kinetic studies performed at 25 oC were compromised by the nature of the compounds tested. This is 
shown in Figure 1B, where the “overshoot” of long RT antagonist 27 happened before the t1 
checkpoint of 20 min, which did not happen at 10 oC.  A significant correlation was also observed 
between the antagonist affinities (Ki values) determined in equilibrium displacement experiments 
and their kinetic KD values derived from competition association experiments (Figure 2B), despite 
the differences in assay temperature (25 oC vs 10 oC). Interestingly, the kinetic association rate 
constants (kon) did not show any significant correlation with affinity (Figure 2C), whilst the 
dissociation rate constants (koff) had a fair correlation with affinity (Figure 2D). 
The representative long RT and short RT antagonists (27 and 5) were selective for the hA3 receptor 
when compared to other adenosine receptors (i.e. human adenosine A1 and A2A receptor, Table S1). 
These two antagonists (27 and 5) with comparable association rate constants but distinct 
dissociation rate constants (or RTs) were further analyzed in a [35S]GTPγS binding assay in which we 
studied the (in)surmountable antagonism induced by the two compounds (Figure 3).  
Moreover, a kon-koff-KD “kinetic map” (Figure 4) was constructed based on the compounds’ divergent 
affinities (expressed as kinetic KD values) and kinetics parameters, yielding a division of these 
antagonists into three different sub-categories: antagonists that show similar koff values (< 2-fold) but 
due to differing kon values (> 28-fold) have different KD values (~100-fold, Group A); antagonists that 
display similar KD values (< 10-fold) despite showing divergent koff and kon values (17-fold and 30-fold, 
Group B); antagonists with similar kon values (< 5-fold), but due to differing koff values (~290-fold) 
have different KD values (> 110-fold, Group C). Additionally, we applied molecular modeling to 
compare the binding behavior in some molecular detail of several antagonists with similar affinities 
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Figure 2: The correlations between the negative logarithm of the human adenosine A3 receptor antagonists’ 
dissociation rates (pkoff) and their kinetic rate index (KRI) (A), the human adenosine A3 receptor antagonists’ 
affinity (pKi) and their “kinetic KD” (pKD) (B), association rate constants (logkon) (C), dissociation rate constants 
(pkoff) (D). The central line corresponds to the linear regression of the data, the dotted lines represent the 95% 
confidence intervals for the regression. Data used in these plots are detailed in Tables 1 - 3. Data are expressed 
as mean from at least three independent experiments. 
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Figure 3: 2-Cl-IB-MECA-stimulated [35S] GTPγS binding to hA3R stably expressed on CHO cell membranes (25 °C) 
in the absence or presence of long-residence-time antagonist 27 (A and B, normalized and combined, n ≥3), or 
short-residence-time antagonist 5 (C and D, normalized and combined, n ≥3). Antagonist 27 (A), 5 (C) were 
incubated for 60 min prior to the challenge of the hA3R agonist 2-Cl-IB-MECA, at a concentration ranging from  
0.1 nM to 10 µM, for another 30 min. Antagonist 27 (B), 5 (D) were coincubated with 2-Cl-IB-MECA, at the 
same concentration range, for 30 min. The agonist curves were generated in the presence of increasing 
concentrations of antagonists, namely 30-, 100-, 300-fold their respective Ki values. Curves were fitted to a 
four parameter logistic dose-response equation. Data is from at least three independent experiments 
performed in duplicate, normalized according to the maximal response (100%) produced by 2-Cl-IB-MECA 
alone. The shift in agonist EC50 values was determined to perform Schild analyses. Two-way ANOVA with 
Dunnett’s post-test was applied for the comparison of Emax by agonist control, * p < 0.05, ** p < 0.01, *** p < 
0.001, **** p < 0.0001, **** p < 0.0001, ns for not significant. 
 
Structure-Affinity Relationships (SAR) and Structure-Kinetics relationships (SKR). 
According to previous studies from our group,23, 24 methoxy-substitution at the C8 position (Table 1) 
of the pyrido[2,1-f]purine-2,4-dione scaffold yielded selective hA3R antagonists with good affinity 
(3.2 nM for 1 as a reference compound). From our preliminary studies, this methoxy-group appeared 
important for slow dissociation (1 vs Compound S2 from Figure S1, Table S2). Due to the nanomolar 
affinity and close-to-unity KRI value of 1, it was treated as the starting point of this SAR and SKR 
study, having, on further analysis, an association rate constant of (8.5 ± 1.2) x 105 M-1s-1 and a 
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dissociation rate constant of (3.2 ± 0.02) x 10-4 s-1 (RT = 52 min). Next, we decided to investigate R1 
substitutions (Table 2), beginning with antagonist 5 (R1 = H).     
The substitutions at R1 (Table 2).  
Firstly, an increase in alkyl chain length was investigated, indicating an elongated carbon chain had a 
cumulative effect on KRI (5, 6, 7, 8, 10, 11), with the exception of antagonist 9 (KRI values from 0.38 
to 4.06). One could point to a possible correlation between lipophilicities and dissociation rate 
constants (and consequently RTs) to explain this trend (Figure S2A). However, with all of the 
antagonists kinetically characterized, no such correlation was observed (Figure S2B). Therefore other 
reasons should be taken into account as to why elongating the carbon chain has such a profound 
effect on the ligand’s dissociation rate. The role of membrane-drug interactions in determining the 
pharmacological profile is a possible reason, especially the role long carbon tails have in such 
interactions.28 Interesting to point out is the affinity of antagonist 11 which, had a traditional lead 
selection process taken place, would most likely have resulted in the elimination of this compound 
due the more favorable affinity and hydrophilic properties of its shorter carbon chain counterparts 
(8 or 9) (affinities: 6.8 nM vs 1.5 nM or 3.5 nM, KRI values: 4.06 vs 1.29 or 1.11). This would have 
overlooked the efficacy this compound could offer due to its longer residence time. 
Secondly, the presence of a more rigid substitution of the R1 group of saturated equivalents 
(antagonists 1 and 8) led to antagonists 12 and 14, with similar improvement in the affinity pairs (12 
and 14: 5.9 nM and 1.4 nM; 1 and 8: 3.2 nM and 1.5 nM) and KRI values (12 and 14: 0.72 and 1.23; 1 
and 8: 0.99 and 1.29). Further rigidification with alkyne (13) rather than alkene (12) maintained 
affinities (4.3 nM vs 5.9 nM) and increased KRI values (1.20 vs 0.72). This alkyne could be the starting 
point for a further study on “click-chemistry” for introducing e.g., fluorescent tags.29-31  
Thirdly, the introduction of a polar atom or group in antagonist 15 or 16, respectively, led to a 






changes in KRI values between antagonist 1 and its polar counterparts 15 and 16 can be considered 
minor (0.99 vs 0.70 and 1.04). Of note, by comparing affinities and kinetic profiles of polar 
antagonist 15 with its non-polar equivalent 1, we found the polarity at the “lipophilic carbon chain” 
resulted in slower association (kon of (4.3 ± 0.8) x 105 M-1s-1 vs (8.5 ± 1.2) x 105 M-1s-1) but faster 
dissociation (koff of (6.3 ± 0.7) x 10-4 s-1 vs (3.2 ± 0.02) x 10-4 s-1), with a concomitant decrease in 
affinity (23 nM vs 3.2 nM).  
Moreover, the bulkiness of the substituents was studied with branched carbon side chains (17, 18, 
19, 20 and 21) or aliphatic rings (2 and 22). As to the branched carbon side chains, compound 
affinities remained in the nanomolar range, while in terms of KRI values, 2-carbon-linker branched 
side chains (17 and 18) caused larger KRI values than those of either their linear counterparts (8 and 
9) or 3-carbon-linear branched side chains (19 and 20) (17: 1.64 vs 1.29 or 1.39;  18: 1.73 vs 1.11 or 
0.95). Although the association rate constants of 17 and 18 were similar to other antagonists in 
Table 2, the dissociation rate constants suggest their branched side chains have an extra “anchoring” 
effect, compared with the linear counterparts. For example, the koff of 18 with a 5-carbon branched 
side chain was quite similar to 10 or 11 having a 6 or 7-carbon linear side chain ((1.1 ± 0.4) x 10-4 s-1 
vs (8.2 ± 1.3) x 10-5 s-1 or (6.2 ± 0.2) x 10-5 s-1). The presence of a slightly less polar but larger silicon 
atom (21) instead of carbon (18) made the KRI value decrease (1.36 vs 1.73), although the affinity 
remained virtually the same (2.7 nM vs 3.5 nM).  
Interestingly, another reported analogue (2)23 of compound 1, with cyclopropylmethyl substitution 
at the R1 group, led to unique kinetic parameters, i.e. a combination of a fast association rate 
constant ((2.8 ± 0.5) x 106 M-1s-1 vs (8.5 ± 1.2) x 105 M-1s-1) and a slow dissociation rate constant ((6.0 
± 1.7) x 10-5 s-1 vs (3.2 ± 0.02) x 10-4 s-1), although the affinities of 2 and 1 were similar (1.0 ± 0.03 nM 
vs 3.2 ± 0.1 nM, respectively). The RT of compound 2 was the longest in Table 2 with 315 min. For 
the antagonist with cyclobutylmethyl (22), affinity (2.7 nM vs 1.0 nM) and KRI value (1.48 vs 2.68) 






Although the dissociation rate constants of the antagonists in Table 2 varied greatly depending on 
the R1 substituent, the association rate constants were more similar (within 5-fold). Association rate 
constants are often reasoned to be caused by a diffusion limited process whereby the collision rate 
of ligand and receptor determines the rate of ligand-receptor complex formation.32 When no 
conformational changes are required for the receptor and ligand to bind and when taking into 
account the proportion of the receptor responsible for binding, this sets the association rate 
constant at observed limits of around 107 M-1s-1.33 As the association rate constants for all R1 
substituted compounds were slower than the diffusion limit by at least 3.5 fold (2), we hypothesize 
target engagement for R1 substituted antagonists is more hampered than imposed by the diffusion 
limit.    
The substitutions at R2-group (Table 3).  
From Table 2 we learned that cyclopropylmethyl-substituted antagonist 2 exhibited a kinetic profile 
as a long RT compound whilst showing the affinity previously reported.23 As a result, this compound 
became the starting point for our exploration of the substitutions (R2-group) on the aromatic ring.  
Introduction of a non-polar alkyl substituent on antagonist 2’s benzyl ring (24, 25, 26), resulted in a 
decrease in KRI values (from 2.68 to 0.81), while slight variations in affinity were observed. Then, 
introduction of a polar methoxy substituent on antagonist 2’s benzyl ring, led to mixed results with a 
small decrease in RT at para-position, and a slight increase in RT at meta-position in 28 (250 min vs 
315 min) and 27 (376 min vs 315 min), respectively. In particular, the long residence time for 27 in 
combination with its sub-nanomolar affinity (0.38 nM), made this compound stand out in the series.  
Next, halogen substitutions on antagonist 2’s benzyl ring were examined. Apparently, the position of 
halogen substitution is important for affinity as para-substitution in antagonist 30 and 32 yielded 
similar affinity compared to 2 (1.2 nM vs 1.2 nM vs 1.0 nM). The one compound with meta-






substituted compound 31 had the largest KRI value (3.12) among the halogen-substituted 
antagonists; the para-bromo substituted compound 32 was similar in this respect to para-chloro 
substituted 30 (1.19 vs 1.11). In a full competition association experiment we determined the rate 
constants for 31, and learned it had the longest RT of all compounds kinetically characterized (391 
min), concomitant with the slowest association rate constant of the compounds kinetically 
characterized ((1.0 ± 0.1) x 105 M-1s-1). Previous theoretical studies have indicated the strength of 
halogen bonding can be increased through the introduction of electron withdrawing groups onto 
halobenzenes.34 Such would be the case for 31 where the additional chloro substituent forms a 
stronger halogen bonding interaction with the R2 binding pocket. Introducing a phenethyl (33) rather 
than benzyl substituent (2) led to a decrease in affinity (7.7 nM vs 1.0 nM), whilst the KRI value was 
also strongly affected (1.09 vs 2.68). This observation parallels our previous findings that the binding 
pocket for the R2 substituent is of limited size.23  
Functional Assay.  
Following kinetic characterization, a long (27) and a short (5) RT compound were chosen for 
functional characterization in a [35S]GTPγS binding assay, also because for these two compounds the 
kon values were similar ((4.8 ± 0.2) x 105 M-1s-1 vs (5.3 ± 1.5) x 105 M-1s-1). This difference allowed a 
possible link to be made between RTs and efficacies.  
Pretreatment of hA3 receptor membranes with increasing concentrations of the long RT antagonist 
27, before stimulation by the A3 receptor agonist 2-Cl-IB-MECA, induced insurmountable antagonism. 
In other words, the 2-Cl-IB-MECA concentration-effect curves were shifted to the right with a 
concomitant decrease in the maximal response (Figure 3A). Conversely, the short RT antagonist 5 
displayed surmountable antagonism, shifting 2-Cl-IB-MECA’s curves to the right without affecting its 







Table 4. Functional activity of hA3 receptor antagonists from [35S]GTPγS binding assays 
 
 


























a RTs were obtained from Tables 1 and 2. 
b Obtained from Schild analyses.  
c N.A.: not applicable. 
 
In this experimental set-up, the Schild-slope of 5 generated from Schild-plots was close to unity 
(Table 4), and the compound’s pA2 value was comparable with its pKi value (6.8 ± 0.4 vs 7.0 ± 0.02). 
We also performed co-incubation experiments with these antagonists in the presence of 2-Cl-IB-
MECA. In this experimental set-up, all antagonists produced a rightward shift of the 2-Cl-IB-MECA 
concentration-effect curves without a suppression of the maximal response (Figure 3C and D). 
Notably, the Schild-slopes of both long and short RT antagonists (27 and 5) were close to unity (0.9 ± 
0.2 for 27, 1.0 ± 0.2 for 5, Table 4). In addition, the pA2 value of 5 was comparable with the result 
from the pre-incubation condition (7.2 ± 0.4 vs 6.8 ± 0.4, Table 4), and the pA2 value of 27 was also in 






Kinetic Map.  
Using the association (kon) and dissociation (koff) rate constants obtained from competition 
association experiments (Tables 1-3), a kinetic map (Figure 4) was constructed by plotting these 
values on the y-axis and x-axis, respectively. The dashed diagonal parallel lines represent the 
kinetically derived KD values (KD = koff/kon). Out of this map three subgroups emerged. Group A 
represents compounds that exhibit similar koff values, but with vastly different kon values. As a 
consequence a diverse range of KD values was observed. Previous SKR studies have primarily focused 
on optimizing dissociation rates and RTs for predicting in-vivo efficacy and creating a kinetically 
favorable ligand. Yet recently, there has been greater acknowledgment of the important role that 
the association rate constants may play in determining the efficacy of a drug as the result of 
increased rebinding or increased drug-target selectivity.19 A kinetic map would thus allow for the 
selection of compounds with appropriate RTs whilst exploring the role of association rate constants 
in determining efficacy by choosing a rapidly or slowly associating compound, i.e. 2 or 31 ((2.8 ± 0.5) 
x 106 M-1s-1 vs (1.0 ± 0.1) x 105 M-1s-1). Group B displays ligands that exhibit a narrow range of affinity 
(KD: 0.1 nM - 1 nM), yet a wide range of koff values that result in RTs ranging from 20 min to 391 min. 
This information would have gone unnoticed in a traditional SAR hit-to-lead approach and would 
most likely have led to the selection of high affinity compounds not in possession of a potentially 
efficacy promoting long residence time. Thus, combining SAR with SKR aspects in lead optimization 
would allow the selection of not only potent but also long RT compounds through the drug 
development pipeline. Lastly group C represents compounds that present similar kon values but due 
to differing koff values show considerable differences in affinities (KD). This illustrates the differences 
that were observed in the binding kinetics of the R1 and R2 substituents, as group C mainly consists 
of R1 substituents (non-cyclopropylmethyl substituents), whilst group A mainly consists of R2 
substituents (cyclopropylmethyl substituents). This difference also suggests a different mode of 













Figure 4: Kinetic map (y axis: kon in M-1·s-1, x axis: koff in s-1) of all compounds that were kinetically characterized 
in this study. kon and koff values were obtained through competition association assays performed at the hA3R. 
The kinetically derived affinity (KD = koff/kon) is represented through diagonal parallel lines. Group A: 
compounds that show similar koff values but due to differing kon values have different KD values. Group B: 
compounds that display similar KD values despite showing divergent koff and kon values. Group C: compounds 
with similar kon values, but due to differing koff values have different KD values.  
 
Altogether, the construction of a kinetic map allows for a more detailed categorization of 
compounds’ affinities as dictated by their kinetic rate constants. In previous studies, such a 
separation has explained the different therapeutic effects molecules exhibit highlighting the benefits 
of such an in-depth analysis.35, 36  
Given the putative link between RT and clinical efficacy, it may be postulated that the lack of hA3R 
antagonists progressing from preclinical trials is due to insufficient selection criteria employed in 
these initial phases of hA3R drug screening. As previously reported, hA3R antagonists are reasoned to 
be beneficial in the treatment of Chronic Obstructive Pulmonary Disease (COPD).37 For this 
indication, a number of antagonists are available that act at the muscarinic M3 receptor.38 For these 
therapeutics their dosing regime and thus duration of action have been linked to their RT. For 
example, aclidinium which requires a twice daily dosing regimen, exhibits a much shorter RT than 
tiotropium that in turn requires only once daily dosing.16 This extended duration of action that 
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enables long-lasting efficacy and practical dosing regimens at the muscarinic M3 receptor is thought 
to be a beneficial feature in the treatment of chronic illnesses.39, 40 As hA3R antagonists can be used 
to treat chronic COPD but also a number of other chronic disorders, we could imagine that 
considering the ligand’s kinetic profile early in the drug screening process, would reduce the 
likelihood of failure due to insufficient efficacy in future clinical trials. Perhaps when selecting hA3R 
antagonists with a favorable long RT, i.e. the group A in the kinetic map, will we see the therapeutic 
potential of the hA3R fulfilled. 
Computational studies.   
Finally, we decided to further investigate the ligand-receptor interactions using a homology model of 
the adenosine A3 receptor, based on the crystal structure of the adenosine A2A receptor (PDB: 
4EIY)41. WaterMap calculations were applied to try and explain the variance in kinetic profiles of 
different ligands by unfavorable hydration42, 43.  
Antagonist 2 (in black stick representation) was docked in the homology model. As a first step it was 
placed inside the transmembrane bundle, with the tricyclic ring system surrounded by TM3, TM6 
and EL2. Hydrogen bonding was constrained between the amide-hydrogen (-NH2, δ+) from Asn2506.55 
and the carbonyl-oxygen (-C=O, δ-) at the C4-position of the pyrido[2,1-f]purine-2,4-dione scaffold 
(Figure 5, left). In order to compare differences between the ligands, an “apo” WaterMap of the hA3 
receptor was generated. Hydration sites shown as red and orange spheres represent positions 
where “unstable” water molecules are found. Antagonist 10 (hexyl-substitution), with comparable 
koff ((8.2 ± 1.3) x 10-5 s-1 vs (6.0 ± 1.7) x 10-5 s-1) to 2 but 10-fold slower kon ((2.3 ± 1.0) x 105 M-1s-1 vs 
(2.8 ± 0.5) x 106 M-1s-1), was  docked with two different binding modes in the same binding site 
(Figure 5, up-right, cyan and grey sticks). We found additional unstable waters (8, 11, 22 in Figure 5, 
up-right) surrounding the lipophilic substituents of the compounds, which could be explained as 







Figure 5. Docking of antagonist 2 into the binding site of the homology model of the adenosine A3 receptor 
based on the crystal structure of the adenosine A2A receptor (PDB: 4EIY).41 Antagonist 2 is represented by black 
sticks, and residues within 5 Å of 2 are visualized as orange sticks. The protein is represented by orange 
ribbons. Ligand and residues atoms color code: red = oxygen, blue = nitrogen, white = hydrogen. The overlay of 
consecutively numbered hydration sites (colored spheres; for color code, see below) were calculated by 
WaterMap (Left). Hydration sites shown as red and orange spheres represent positions were “unstable” water 
molecules can be found, which should be displaced by antagonist 2.  White spheres symbolize “stable” water 
molecules, which are in exchange with the bulk solvent. Two different binding modes are represented for 
antagonist 10 (cyan and grey sticks), which shows that the flexible hexyl chain can displace different hydration 
sites (8 for grey and 11 for cyan). For the key hydration sites (8, 11, 22, 32, 37) surrounding the lipophilic 
“tails”, calculated ΔG values (in kcal/mol) with respect to bulk solvent are shown (Up-right). Hydration sites 6, 
39, 42 and 45 are proposed to be displaced by the 3,4 di-chloro substituents of 31; calculated ΔG values (in 
kcal/mol) with respect to bulk solvent are shown (Down-right). 
 
The same WaterMap was used to investigate the kinetic profile of antagonist 31. Indeed, hydration 
sites 6, 39, 42 and 45 are proposed to be displaced by the 3,4-dichloro substituent. Thus, both the 
association and dissociation of 31 were slowed down by these unstable waters. For the association 
process, the lipophilic 3,4-dichloro moiety has difficulty in approaching the occupied unstable 
hydration sites ((1.0 ± 0.1) x 105 M-1s-1, slowest kon in the whole series); the same lipophilic 3,4-
dichloro substituent seems to provide more stabilization to the receptor-ligand complex, thus 






Interestingly, by removing a single chloro atom at either the 3- or 4- position on the benzyl-ring (30 
or 29), association and dissociation rate constants became faster by approximately 10-fold. Although 
the differences in their kon and koff values were modest (2-3 fold), the unstable hydration sites may 
prevent the 4-chloro-substituted antagonist 30 from reaching the hydration sites 6, 39 and 42 that 
interact with the 3-Cl substituent; consequently, both its association and dissociation rate constants 
were faster than of the 3-chloro-substituted counterpart 29 (kon: (3.0 ± 0.3) x 106 M-1s-1 vs (8.2 ± 1.3) 
x 105 M-1s-1; koff: (8.2 ± 0.2) x 10-4 s-1 vs (4.7 ± 0.7) x 10-4 s-1). 
Conclusions 
We have demonstrated that, next to affinity, additional knowledge of target binding kinetics is useful 
for selecting and developing new hA3R antagonists in the early phase of drug discovery. By 
introducing proper substituents at the N3 position or the N1 benzyl ring of a series of 
pyridopurinediones, divergences in kinetic profiles were observed, while almost all compounds had 
high and often similar affinity. Two representative ligands (5 and 27) were tested in [35S]GTPγS 
binding assays, confirming the link between their RTs and their (in)surmountable antagonism. 
According to these findings, a kon-koff-KD kinetic map was constructed and subsequently the 
antagonists were divided into three sub-groups. Additionally, we also performed a computational 
modelling study that sheds light on the crucial interactions (including with water molecules) for both 
the association and dissociation kinetics of this family of antagonists. It should be mentioned that 
the kinetic parameters were derived at the hA3R, which may be different in e.g., rodents used in 
advanced animal models. Still, this study suggests that favorable long RTs would be a proper 
indicator in the development of hA3R antagonists for chronic inflammatory conditions, e.g. COPD. 
Experimental section 
Chemistry. All solvents and reagents were purchased from commercial sources and were of 






the reactions, using Merck silica gel F254 plates. Grace Davison Davisil silica column material (LC60A, 
30–200 µm) was used to perform column chromatography. Microwave reactions were performed in 
an Emrys Optimizer (Biotage AB, formerly Personal Chemistry). 1H and 13C NMR spectra were 
recorded on a Bruker DMX-400 (400 MHz) spectrometer, using tetramethylsilane as internal 
standard. Chemical shifts are reported in δ (ppm) and the following abbreviations are used: s, 
singlet; d, doublet; dd, double doublet; t, triplet; m, multiplet. The analytical purity of the final 
compounds is 95% or higher and was determined by high-performance liquid chromatography 
(HPLC) with a Phenomenex Gemini 3 µm C18 110A column (50 x 4.6 mm, 3 µm), measuring UV 
absorbance at 254 nm. The sample preparation and HPLC method was as follows: 0.3–0.6 mg of 
compound was dissolved in 1 mL of a 1:1:1 mixture of CH3CN/H2O/t-BuOH and eluted from the 
column within 15 min at a flow rate of 1.3 mL/min. The elution method was set up as follows: 1–4 
min isocratic system of H2O/CH3CN/1% TFA in H2O, 80:10:10; from the 4th min a gradient was 
applied from 80:10:10 to 0:90:10 within 9 min, followed by 1 min of equilibration at 0:90:10 and 1 
min at 80:10:10. Liquid chromatography–mass spectrometry (LC–MS) analyses were performed 
using a Thermo Finnigan Surveyor—LCQ Advantage Max LC–MS system and a Gemini C18 
Phenomenex column (50 x 4.6 mm, 3 µm). The elution method was set up as follows: 1–4 min 
isocratic system of H2O/CH3CN/1% TFA in H2O, 80:10:10; from the 4th min a gradient was applied 
from 80:10:10 to 0:90:10 within 9 min, followed by 1 min of equilibration at 0:90:10 and 1 min at 
80:10:10. 
1-Benzyl-8-methoxy-1H,3H-pyrido[2,1-f]purine-2,4-dione (5.)24 6-Amino-1-benzyluracil (4) 25 (10.8 g, 
49.7 mmol, 1.00 eq.) was suspended in CH3CN (370 mL). N-bromosuccinimide (17.7 g, 99.4 mmol, 
2.00 eq.) was added to the suspension and the mixture was heated at 80 ⁰C for 1 hour, after which 
full conversion was shown by TLC (1:9 CH3OH/CH2Cl2 + 3% triethylamine). Subsequently 4-
methoxypyridine (15.1 mL, 149.2 mL, 3.00 eq.) was added and the mixture was heated at 80 ⁰C 
during 10 hours. Full consumption of the bromo intermediate was shown by TLC (1% CH3OH/CH2Cl2). 






ether. This yielded the desired compound as a white solid (10.2 g, 31.6 mmol, 64%). 1H NMR 
(400MHz, DMSO-d6) δ: 11.11 (s br, 1H), 8.72 (d, J = 7.2 Hz, 1H), 7.39-7.29 (m, 4H), 7.28-7.22 (m, 2H), 
6.91 (dd, J = 7.2, 2.0 Hz, 1H), 5.19 (s, 2H), 3.89 (s, 3H) ppm. NMR was according to literature data.24 
General procedure for the preparation of N3-substitited 1-benzyl-8-methoxy-1H,3H-pyrido[2,1-
f]purine-2,4-diones (1, 2, 6-22).24 The compounds were synthesized using the procedure described 
by Priego et al.,24 but 5 eq. of the alkyl halide was used instead of 1.5 eq. and the reaction mixture 
was heated to 80 oC overnight in all cases. The pure compounds were obtained by silica column 
chromatography using a mixture of petroleum ether/ethyl acetate (2:1) as eluent, if not otherwise 
stated. 
1-Benzyl-8-methoxy-3-propyl-1H,3H-pyrido[2,1-f]purine-2,4-dione (1).24 The pure product was 
obtained by column chromatography using petroleum ether/ethyl acetate (1:1) as eluent, yielding a 
white solid 113 mg, 0.31 mmol, 60%. 1H NMR (400MHz, CDCl3) δ: 8.83 (d, J = 7.2 Hz, 1H), 7.54 (d, J = 
7.2 Hz, 2H), 7.34-7.25 (m, 3H), 6.98 (d, J = 2.0 Hz, 1H), 6.74 (dd, J = 7.6, 2.8 Hz, 1H), 5.37 (s, 2H), 4.02 
(t, J = 7.6 Hz, 2H), 3.92 (s, 3H), 1.74 (sextet, J = 7.6 Hz, 2H), 0.99 (t, J = 7.6 Hz, 3H) ppm.24 MS [ESI+H]+: 
calcd for C20H20N4O3, 364.15; found, 365.0. 
1-Benzyl-3-(cyclopropylmethyl)-8-methoxypyrido[2,1-f]purine-2,4(1H,3H)-dione (2).23 The pure 
product was obtained by column chromatography using a mixture of 2% CH3OH/CH2Cl2  as eluent, 
yielding a white solid, 1.51 g, 3.98 mmol, 86%. 1H NMR (400MHz, CDCl3) δ: 8.82 (d, J = 7.2 Hz, 1H), 
7.54 (d, J = 7.2 Hz, 2H), 7.33-7.23 (m, 3H), 6.97 (d, J = 2.4 Hz, 1H), 6.73 (dd, J = 8.4, 2.4 Hz, 1H), 5.37 
(s, 2H), 3.94 (d, J = 7.4 Hz, 2H), 3.92 (s, 3H), 1.35-1.25 (m, 1H), 0.47-0.44(m, 4H) ppm. MS [ESI+H]+: 
calcd for C21H20N4O3, 376.15; found, 376.9. 
1-Benzyl-8-methoxy-3-methylpyrido[2,1-f]purine-2,4(1H,3H)-dione (6). Reaction was performed in a 
sealed tube and 50 eq. of methyl iodide was used. The residue was purified by silica column 






25 mg, 0.074 mmol, 15%. 1H NMR (400MHz, CDCl3) δ: 8.83 (d, J = 7.6 Hz, 1H), 7.54 (d, J = 7.2 Hz, 2H), 
7.33-7.24 (m, 3H), 6.99 (d, J = 2.4 Hz, 1H), 6.75 (dd, J = 7.6, 2.4 Hz, 1H), 5.37 (s, 2H), 3.93 (s, 3H), 3.45 
(s, 3H) ppm. MS [ESI+H]+: calcd for C18H16N4O3, 336.12; found, 337.2. 
1-Benzyl-3-ethyl-8-methoxypyrido[2,1-f]purine-2,4(1H,3H)-dione (7). The pure product was obtained 
by column chromatography using petroleum ether/ethyl acetate (1:1) as eluent, yielding a white 
solid, 58 mg, 0.17 mmol, 33%. 1H NMR (400MHz, CDCl3) δ: 8.83 (d, J = 7.2 Hz, 1H), 7.54 (d, J = 7.2 Hz, 
2H), 7.33-7.24 (m, 3H), 6.98 (d, J = 2.0 Hz, 1H), 6.74 (dd, J = 7.6, 2.8 Hz, 1H), 5.36 (s, 2H), 4.12 (q, J = 
7.2 Hz, 2H), 3.92 (s, 3H), 1.28 (t, J = 7.2 Hz, 3H) ppm. MS [ESI+H]+: calcd for C19H18N4O3, 350.14; 
found, 351.0. 
1-Benzyl-3-butyl-8-methoxypyrido[2,1-f]purine-2,4(1H,3H)-dione (8). Purified by column 
chromatography using petroleum ether/EtOAc (3:1), yielding a white solid 10 mg, 0.026 mmol, 5%. 
1H NMR (400MHz, CDCl3) δ: 8.83 (d, J = 7.6 Hz, 1H), 7.54 (d, J = 6.8 Hz, 2H), 7.24-7.33 (m, 3H), 6.98 (d, 
J = 2.4 Hz, 1H), 6.74 (dd, J = 7.4, 2.6 Hz, 1H), 5.36 (s, 2H), 4.04 (t, J = 7.6 Hz, 2H), 3.93 (s, 3H), 1.70-
1.64 (m, 2H), 1.40 (sextet, J = 3.6 Hz, 2H), 0.95 (t, J = 7.2 Hz, 3H) ppm. MS [ESI+H]+: calcd for 
C21H22N4O3, 378.17; found, 378.9. 
1-Benzyl-8-methoxy-3-pentyl-1H,3H-pyrido[2,1-f]purine-2,4-dione (9). White solid, 110 mg, 0.28 
mmol, yield 56%. 1H NMR (400MHz, CDCl3) δ: 8.83 (d, J = 7.6 Hz, 1H), 7.56 (d, J = 7.2 Hz, 2H), 7.34-
7.25 (m, 3H), 6.97 (d, J = 2.0 Hz, 1H), 6.74 (dd, J = 7.6, 2.8 Hz, 1H), 5.37 (s, 2H), 4.05 (t, J = 7.6 Hz, 2H), 
3.93 (s, 3H), 1.72-1.66 (m, 2H), 1.39-1.37 (m, 4H), 0.91 (t, J = 7.2 Hz, 3H) ppm. MS [ESI+H]+: calcd for 
C22H24N4O3, 392.18; found, 393.1. 
1-Benzyl-3-hexyl-8-methoxypyrido[2,1-f]purine-2,4(1H,3H)-dione (10). White solid, 90 mg, 0.22 
mmol, yield 44%. 1H NMR (400MHz, CDCl3) δ: 8.83 (d, J = 7.2 Hz, 1H), 7.55 (d, J = 6.8 Hz, 2H), 7.34-






3.92 (s, 3H), 1.69 (pentet, J = 7.6 Hz, 2H), 1.40-1.26 (m, 6H), 0.89 (t, J = 7.2 Hz, 3H) ppm. MS [ESI+H]+: 
calcd for C23H26N4O3, 406.20; found, 407.1. 
1-Benzyl-3-heptyl-8-methoxypyrido[2,1-f]purine-2,4(1H,3H)-dione (11). Column chromatography 
using a mixture of petroleum ether/ethyl acetate (3:1) as eluent yielded 131 mg of the pure product 
as white solid,  0.31 mmol, 62%. 1H NMR (400MHz, CDCl3) 1H NMR (400MHz, CDCl3) δ: 8.80 (d, J = 
7.6 Hz, 1H), 7.54 (d, J = 6.8 Hz, 2H), 7.32-7.25 (m, 3H), 6.95 (d, J = 2.4 Hz, 1H), 6.71 (dd, J = 7.2, 2.4 Hz, 
1H), 5.35 (s, 2H), 4.03 (t, J = 7.6, 2H), 3.90 (s, 3H), 1.67 (pentet, J = 7.6 Hz, 2H), 1.38-1.26 (m, 8H), 
0.87 (t, J = 7.2 Hz, 3H) ppm. MS [ESI+H]+: calcd for C24H48N4O3, 420.22; found, 421.2. 
3-Allyl-1-benzyl-8-methoxypyrido[2,1-f]purine-2,4(1H,3H)-dione (12). Purified by column 
chromatography using petroleum ether/ethyl acetate (1:1) as eluent, yielding a white solid, 73 mg, 
0.20 mmol, 40%. 1H NMR (400MHz, CDCl3) δ: 8.82 (d, J = 7.6 Hz, 1H), 7.55 (d, J = 7.2 Hz, 2H), 7.34-
7.25 (m, 3H), 6.99 (d, J = 2.0 Hz, 1H), 6.75 (dd, J = 7.6, 2.4 Hz, 1H), 6.02-5.92 (m, 1H), 5.38 (s, 2H), 
5.29 (dd, J = 17.2, 1.2 Hz, 1H), 5.20 (d, J = 10.0 Hz, 1H), 4.68 (d, J = 5.6 Hz, 2H), 3.93 (s, 3H) ppm. MS 
[ESI+H]+: calcd for C20H18N4O3, 362.14; found, 363.0. 
1-Benzyl-8-methoxy-3-(prop-2-yn-1-yl)pyrido[2,1-f]purine-2,4(1H,3H)-dione (13). The pure product 
was obtained by column chromatography using petroleum ether/ethyl acetate (1:1) as eluent, 
yielding a white solid, 60 mg, 0.17 mmol, 3%. 1H NMR (400MHz, CDCl3) δ: 8.82 (d, J = 7.2 Hz, 1H), 
7.57 (d, J = 6.8 Hz, 2H), 7.36-7.26 (m, 3H), 6.99 (d, J = 2.4 Hz, 1H), 6.76 (dd, J = 7.2, 2.4 Hz, 1H), 5.38 
(s, 2H), 4.83 (d, J = 2.4 Hz, 2H), 3.94 (s, 3H), 2.19 (t, J = 2.4 Hz, 1H) ppm. MS [ESI+H]+: calcd for 
C20H16N4O3, 360.12; found, 361.1. 
1-Benzyl-3-(but-3-en-1-yl)-8-methoxypyrido[2,1-f]purine-2,4(1H,3H)-dione (14). White solid, 18 mg, 
0.05 mmol, yield 10%. 1H NMR (400MHz, CDCl3) δ: 8.84 (d, J = 7.6 Hz, 1H), 7.54 (d, J = 7.2 Hz, 2H), 






2H), 5.08 (dd, J = 16.8, 1.2 Hz, 1H), 5.02 (d, J = 10.4, 1H), 4.15 (t, J = 7.2 Hz, 2H), 3.95 (s, 3H), 2.48 (q, J 
=  7.2 Hz, 2H) ppm. MS [ESI+H]+: calcd for C21H20N4O3, 376.15; found, 376.9. 
1-Benzyl-8-methoxy-3-(2-methoxyethyl)-1H,3H-pyrido[2,1-f]purine-2,4-dione (15). Purified by column 
chromatography using a mixture of 2% CH3OH in CH2Cl2 yielded the product as a white solid, 70 mg,  
0.18 mmol, 37%. 1H NMR (400MHz, CDCl3) δ: 8.83 (d, J = 7.2 Hz, 1H), 7.54 (d, J = 6.8 Hz, 2H), 7.33-
7.24 (m, 3H), 6.98 (d, J = 2.4 Hz, 1H), 6.74 (dd, J = 7.6, 2.4 Hz, 1H), 5.36 (s, 2H), 4.30 (t, J = 6.0 Hz, 2H), 
3.93 (s, 3H), 3.68 (t, J = 6.0 Hz, 2H), 3.36 (s, 3H) ppm. MS [ESI+H]+: calcd for C20H20N4O3, 380.15; 
found, 380.8. 
1-Benzyl-3-(3-hydroxypropyl)-8-methoxypyrido[2,1-f]purine-2,4(1H,3H)-dione (16). Purified by 
column chromatography using a mixture of petroleum ether/EtOAc (1:2), followed by 
recrystallization from CH3OH/EtOAc. Yield: white solid, 106 mg, 0.28 mmol, 28%. 1H NMR (400MHz, 
CDCl3) δ:  8.80 (d, J = 7.2 Hz, 1H), 7.53 (d, J = 7.6 Hz, 2H), 7.33-7.24 (m, 3H), 6.99 (d, J = 2.4 Hz, 1H), 
6.76 (dd, J = 7.6, 2.4 Hz, 1H), 5.37 (s, 2H), 4.22 (t, J = 6.0 Hz, 2H), 3.93 (s, 3H), 3.53 (t, J = 5.6 Hz, 2H), 
1.92 (pentet, J = 5.6 Hz, 2H) ppm. MS [ESI+H]+: calcd for C20H20N4O3, 380.15; found, 380.9. 
1-Benzyl-3-isobutyl-8-methoxypyrido[2,1-f]purine-2,4(1H,3H)-dione (17). White solid, 0.08 mmol, 29 
mg, yield 15%.  1H NMR (400MHz, CDCl3) δ: 8.86 (d, J = 7.2 Hz, 1H), 7.55 (d, J = 7.2 Hz, 2H), 7.33-7.28 
(m, 3H), 7.00 (d, J = 2.0 Hz, 1H), 6.76 (dd, J = 7.6, 2.4 Hz, 1H), 5.39 (s, 2H), 3.95 (s, 3H), 3.92 (d, J = 7.6 
Hz, 2H), 2.22 (nonet, J = 7.2 Hz, 1H), 0.97 (d, J = 6.8 Hz, 6H) ppm. MS [ESI+H]+: calcd for C21H22N4O3, 
378.17; found, 379.0. 
1-Benzyl-8-methoxy-3-(3-neopentyl)-1H,3H-pyrido[2,1-f]purine-2,4-dione (18). Purified by column 
chromatography using a mixture of 1% CH3OH in CH2Cl2 as eluent, yielding the product as a white 
solid, 0.025 mmol, 20mg, 5%. 1H NMR (400MHz, CDCl3) δ: 8.84 (d, J = 7.2 Hz, 1H), 7.52 (d, J = 7.2 Hz, 
2H), 7.32-7.25 (m, 3H), 6.98 (d, J = 2.4 Hz, 1H), 6.73 (dd, J = 7.2, 2.4 Hz, 1H), 5.37 (s, 2H), 3.99 (s, 2H), 






1-Benzyl-3-isopentyl-8-methoxypyrido[2,1-f]purine-2,4(1H,3H)-dione (19). Yield: white solid, 104 mg, 
0.26 mmol, 53%. 1H NMR (400MHz, CDCl3) δ: 8.83 (d, J = 7.2 Hz, 1H), 7.53 (d, J = 7.2 Hz, 2H), 7.33-
7.24 (m, 3H), 6.98 (d, J = 2.4 Hz, 1H), 6.74 (dd, J = 7.6, 2.4 Hz, 1H), 5.36 (s, 2H), 4.08-4.04 (m, 2H), 
3.93 (s, 3H), 1.69 (nonet, J = 6.8 Hz, 1H), 1.59-1.53 (m, 2H), 0.98 (d, J = 6.4 Hz, 6H) ppm. MS [ESI+H]+: 
calcd for C22H24N4O3, 392.18; found, 393.1. 
1-Benzyl-3-(3,3-dimethylbutyl)-8-methoxy-pyrido[2,1-f]purine-2,4(1H,3H)-dione (20). Yield: white 
solid, 81 mg,  0.20 mmol, 40%. 1NMR (400MHz, CDCl3) δ: 8.84 (d, J = 7.6 Hz, 1H), 7.55 (d, J = 7.2, 2H), 
7.35-7.27 (m, 3H), 6.98 (d, J = 2.4 Hz, 1H), 6.74 (dd, J = 7.2, 2.4 Hz, 1H), 5.38 (s, 2H), 4.12-4.08 (m, 
2H), 3.93 (s, 3H), 1.61-1.57 (m, 2H), 1.04 (s, 9H) ppm. MS [ESI+H]+: calcd for C23H26N4O3, 406.20; 
found, 407.1. 
1-Benzyl-8-methoxy-3-((trimethylsilyl)methyl)pyrido[2,1-f]purine-2,4(1H,3H)-dione (21). White solid, 
137 mg,  0.34 mmol, yield 67%. 1H NMR (400MHz, CDCl3) δ: 8.84 (d, J = 7.2 Hz, 1H), 7.50 (d, J = 6.8 
Hz, 2H), 7.32-7.24 (m, 3H), 6.98 (d, J = 2.4 Hz, 1H), 6.73 (d, J = 7.2, 2.4 Hz, 1H), 5.39 (s, 2H), 3.93 (s, 
3H), 3.64 (s, 2H),  0.08 (s, 9H) ppm. MS [ESI+H]+: calcd for C21H24N4O3Si, 408.16; found, 409.2. 
1-Benzyl-3-(cyclobutylmethyl)-8-methoxypyrido[2,1-f]purine-2,4(1H,3H)-dione (22). White solid, 90 
mg,  0.23 mmol, yield 46%. 1H NMR (400MHz, CDCl3) δ: 8.82 (d, J = 7.2 Hz, 1H), 7.53 (d, J = 7.2 Hz, 
2H), 7.33-7.13 (m, 3H), 6.69 (d, J = 1.8 Hz, 1H), 6.73 (dd, J = 7.2, 2.4 Hz, 1H), 5.35 (s, 2H), 4.11 (d, J = 
7.6 Hz, 2H), 3.92 (s, 3H), 2.83-2.72 (m, 1H), 2.05-1.95 (m, 2H), 1.90-1.79 (m, 4H) ppm. MS [ESI+H]+: 
calcd for C22H22N4O3, 390.17; found, 391.2. 
3-(Cyclopropylmethyl)-8-methoxypyrido[2,1-f]purine-2,4(1H,3H)-dione (23).23 Prepared following a 
slightly modified procedure described by Priego et al. In total 4 portions of 8 eq. of ammonium 
formate (after 0, 2, 4 and 6 hours)  and 3 portions of 0.15 eq. of 20% Pd(OH)2 (0, 4 and 6 hours) were 
added, after which full conversion was reached after overnight reflux visualized by TLC (3% 






hot DMF. The combined organic layer was concentrated in vacuo which resulted in a quantitative 
yield. 1H-NMR in accordance to data in literature.23 
General procedure for the preparation of N1-substitited-3-cyclopropylmethyl-8-methoxy-1H,3H-
pyrido[2,1-f]purine-2,4-diones (24-33).23 The compounds were synthesized according to the 
procedure described by Priego et al.2 Purification by silica column chromatography using an eluent 
mixture of petroleum ether/ethyl acetate (3:1) yielded the pure final products. 
3-(Cyclopropylmethyl)-8-methoxy-1-(3-methylbenzyl)pyrido[2,1-f]purine-2,4(1H,3H)-dione (24). 
White solid, 79 mg, 0.20 mmol, yield 57%. 1H NMR (400MHz, CDCl3) δ: 8.84 (d, J = 7.2 Hz, 1H), 7.36 
(s, 2H), 7.22 (t, J = 7.6 Hz, 1H), 7.09 (d, J = 7.6 Hz, 1H), 6.99 (d, J = 2.4 Hz, 1H), 6.75 (dd, J = 7.2, 2.4 Hz, 
1H), 5.36 (s, 2H), 3.97 (d, J = 7.2 Hz, 2H), 3.94 (s, 3H), 2.34 (s, 3H), 1.37-1.31 (m, 1H), 0.52-0.45 (m, 
4H) ppm. MS [ESI+H]+: calcd for C22H22N4O3, 390.17; found, 391.0. 
3-(Cyclopropylmethyl)-8-methoxy-1-(4-methylbenzyl)pyrido[2,1-f]purine-2,4(1H,3H)-dione (25).23 
3-(Cyclopropylmethyl)-1-(4-ethylbenzyl)-8-methoxypyrido[2,1-f]purine-2,4(1H,3H)-dione (26). White 
solid, 43 mg, 0.11 mmol, yield 21%. 1H NMR (400MHz, CDCl3) δ: 8.82 (d, J = 7.6 Hz, 1H), 7.48 (d, J = 
8.0 Hz, 2H), 7.14 (d, J = 8.0 Hz, 2H), 6.98 (d, J = 2.0 Hz, 1H), 6.73 (dd, J = 7.2, 2.4 Hz, 1H), 5.34 (s, 2H), 
3.95-3.93 (m, 5H), 2.60 (q, J = 7.6 Hz, 2H), 1.34-1.28 (m, 1H), 1.19 (t, J = 7.6 Hz, 3H), 0.50-0.42 (m, 4H) 
ppm. MS [ESI+H]+: calcd for C23H24N4O3, 404.18; found, 405.2. 
3-(Cyclopropylmethyl) -8-methoxy-1-(3-methoxybenzyl)pyrido[2,1-f]purine-2,4(1H,3H)-dione (27). 
White solid, 20 mg,  0.049 mmol, yield 14%. 1H NMR (400MHz, CDCl3) δ: 8.83 (d, J = 7.6 Hz, 1H), 7.23 
(t, J = 8.0 Hz, 1H), 7.15-7.10 (m, 2H), 6.97 (d, J = 1.6 Hz, 1H), 6.80 (dd, J = 8.4, 2.4 Hz, 1H), 6.74 (dd, J = 
7.6, 2.4 Hz, 1H), 5.35 (s, 2H), 3.96-3.92 (m, 5H), 3.77 (s, 3H), 1.35-1.28 (m, 1H), 0.50-0.45 (m, 4H) 










1-(4-Bromobenzyl)-3-(cyclopropylmethyl)-8-methoxypyrido[2,1-f]purine-2,4(1H,3H)-dione (32). White 
solid, 22 mg,  0.048 mmol, yield 14%. 1H NMR (400MHz, CDCl3) δ: 8.85 (d, J = 7.2 Hz, 1H), 7.46 (s, 4H), 
6.99 (d, J = 1.6 Hz, 1H), 6.87 (dd, J = 7.2, 2.0 Hz, 1H), 5.33 (s, 2H), 3.99-3.85 (m, 5H), 1.34-1.24 (m, 
1H), 0.50-0.44 (m, 4H) ppm. MS [ESI+H]+: calcd for C21H19N4O3, 454.06; found, 455.0. 
3-(Cyclopropylmethyl) -8-methoxy-1-phenylethylpyrido[2,1-f]purine-2,4(1H,3H)-dione (33). White 
solid, 112 mg,  0.29 mmol, yield 82%. 1H NMR (400MHz, CDCl3) δ: 8.81 (d, J = 7.2 Hz, 1H), 7.35-7.25 
(m, 4H), 7.20 (t, J = 7.2 Hz, 1H), 6.96 (d, J = 2.4 Hz, 1H), 6.73 (dd, J = 7.2, 2.4 Hz, 1H), 4.40 (t, J = 8.0 
Hz, 2H), 3.95-3.90 (m, 5H), 3.12 (t, J = 8.0 Hz, 2H), 1.32-1.23 (m, 1H), 0.49-0.40 (m, 4H) ppm. MS 
[ESI+H]+: calcd for C22H22N4O3, 390.17; found, 391.0. 
Biology. Chemicals and Reagents. [3H]8-Ethyl-4-methyl-2-phenyl-(8R)-4,5,7,8-tetrahydro-1H- 
imidazo[2,1-i]-purin-5-one26 ([3H]34, specific activity 56 Ci·mmol-1) was a gift from Prof. C.E. Müller 
(University of Bonn, Germany). Unlabeled 34 was purchased from Tocris Ltd. (Abingdon, UK). 5’-N-
ethylcarboxamidoadenosine (NECA) was purchased from Sigma-Aldrich (Steinheim, Germany). 
Adenosine deaminase (ADA) was purchased from Boehringer Mannheim (Mannheim, Germany). 
Bicinchoninic acid (BCA) and BCA protein assay reagents were purchased from Pierce Chemical 
Company (Rockford, IL, USA). Chinese hamster ovary cells stably expressing the human adenosine A3 
receptor (CHOhA3) were a gift from Dr. K-N Klotz (University of Würzburg, Germany). All other 
chemicals were obtained from standard commercial sources and were of analytical grade. 
Cell Culture and Membrane Preparation. Chinese Hamster Ovary (CHO) cells, stably expressing the 






as previously described44. Protein determination was done through use of the bicinchoninic acid 
(BCA) method45.  
Radioligand Displacement Assay. Membrane aliquots containing ~15 μg of CHOhA3 protein were 
incubated in a total volume of 100 μL assay buffer (50 mM Tris-HCl, 5 mM MgCl2, supplemented with 
0.01% CHAPS and 1 mM EDTA, pH 7.4) at 25 °C for 120 min. Displacement experiments were 
performed using 6 concentrations of competing antagonist in the presence of a final concentration 
of ~10 nM [3H] 34. At this concentration, total radioligand binding did not exceed 10% of that added 
to prevent ligand depletion. Nonspecific binding (NSB) was determined in the presence of 100 μM 
NECA. Incubation was terminated by rapid filtration performed on 96-well GF/B filter plates (Perkin 
Elmer, Groningen, the Netherlands), using a PerkinElmer Filtermate-harvester (Perkin Elmer, 
Groningen, the Netherlands). After drying the filter plate at 50 oC for 30 min, the filter-bound 
radioactivity was determined by scintillation spectrometry using the 2450 MicroBeta2 Plate Counter 
(Perkin Elmer, Boston, MA). 
Radioligand association and dissociation assays. Association experiments were performed by 
incubating membrane aliquots containing ~15 μg of CHOhA3 membrane in a total volume of 100 μL 
of assay buffer at 10 or 25 °C with ~10 nM [3H] 34. The amount of radioligand bound to the receptor 
was measured at different time intervals during a total incubation of 120 min. Dissociation 
experiments were performed by preincubating membrane aliquots containing ~15 μg of protein in a 
total volume of 100 μL of assay buffer at 10 or 25 °C for 60 min. After the preincubation, radioligand 
dissociation was initiated by the addition of 5 μl 100 μM unlabeled NECA. The amount of radioligand 
still bound to the receptor was measured at various time intervals for a total of 120 min to ensure 
that full dissociation from hA3 receptor was reached. Incubations were terminated and samples were 
obtained as described under Radioligand Displacement Assay. 
Radioligand Competition Association Assay. The binding kinetics of unlabeled ligands were 






and Mahan.46 The competition association assay was initiated by adding membrane aliquots (15 
μg/well) at different time points for a total of 240 min to a total volume of 100 μl of assay buffer at 
10 °C or 25 °C with ~10 nM [3H] 34 in the absence or presence of a single concentration of competing 
hA3R antagonists (i.e. at their IC50 value). Incubations were terminated and samples were obtained 
as described under Radioligand Displacement Assay. The “dual-point” competition association 
assays were designed as described previously,27 where in this case the two time points were selected 
at 20 (t1)  and 240 min (t2). 
[35S] GTPγS Binding Assay. The assays were performed by incubating 15 µg of homogenized CHOhA3 
membranes in a total volume of 80 µl assay buffer (50 mM Tris-HCl buffer, 5 mM MgCl2, 1 mM EDTA, 
0.05% BSA and 1 mM DTT, pH 7.4) supplemented with 1 µM GDP and 5 µg saponin. The assays were 
performed in a 96-well plate format, where DMSO stock solutions of the compounds were added 
using a HP D300 Digital Dispenser (Tecan, Männedorf, Switserland). The final concentration of 
organic solvent per assay point was ≤0.1%. In all cases, the basal level of [35S] GTPγS binding was 
measured in untreated membrane samples, whereas the maximal level of [35S] GTPγS binding was 
measured by treatment of the membranes with 10 μM 2-Cl-IBMECA. For the insurmountability 
experiments, membrane preparations were pre-incubated with or without antagonists (30-, 100-, 
300-fold Ki values) for 60 min at 25 oC, prior to the addition of 2-Cl-IBMECA (10 µM to 0.1 nM) and 
20 µl [35S] GTPγS (final concentration ~0.3 nM), after which incubation continued for another 30 min 
at 25 oC. For the surmountability (control) experiments, antagonists and 2-Cl-IBMECA were co-
incubated with [35S] GTPγS for 30 min at 25 oC. For all experiments, incubations were terminated and 
samples were obtained as described under Radioligand Displacement Assay, by using GF/B filters 
(Whatman International, Maidstone, UK). 
Data Analysis. All experimental data were analyzed using the nonlinear regression curve fitting 
program GraphPad Prism 6.0 (GraphPad Software, Inc., San Diego, CA). From displacement assays, 






IC50 values were converted into Ki values using the Cheng-Prusoff equation to determine the affinity 
of the ligands.47  The observed association rates (kobs) derived from both assays were obtained by 
fitting association data using one phase exponential association. The dissociation rates were 
obtained by fitting dissociation data to a one phase exponential decay model. The kobs values were 
converted into association rate constants (kon) using the equation kon = (kobs – koff)/[L], where [L] is 
the amount of radioligand used for the association experiments. The association and dissociation 
rates were used to calculate the kinetic KD using the equation KD = koff/kon. Association and 
dissociation rate constants for unlabeled compounds were calculated by fitting the data into the 









































































where k1 is the kon of the radioligand (M-1s-1), k2 is the koff of the radioligand (s-1), L is the radioligand 
concentration (nM), I is the concentration of the unlabeled competitor (nM), X is the time (s) and Y is 
the specific binding of the radioligand (DPM). The control curve (without competitor) from 
competition association assays generates the k1 value and the k2 value was obtained from 
Radioligand association and dissociation assays. With that the k3, k4 and Bmax can be calculated, 
where k3 represents the kon (M-1s-1) of the unlabeled ligand, k4 stands for the koff (s-1)of the unlabeled 
ligand and Bmax equals the total binding (DPM). All competition association data were globally fitted. 
The residence time (RT, in min) was calculated using the equation RT = 1/(60*koff), as koff values are 






(agonist) vs response-variable slope” to obtain potency, inhibitory potency or efficacy values of 
agonists and inverse agonists/antagonists (EC50, IC50 or Emax, respectively). In the (in)surmountability 
assays, Gaddum/Schild EC50 shift equations were used to obtain Schild-slopes and pA2 values; 
statistical analysis of two-way ANOVA with Tukey’s post-test was applied. All experimental values 
obtained are means of at least three independent experiments performed in duplicate, unless stated 
otherwise. R2 and P values were calculated using the GraphPad Prism linear regression analysis 
function. LogP (log partition coefficient) values were calculated using Chemdraw Professional 15.0 
(Cambridge Soft, Perkin Elmer, Waltham Mass). 
Computational studies.  A ligand optimized homology model of the hA3R was generated, following a 
similar approach as has been used before48 and using the Maestro software package (Schroedinger 
Inc, New York). In short: first different homology models were constructed based on the high 
resolution crystal structure of the adenosine A2A receptor (PDB: 4EIY),41 and using a sequence 
alignment from GPCRDB.49, 50 In the subsequent steps we iteratively optimized the model using 
Prime.51-53 During every step the best model was selected based on enrichment (BEDROC-160.9 and 
ROC). For this we used a set of 100 diverse antagonists from ChEMBL54 obtained by “Cluster 
Molecules”.55 We matched 50 decoys to every ligand ionization state, using the DUD-e web service.56 
The final model used here showed excellent enrichment (BEDROC-160.9: 0.55 ROC: 0.80). We 
introduced  a long residence time ligand, 2, in the putative ligand binding site using Induced fit 
docking,57 with H-bond constraints on Asn2506.55.  Based on this we generated a WaterMap42, 43 of 
the apo state of the receptor. Other ligands were docked using core-constrained docking (using the 
core of 2 as constraints). Figures were rendered using PyMol.58 
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The binding affinities of short RT antagonist (5) and long RT antagonist (27) at human adenosine A1 
and A2A receptors, the KRI values of pyrido[2,1-f]purine-2,4- dione derivatives without methoxy-
substitution at C-8 position, the comparison with their methoxy-substituted counterparts, and the 
correlation between pkoff and Log P of the compounds.  
1. Binding affinities of short RT antagonist (5) and long RT antagonist (27) at human adenosine A1 
and A2A receptors.            
Binding affinities of antagonist 5 at hA1 and hA2A receptors have been reported before,1 whilst 
binding affinities of antagonist 27 at hA1 and hA2A receptors were determined as described 
previously.2, 3 Percentage displacement of antagonists (n=2, average) or Ki ± SEM (nM, n=3) at human 
adenosine A1 and A2A receptors are listed in Table S1.  
Table S1. Binding affinities of short RT antagonist (5) and long RT antagonist (27) at human 
adenosine A1 and A2A receptors. 
 
                                                                                                                                                                                                   
a Displacement of [3H]DPCPX from CHO cell membranes expressing the human adenosine A1 receptor. 
Percentage displacement at 10 µM (n=2, average) or Ki ± SEM (nM, n=3). 
b Displacement of [3H]ZM241385 from HEK293 cell membranes expressing the human adenosine A2A receptor. 
Percentage displacement at 10 (5) or 1 µM (27, n=2, average), 
c Published data.1  
 
2. The KRI values of pyrido[2,1-f]purine-2,4-dione derivatives without methoxy-substitution at C-8 
position.                                                                                                                                    
Compound hA1 a hA2Ab 
5 49%c 10%c 






The KRI values of pyrido[2,1-f]purine-2,4-dione derivatives without methoxy-substitution at C-8 
position were obtained as described under “the ‘dual-point’ competition association assays”. 
Experiments were designed as described previously,4 where in this case the two time points were 
selected at 20 (t1)  and 240 min (t2). The results are listed in Table S2.  
Table S2. Kinetic Parameters of Pyrido[2,1-f]purine-2,4-dione Derivatives without Methoxy-




















a  KRI ± SEM (n = 3) or KRI (n = 2, individual estimates in parentheses), obtained at 10 oC from dual point 
competition association assays at 10 °C with [3H]34 on CHO cell membranes stably expressing the hA3R.
 






















3. The comparison between the KRI values of pyrido[2,1-f]purine-2,4-dione derivatives without 
methoxy-substitution at C-8 position and their methoxy-substituted counterparts                                                                                                                   






Figure S1: Comparison of KRI values of compounds with (red bars) and without (blue bars) C-8 methoxy 
substitution. KRI values obtained from dual point competition association assay on CHO cells stably expressing 
hA3R at 10 °C. Each data point is the average of two or three independent experiments performed in duplicate.
 
4.  The correlation between pkoff and LogP for antagonists.                                               
LogP values were calculated using Chemdraw Professional 15.0 (Cambridge Soft, Perkin Elmer, 
Waltham, MA, USA). R2 and P values were calculated using the GraphPad Prism linear regression 
analysis function. The correlations are presented in Figure S2. 







Figure S2: Correlation between pkoff and LogP for antagonists with an elongated carbon chain (1, 5, 9, 10 and 
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About this chapter 
The human adenosine A3 (hA3) receptor has been suggested as a viable drug target in inflammatory 
diseases and in cancer. So far, a number of selective hA3 receptor agonists (e.g. IB-MECA and 2-Cl-IB-
MECA) inducing anti-inflammatory or anticancer effects are under clinical investigation. Drug-target 
binding kinetics is increasingly recognized as another pharmacological parameter, next to affinity, for 
compound triage in the early phases of drug discovery. However, such a kinetics-driven analysis has 
not yet been performed for the hA3 receptor. In this study, we first validated a competition 
association assay for adenosine A3 receptor agonists to determine the target interaction kinetics. 
Affinities and Kinetic Rate Index (KRI) values of 11 ribofurano and 10 methanocarba nucleosides 
were determined in radioligand binding assays. Afterwards, 15 analogues were further selected (KRI 
<0.70 or KRI >1.35) for full kinetics characterization. The structure-kinetics relationships (SKRs) were 
derived and longer residence times were associated with methanocarba and enlarged adenine N6 
and C2 substitutions. In addition, from a kon-koff-KD kinetic map we divided the agonists into three 
subgroups. A residence time “cliff” was observed, which might be relevant to (N)-methanocarba 
derivatives’ rigid C2-arylalkynyl substitutions. Our findings provide substantial evidence that, next to 
affinity, additional knowledge of binding kinetics is useful for developing and selecting new hA3R 








The adenosine A3 receptor is the youngest member discovered in the family of adenosine receptors 
(A1, A2A, A2B and A3), all of which belong to class A G protein-coupled receptors (GPCR).1 Unlike the 
other subtypes, the adenosine A3 receptor is endogenously activated by both adenosine and 
inosine.2 Following agonist activation, the receptor causes a decrease in cAMP levels as it primarily 
couples to Gi protein. The adenosine A3 receptor is widely distributed throughout the body, albeit at 
low expression levels, and its activation can affect numerous organs, tissues and systems. However, 
this receptor is overexpressed in inflammatory and cancer cells, reflecting its importance as a 
therapeutic target and biological marker in these tissues.3, 4 Moreover, the adenosine A3 receptor is 
rapidly internalized within 30 min after agonist exposure.5, 6 It is unresolved whether receptor 
desensitization terminates agonist-induced signaling or if this signaling persists after internalization.7  
Since agonists cause effects of anti-inflammation, cardioprotection and neuroprotection, numerous 
potent and selective agonists have been extensively studied and developed.8-13 Most of these 
agonists are derivatives of adenosine, with substitutions on the adenine nucleobase or the ribose 
moiety. In particular, IB-MECA and 2-Cl-IB-MECA are two potent clinical candidates with excellent 
bioavailability and safety profiles. Selective hA3 receptor agonists are being evaluated for the 
treatment of chronic inflammatory diseases (e.g., rheumatoid arthritis or psoriasis), neuropathic 
pain and cancer (i.e. hepatocellular carcinoma).14-17   
Traditional drug discovery approaches mainly focus on affinity, a parameter that is defined under 
equilibrium conditions. However, it is emerging that selecting ligands based on their affinity alone, 
does not necessarily predict in vivo efficacy very well. This may be due to the dynamic conditions in 
vivo, that often are in contrast to the equilibrium conditions applied in in vitro assays.18 In fact a 
ligand’s kinetic properties may provide a better indication of how a ligand will perform in vivo.19 






criterion. The RT reflects the lifetime of the ligand-receptor complex and can be calculated as the 
reciprocal of the ligand’s dissociation constant.20, 21  
Although the binding kinetics of hA3 receptor agonists are occasionally reported,22, 23 a systematic 
kinetics analysis yielding structure-kinetics relationships (SKRs) has not been conducted. Therefore, 
we firstly validated the binding kinetics of the prototypical hA3 receptor agonists (i.e. IB-MECA and 2-
Cl-IB-MECA), using radioligand displacement and competition association assays. Then, two series of 
ribofurano and methanocarba ([3.1.0]bicyclohexane) adenosine derivatives were evaluated for both 
their affinity (Ki) and kinetics (kinetic rate index values, kon, koff, and RTs). This allowed a complete 
SKR analysis next to a more traditional SAR study. Afterwards, a retrospective evaluation linking 
residence times and in vivo efficacies was discussed.  Last but not least, from a kon-koff-KD kinetic map 
we divided the agonists into three subgroups, providing a possible direction for the further 
development of hA3R agonists. 
Method 
Chemicals and reagents. [3H]8-Ethyl-4-methyl-2-phenyl-(8R)-4,5,7,8-tetrahydro-1H- imidazo[2,1-i]-
purin-5-one ([3H]PSB-11, specific activity 56 Ci·mmol-1) was obtained with the kind help of Prof. C.E. 
Müller (University of Bonn, Germany). 5′-N-methylcarboxamidoadenosine (MECA) was provided by 
one of the authors (KAJ). Unlabeled PSB-11, 1-deoxy-1-[6-[((3-Iodophenyl)methyl)amino]-9H-purin-
9-yl]-N-methyl-β-D-ribofuranuronamide (IB-MECA), and 2-chloro-N6-(3-iodobenzyl)-adenosine-5′-N-
methyluronamide (2-Cl-IB-MECA) were purchased from Tocris Ltd. (Abingdon, UK). 5’-N-
ethylcarboxamidoadenosine (NECA) was purchased from Sigma-Aldrich (Steinheim, Germany). 
LUF5501, LUF5505, LUF5500, LUF5506 and LUF5521 have been synthesized and described previously 
by de Zwart et al.24; LUF5595, LUF5586 and LUF5589 have been described by van Tilburg et al.25; 
MRS7140, MRS5980, MRS7154, MRS7549, MRS5655, MRS5679, MRS5698, MRS5644, MRS5667 and 
MRS7294 have been described by Tosh et al.26-29, and MRS3558 by Tchilibon et al.30. Adenosine 






acid (BCA) and BCA protein assay reagents were purchased from Pierce Chemical Company 
(Rockford, IL, USA). Chinese hamster ovary (CHO) cells stably expressing the human adenosine A3 
receptor (CHOhA3) were a gift from Dr. K-N Klotz (University of Würzburg, Germany). All other 
chemicals were obtained from standard commercial sources and were of analytical grade. 
Cell culture and membrane preparation. CHOhA3 cells were cultured and membranes were prepared 
and stored as previously described.22 Protein determination was done through use of the 
bicinchoninic acid (BCA) method.31  
Radioligand equilibrium displacement assays. Membrane aliquots containing ~15 μg of CHOhA3 
protein were incubated in a total volume of 100 μL assay buffer (50 mM Tris-HCl, 5 mM MgCl2, 
supplemented with 0.01% CHAPS and 1 mM EDTA, pH 7.4) at 10 °C for 240 min. Displacement 
experiments were performed using 6 concentrations of competing agonist in the presence of a final 
concentration of ~10 nM [3H]PSB-11. At this concentration, total radioligand binding did not exceed 
10% of that added to prevent ligand depletion. Nonspecific binding (NSB) was determined in the 
presence of 100 μM NECA. Incubation was terminated by rapid filtration performed on 96-well GF/B 
filter plates (Perkin Elmer, Groningen, the Netherlands), using a PerkinElmer Filtermate-harvester 
(Perkin Elmer, Groningen, the Netherlands). After drying the filter plate at 50 oC for 30 min, the 
filter-bound radioactivity was determined by scintillation spectrometry using the 2450 MicroBeta2 
Plate Counter (Perkin Elmer, Boston, MA). 
Radioligand competition association assays. The binding kinetics of unlabeled ligands were 
quantified using the competition association assay based on the theoretical framework by Motulsky 
and Mahan.32 The competition association assay was initiated by adding membrane aliquots (15 
μg/well) at different time points for a total of 240 min to a total volume of 100 μl of assay buffer at 
10 °C with ~10 nM [3H]PSB-11 in the absence or presence of a single concentration of competing hA3 
receptor agonists (i.e. at their IC50 value), and, in some experiments indicated, in the simultaneous 






Radioligand Displacement Assay. The “dual-point” competition association assays were designed as 
described previously,33 where in this case the two time points were selected at 20 min (t1) and 240 
min (t2). 
Data analysis. All experimental data were analyzed using the nonlinear regression curve fitting 
program GraphPad Prism 7.0 (GraphPad Software, Inc., San Diego, CA). From displacement assays, 
IC50 values were obtained by non-linear regression analysis of the displacement curves. The obtained 
IC50 values were converted into Ki values using the Cheng-Prusoff equation to determine the affinity 
of the ligands,34 using a KD value for the radioligand of 1.04 nM at 10 oC as determined from 
radioligand association and dissociation assays, as previously reported.35 The residence time (RT, in 
min) was calculated using the equation RT = 1/(60 * koff) ), as koff is in s-1. Association and dissociation 
rate constants for unlabeled compounds were calculated by fitting the data into the competition 









































































where k1 is the kon of the radioligand (M-1s-1), k2 is the koff of the radioligand (s-1), L is the radioligand 
concentration (nM), I is the concentration of the unlabeled competitor (nM), X is the time (s) and Y is 
the specific binding of the radioligand (DPM). The control curve (without competitor) from 
competition association assays generates the k1 value, and the k2 value was obtained from previous 






where k3 represents the kon (M-1s-1) of the unlabeled ligand, k4 stands for the koff (s-1) of the unlabeled 
ligand and Bmax equals the total binding (DPM). All competition association data were globally fitted. 
Results 
The effects of GTP on affinities and kinetics of the reference hA3 receptor agonists IB-MECA and 2-Cl-
IB-MECA 
Firstly, we determined the effects of GTP (1 mM) on both the affinities and binding kinetics of the 
reference hA3 receptor agonists IB-MECA and 2-Cl-IB-MECA. Under the two different assay 
conditions (i.e. in the absence or presence of GTP) the affinities of IB-MECA and 2-Cl-IB-MECA were 
significantly different (Table 1). We observed a rightward shift of the displacement curves in the 
presence of GTP (Figure 1A, closed symbols), representing an approx. 3–fold decrease in affinity for 
both compounds. Of note, under both experimental conditions, monophasic displacement curves 
were obtained with pseudo-Hill coefficients close to unity (Table 1). 
Furthermore, there were significant differences between the kinetics of hA3 receptor agonists tested 
in the absence or presence of 1 mM GTP. In the competition association assays without GTP, both 
IB-MECA and 2-Cl-IB-MECA produced a typical “overshoot”, representative of a slower dissociation 
from the hA3 receptor than the radioligand [3H]PSB-11 (Figure 1B). This overshoot, however, 
disappeared in the experiments with GTP (Figure 1C). Thus, their KRI values were decreased from 
well-above-unity in the absence of GTP to close-to-unity in the presence of GTP. The koff values of IB-
MECA and 2-Cl-IB-MECA determined by the Motulsky-Mahan model32 were (1.8 ± 0.2) x 10-4 s-1 and 
(7.2 ± 1.1) x 10-5 s-1 in the absence of GTP, respectively (Table 1), which were smaller than the 
corresponding values determined in the presence of GTP (IB-MECA: (8.5 ± 3.0) x 10-4 s-1; 2-Cl-IB-
MECA: (5.7 ± 1.5) x 10-4 s-1, Table 1). Consequently, the calculated RTs in the absence of GTP were 
longer than the values derived when GTP was present (IB-MECA: 95 min vs 20 min; 2-Cl-IB-MECA 231 






two assay conditions were similar. Therefore, in order to define a more agonist-relevant receptor 
interaction, we decided to use the competition association assay in the absence of GTP for the 
determination of the affinities and the binding kinetics of other unlabeled hA3 receptor agonists in 
the remainder of the study.  


























(5.9 ± 0.9) x 
105 ns 
(1.8 ± 0.2) x 
10-4 ns 
95 ± 13 
* 











(4.0 ± 0.5) x 
105 ns 





0.18 ± 0.04 
(9.7) 
 
+ 1 mM GTP 
IB-MECA 






(4.5 ± 2.5) x 
105 
(8.5 ± 3.0) x 
10-4 
20 ± 7 




8.0 ± 0.08 
(10) 
-1.1 ± 0.1 
1.07 ± 
0.07 
(4.0 ± 2.3) x 
105 
(5.7 ± 1.5) x 
10-4 
29 ± 8 
1.4 ± 0.9 
(8.9) 
 
a pKi ± SEM (n ≥ 3, mean Ki value in nM), obtained from radioligand binding assays with [3H]PSB-11 on the hA3 
receptor stably expressed on CHO cell membranes. 
b KRI ± SEM (n = 3) obtained from dual-point competition association assays with [3H]PSB-11 on the hA3 
receptor stably expressed on CHO cell membranes. 
c kon ± SEM (n ≥ 3), obtained from competition association assays with [3H]PSB-11 on the hA3 receptor stably 
expressed on CHO cell membranes. 
d koff ± SEM (n ≥ 3), obtained from competition association assays with [3H]PSB-11 on the hA3 receptor stably 
expressed on CHO cell membranes. 
e RT = 1/(60*koff); RT is expressed in min, whereas koff is expressed in s-1. 






Student’s t-test was applied for the comparison of values of pKi, KRI, kon, koff, RT obtained in the absence vs 
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Figure 1: Displacement of specific [3H]PSB-11 binding from the recombinant hA3 receptor stably expressed on 
CHO cell membranes by IB-MECA and 2-Cl-IB-MECA in the absence (closed symbols) or presence of 1 mM GTP 
(open symbols) (A); [3H]PSB-11 competition association experiments in the absence (B) or presence (C) of 1 
mM GTP with IB-MECA (blue) or 2-Cl-IB-MECA (red). Combined graphs are shown from at least three 
experiments performed in duplicate (see Table 1 for pKi values and kinetic parameters). Note, t1, t2 are 
indicated, which are the two time points used in KRI determinations. 
 
Binding affinity (Ki) of hA3 receptor agonists  
The binding affinities of 22 human A3 receptor agonists in total were determined in equilibrium 
radioligand displacement studies. All agonists were able to concentration-dependently inhibit 
specific [3H]PSB-11 binding to the human A3 receptor and their affinities are listed in Tables 2 and 3. 
The agonists displayed moderate to high binding affinities, ranging from 82 nM for agonist MRS5679 
to 0.72 nM for agonist MRS5980, while the reference agonists IB-MECA and 2-Cl-IB-MECA had an 
affinity of 2.9 and 3.5 nM, respectively. 
Kinetic Rate Index (KRI) values of hA3 receptor agonists 
Subsequently, these hA3 receptor agonists were screened in what is termed a “dual-point” 
competition association assay. The specific binding of [3H]PSB-11 was measured after 20 and 240 
minutes in the absence and presence of a single concentration (i.e. IC50) of unlabeled hA3 receptor 
agonists, which yielded their Kinetic Rate Index (KRI). The KRI values of the hA3 receptor agonists 
ranged from 0.64 (LUF5501) to 5.56 (MRS5679) (Tables 2 and 3). Agonists with a KRI value larger 
than unity are considered to have a slower dissociation rate, and thus a longer RT, than the 
radioligand used, i.e. [3H]PSB-11, and vice versa. Agonists having KRI values below 0.70 (LUF5501 and 
LUF5505) or above 1.35 (LUF5521, IBMECA to LUF5595, LUF5589, MRS7140, MRS5980, and 











Agonists R1 R2 R3 
pKi 
(mean Ki in 








Kinetic KD  
(mean pKD)f 
LUF5501 H -Ph-3-Cl -CH2OH 




(1.7 ± 0.2) 
x 105 
(1.6 ± 0.2) x 
10-3 
10 ± 1.3 9.2 ± 1.4 (8.0) 
LUF5505 H -Ph-3-Br -CH2OH 




(8.8 ± 1.4) 
x 104 
(1.1 ± 0.04) 
x 10-3 
16 ± 0.6 12 ± 1.9 (7.9) 
LUF5500 H -Ph-4-Cl -CH2OH 




N.D. N.D. N.D. N.D. 
LUF5506 H -Ph-4-I -CH2OH 




N.D. N.D. N.D. N.D. 
LUF5521 H -Ph-4-I -CONHCH2CH3 
7.9 ± 0.06 
(14) 
2.06 ± 0.82 
(1.9 ± 0.3) 
x 105 
(1.4 ± 0.1)   
x 10-4 
117 ± 12 0.76 ± 0.13 (9.1) 
MECA H -CH2Ph -CONHCH3 
7.4 ± 0.04 
(42) 


















a pKi ± SEM (n ≥ 3, mean Ki value in nM), obtained from radioligand binding assays with [3H]PSB-11 on the hA3 receptor stably expressed on CHO cell membranes. 
b KRI ± SEM (n = 3) or KRI (n1,n2) (n = 2), obtained from dual-point competition association assays with [3H]PSB-11 on the hA3 receptor stably expressed on CHO cell 
membranes. 
c kon ± SEM (n ≥ 3), obtained from competition association assays with [3H]PSB-11 on the hA3 receptor stably expressed on CHO cell membranes. 
d koff ± SEM (n ≥ 3), obtained from competition association assays with [3H]PSB-11 on the hA3 receptor stably expressed on CHO cell membranes. 
e RT = 1/(60 * koff); RT is expressed in min, whereas koff is expressed in s-1. 
f KD = koff/kon, expressed in nM  
g values taken from Table 1 
h N.D. = not determined 
IB-MECAg H -CH2Ph-3-I -CONHCH3 
8.5 ± 0.07 
(2.9) 
1.55 ± 0.07 
(5.9 ± 0.9) 
x 105 
(1.8 ± 0.2)   
x 10-4 
95 ± 13 0.30 ± 0.06 (9.5) 
2-Cl-IB-MECAg -Cl -CH2Ph-3-I -CONHCH3 
8.5 ± 0.1 
(3.5) 
2.02 ± 0.06 
(4.0 ± 0.5) 
x 105 
(7.2 ± 1.1)   
x 10-5 
231 ± 34 0.18 ± 0.04 (9.7) 





(9.6 ± 3.1) 
x 105 
(2.3 ± 1.0)   
x 10-4 
72 ± 30 0.24 ± 0.13 (9.6) 
LUF5586 H -CH2Ph-3-I -CH2OCH2CH3 




N.D. N.D. N.D. N.D. 
LUF5589 -Cl -CH2Ph-3-I -CH2OCH2CH3 8.7 ± 0.08 
(2.2) 
1.66 ± 0.21 (8.4 ± 0.7) 
x 105 
(1.2 ± 0.3) x 
10-4 
138 ± 37 
0.14 ± 0.04 (9.8) 
MRS7294 -C≡C-C4H2S-5-Cl -CH3 -CH2OH 




(8.2 ± 3.8) 
x 105 
(1.3 ± 0.2) x 
10-4 












Agonists X R1 R2 
pKi 









Kinetic KD  
(mean pKD)f 
  MRS7294 g  N -C≡C-C4H2S-5-Cl -CH3 8.4 ± 0.05 (3.7) 
1.63  
(1.50; 1.75) 
(8.2 ± 3.8) 
x 105 
(1.3 ± 0.2)  
x 10-4 
125 ± 14 0.16 ± 0.02 (9.8) 
MRS5980 N -C≡C-C4H2S-5-Cl -CH3 9.2 ± 0.09 (0.72) 
1.97  
(1.87; 2.06) 
(9.0 ± 2.3) 
x 105 
(4.0 ± 1.0)  
x 10-5 
417 ± 104 
0.044 ± 0.016 
(10.4) 
MRS7140 C -C≡C-C4H2S-5-Cl -CH3 8.3 ± 0.08 (5.2) 
1.94  
(1.82; 2.07) 
(3.2 ± 1.2) 
x 105 
(8.5 ± 0.3)  
x 10-5 
196 ± 8 0.27 ± 0.10 (9.6) 
MRS7154 N -C≡C-C4H2S-5-Cl -CH2CH2CH3 8.7 ± 0.06 (2.2) 
1.67  
(1.75; 1.59) 
(4.0 ± 0.7) 
x 105 
(6.2 ± 1.2)  
x 10-5 
270 ± 51 0.15 ± 0.04 (9.8) 
MRS3558 N -Cl -CH2Ph-3-Cl 9.1 ± 0.2 (1.0) 
1.49  
(1.33; 1.64) 
(5.7 ± 0.8) 
x 105 
(1.0 ± 0.2)  
x 10-4 

















a pKi ± SEM (n ≥ 3, mean Ki value in nM), obtained from radioligand binding assays with [3H]PSB-11 on the hA3 receptor stably expressed on CHO cell membranes. 
b KRI ± SEM (n = 3) or KRI (n1,n2) (n = 2), obtained from dual-point competition association assays with [3H]PSB-11 on the hA3 receptor stably expressed on CHO cell 
membranes. 
c kon ± SEM (n ≥ 3), obtained from competition association assays with [3H]PSB-11 on the hA3 receptor stably expressed on CHO cell membranes. 
d koff ± SEM (n ≥ 3), obtained from competition association assays with [3H]PSB-11 on the hA3 receptor stably expressed on CHO cell membranes. 
e RT = 1/(60 * koff); RT is expressed in min, whereas koff is expressed in s-1. 
f KD = koff/kon, expressed in nM 
g MRS7294 has a ribofurano ring (see also Table 2). 
MRS5655 N -C≡C-Ph -CH2Ph-3-Cl 8.5 ± 0.09 (3.6) 
2.58  
(2.05; 3.12) 
(4.0 ± 0.8) 
x 105 
(1.8 ± 0.3)  
x 10-5 
909 ± 165 
0.046 ± 0.013 
(10.3) 
MRS5644 N -C≡C-Ph -CH3 8.6 ± 0.01 (2.4) 
2.42  
(2.28; 2.56) 
(4.5 ± 1.8) 
x 105 




0.031 ± 0.013 
(10.5) 
 MRS5698 N 
-C≡C-(3,4-di-F-
Ph) 
-CH2Ph-3-Cl 8.1 ± 0.2 (9.4) 
4.21  
(3.75; 4.67) 
(1.3 ± 0.4) 
x 105 









-CH2Ph-3-Cl 7.1 ± 0.05 (82) 
5.56  
(6.00; 5.11) 




-CH3 8.3 ± 0.05 (4.6) 
3.34  
(3.14; 3.55) 
(1.8 ± 0.3) 
x 105 











Binding kinetics of selected hA3 receptor agonists using the competition association assay 
Next, the kinetic binding parameters of selected agonists that had either low or high KRI values were 
determined using the competition association assay with [3H]PSB-11. Association rate constants 
varied by only 11-fold, ranging from (8.8 ± 1.4) x 104 M-1s-1 for LUF5505 to (9.6 ± 3.1) x 105 M-1s-1 for 
LUF5595 (Tables 2 and 3). There was a more pronounced 188-fold difference in dissociation rate 
constants, in line with the divergent KRI values (LUF5501: (1.6 ± 0.2) x 10-3 s-1 vs MRS5698: (8.5 ± 0.7) 
x 10-6 s-1). The shortest RT agonist, LUF5501, presented a gradually ascending curve in the 
competition association assays (Figure 2A). Of note, the dissociation of MRS5679, with the largest 
KRI value (5.56), was determined as very slow and not readily quantitated under the current method. 
The very prominent “overshoot” in the competition association curve was already indicative of a 
much slower dissociation rate than [3H]PSB-11 (Figure 2B). Notably, a significant correlation 
between the negative logarithm of the dissociation rate constants for the selected agonists and their 
KRI values derived from the kinetic assays was obtained (Figure 3A), which confirmed that a 
compound’s KRI value is a good predictor for its dissociation rate constant. Besides, a significant 
correlation was also observed between the agonist affinities (pKi values) determined in equilibrium 
displacement experiments and their pKD values (“kinetic KD values”) derived from competition 
association experiments, although the pKD values were on average one log unit higher than the pKi 
values (Figure 3B). As to the kinetic rate constants (kon or koff) of the hA3 receptor agonists, their 
association rate constants showed a better correlation with affinity than their dissociation rate 
constants (Figure 3C and 3D). Furthermore, a kon-koff-KD “kinetic map” (Figure 4) was constructed 
based on the compounds’ divergent affinities (expressed as kinetic KD values) and rate constants, 
yielding a division of these agonists into three different sub-categories: agonists that show koff values 
in a lower range but due to divergent kon values have various KD values (Group A); agonists that show 
koff values in a median range but due to divergent kon values (although smaller than in Group A) have 
different KD values (Group B); and two agonists that have relatively poor affinity due to larger koff 
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Figure 2: Competition association experiments with [3H]PSB-11 binding to the recombinant hA3 receptor stably 
expressed on CHO cell membranes (10 °C) in the absence or presence of unlabeled short-residence-time 
agonist LUF5501 (A), or long-residence-time agonist MRS5679 (B). Representative graphs are shown from one 
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Figure 3: The correlations between the negative logarithm of each hA3 receptor agonist dissociation rate 
constants (pkoff) and the kinetic rate index (KRI) (A), the A3 receptor agonist affinity (pKi) and the “kinetic KD” 
(pKD) (B), logarithm of association rate constants (logkon) (C) and negative logarithm of dissociation rate 
constants (pkoff) (D). Data used in these plots are detailed in Tables 2 and 3. 
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Figure 4: Kinetics map (y axis: kon in M-1·s-1, x axis: koff in s-1) of all compounds that were kinetically 
characterized in this study. kon and koff values were obtained through competition association assays. The 
kinetically derived affinity (KD= koff/kon) is represented through diagonal parallel lines. The ribofurano 






Structure−Affinity Relationships (SAR) and Structure−Kinetics Relationships (SKR) of hA3 receptor 
agonists 
First, a series of hA3R agonists with either a natural or 5’-modified ribose moiety was investigated 
(Table 2). LUF5501-LUF5506 have an intact ribofurano moiety and a halogen substitution at the N6 
phenyl group of the core scaffold. 3-Chlorophenyl substitution (LUF5501) provided somewhat better 
affinity than 3-bromophenyl (LUF5505) or 4-chlorophenyl (LUF5500) substitution (31 nM vs 78 nM; 
31 nM vs 51 nM, respectively). The affinity of the 4-iodophenyl substituted derivative (LUF5506) was 
similar to LUF5501 (31 nM vs 29 nM). Meanwhile, their KRI values showed that halogen substitution 
at meta-position led to lower KRI values than those at para-position of the phenyl ring. The KRI 
values of LUF5501 and LUF5505 were at the lower end (< 0.7) with 0.64 and 0.65, respectively. The 
full-curve competition association experiments confirmed their similar fast dissociation rates 
(LUF5501: (1.6 ± 0.2) x 10-3 s-1; LUF5505: (1.1 ±  0.04) x 10-3 s-1). Worthy of note, LUF5501 proved to 
have the shortest RT (10 min) among the entire selection of compounds.    
When the 5’-hydroxymethylene group (LUF5506) was substituted by an ethylcarboxamide (-
CONHCH2CH3, LUF5521), affinity (14 nM vs 29 nM) and particularly the KRI increased (2.06 vs 0.99). 
The association and dissociation rates of LUF5521 were (1.9 ± 0.3)  x 105 M-1s-1 and (1.4 ± 0.1) x 10-4 s-
1, respectively, and its RT was calculated as 117 min.    
We then examined benzyl substitutions at the N6 position of the core scaffold, with a 
methylcarboxamide (-CONHCH3) modification of the 5’-position on the ribofuran moiety (MECA, IB-
MECA and 2-Cl-IBMECA). MECA had an affinity of 42 nM with a KRI value of 1.24. When iodine was 
introduced at the 3-position of the benzyl ring, yielding IB-MECA, affinity was strongly increased (2.9 
nM vs 42 nM) as well as the KRI value (1.55 vs 1.24); with a further chlorine atom substitution at the 
C-2 position on the core scaffold (2-Cl-IBMECA) there was no further increase in affinity (3.5 nM vs 
2.9 nM), but its KRI value increased significantly (2.02 vs 1.55), which is the largest value in this series 






105 M-1s-1 vs (4.0 ± 0.5)  x 105 M-1s-1) , however 2-Cl-IBMECA had a slower dissociation rate ((7.2 ± 1.1) 
x 10-5 s-1 vs (1.8 ± 0.2) x 10-4 s-1) as had been immanent already from their KRI values. The RTs of IB-
MECA and 2-Cl-IBMECA were calculated from their dissociation rate constants as 95 min and 231 
min, respectively.  
Interestingly, when the amide at the 5’-position on the ribofurano ring of 2-Cl-IBMECA was changed 
to an ether function (-CH2OC3H5, LUF5595), both association ((9.6 ± 3.1)  x 105 M-1s-1 vs (4.0 ± 0.5)  x 
105 M-1s-1) and dissociation (2.3 ± 1.0) x 10-4 s-1 vs (7.2 ± 1.1) x 10-5 s-1) became faster, even though 
the compound was still a slowly dissociating agonist compared with the radioligand (KRI: 1.37). 
Finally, the effect of the 2-Cl substitution was further confirmed in the comparison between 
LUF5586 and LUF5589. Their affinities were similar (2.8 nM vs 2.2 nM), but with 2-Cl, LUF5589 had a 
higher KRI than LUF5586 (1.66 vs 1.30), and the RT of LUF5589 was determined as 138 min. In 
addition, a larger substituent at the C-2 position (MRS7294) was tolerated with respect to both 
affinity and kinetics, at least in combination with a small N6-methyl substituent. 
Table 3 summarizes our findings on the series of ring-rigidified methanocarba derivatives that 
maintain a receptor-preferred North (N) conformation, with the flexible ribose-substituted MRS7294 
included once more to allow a comparison. MRS7294, MRS5980, MRS7140, MRS7158 and MRS7154 
share a common fragment ((5-chlorothiophen-2-yl)ethynyl) at the C-2-position (R1 group). MRS7294, 
the agonist with unmodified ribofuran moiety, served as the starting of the analysis, which had both 
high affinity (3.7 nM) and a large KRI value (1.63). By competition association experiments its 
association and dissociation rates were determined as (8.2 ± 3.8) x 105 (M-1s-1) and (1.3 ± 0.2) x 10-4 s-
1, respectively; its RT was calculated as 125 min. When the ribofurano ring was changed by the 
methanocarba moiety (MRS5980), the affinity increased to the sub-nanomolar range (0.72 nM vs 3.7 
nM) and its KRI value also increased largely (1.97 vs 1.63). The full-curve competition association 
experiments showed that MRS5980’s association rate was slightly faster ((9.0 ± 2.3) x 105 M-1s-1 vs 






((4.0 ± 1.0) x 10-5 s-1 vs (1.3 ± 0.2) x 10-4 s-1) than its ribose-equivalent. The RT of MRS5980 was 417 
min. When the nitrogen atom at the N-1-position was replaced by a carbon atom (MRS7140), the 
affinity remained high (5.2 nM), and its kinetics profile was not much altered compared with 
MRS5980 (kon: (3.2 ± 1.2) x 105 M-1s-1 vs (9.0 ± 2.3) x 105 M-1s-1; koff: (8.5 ± 0.3) x 10-5 s-1 vs (4.0 ± 1.0) x 
10-5 s-1). Changing the mono-methyl substitution at the N6 position (MRS5980) for di-methyl 
substitution (MRS7158), severely compromised both affinity and KRI value (618 nM vs 0.72 nM; 0.93 
vs 1.97). When mono-substitution at the N6 position (MRS7140) was extended to n-propyl 
(MRS7154), affinity remained high (2.2 nM), like the KRI value (1.67); both association and 
dissociation rates of MRS7154 were quite similar to MRS5980 (kon: (4.0 ± 0.7) x 105 M-1s-1 vs (9.0 ± 
2.3) x 105 M-1s-1; koff: (6.2 ± 1.2) x 10-5 s-1 vs (4.0 ± 1.0) x 10-5 s-1), with RTs of 270 min and 417 min, 
respectively.  
The methanocarba derivatives MRS3558, MRS5655, MRS5679 and MRS5698 share their R2 groups 
(3-chlorobenzyl substitution). When the 2-Cl substituent of MRS3558 was replaced by the bulky and 
rigid phenylethynyl (MRS5655), the affinity decreased from 1.0 nM (MRS3558) to 3.6 nM (MRS5655), 
while the KRI value increased, however (1.49 vs 2.58). In the competition association assays the 
association rate constants of MRS3558 and MRS5655 were similar ((5.7 ± 0.8) x 105 M-1s-1 vs (4.0 ± 
0.8) x 105 M-1s-1), while the dissociation rate constants were 5.6-fold different ((1.0 ± 0.2) x 10-4 s-1 vs 
(1.8 ± 0.3) x 10-5 s-1), leading to a RT for MRS5655 of 909 min. When the phenylethynyl of MRS5655 
was 3,4-di-fluorinated as in MRS5698, the affinity was reduced from 3.6 nM (MRS5655) to 9.4 nM 
(MRS5698), whilst the KRI value increased significantly from 2.58 (MRS5655) to 4.21 (MRS5698), 
with both slower association and dissociation rate constants (kon: (4.0 ± 0.8) x 105 M-1s-1 vs (1.3 ± 0.4) 
x 105 M-1s-1; koff: (1.8 ± 0.3) x 10-5 s-1 vs (8.5 ± 0.7) x 10-6 s-1), thus extending RT from 909 min to 1961 
min. Furthermore, when the phenylethynyl fragment of MRS5655 was expanded to a 4-
biphenylethynyl substitution on the R1 group (MRS5679), the affinity suffered from 3.6 nM 
(MRS5655) to 82 nM (MRS5679); however, its KRI value increased dramatically from 2.58 to 5.56. 






from all these compounds we learned there can be a clear dichotomy between affinity and residence 
time. 
When the benzyl substitutions at the N6 position (R2 in Table 3) were replaced by a simple 
monomethyl (i.e. MRS5655 to MRS5644; MRS5679 to MRS5667), their binding affinities to hA3 
receptors were not compromised (MRS5655/MRS5644: 3.6 nM vs 2.4 nM) or even increased 
(MRS5679/MRS5667: 82 nM vs 4.6 nM), and so were the kinetics profiles of MRS5655 and MRS5644. 
The KRI values of MRS5679 and MRS5667 were both at the higher end (5.56 and 3.34). 
 
 Discussion 
 Effects of GTP on agonist binding to the human adenosine A3 receptor  
In the current study, the binding interactions of unlabeled hA3 receptor agonists were determined in 
radioligand binding experiments with the reference tritiated antagonist [3H]PSB-11. The favorable 
binding characteristics of this radioligand served us particularly well in the competition association 
experiments where robust binding over time could still be measured in the presence of unlabeled 
ligands, essential for the calculation of the association and dissociation rate constants. It is well 
known that antagonists occupy a GPCR irrespective of whether it is coupled to a G protein, whereas 
agonists prefer the G protein-coupled state of the receptor 36. Addition of GTP to the incubation 
mixture induces an uncoupling between receptor and available G protein, which leads to a lower 
apparent receptor affinity for agonists. We confirmed this behavior in our equilibrium displacement 
experiments, in which the two reference agonists IB-MECA and 2-Cl-IB-MECA had a 3-4-fold lower 
affinity in the presence of GTP (Figure 1A, Table 1). Interestingly, all displacement curves had 
pseudo-Hill coefficients of approx. unity (Table 1), suggesting that the agonists recognized one 
receptor state in both the presence and absence of GTP, most likely a G protein-coupled state (no 






states in subsequent competition association assays by measuring these in the absence or presence 
of GTP (Figure 1B). Interestingly, the association rate constants were identical for the two states 
(Table 1). Apparently, the ligand, when approaching the receptor from the extracellular side, is 
insensitive to the coupling status at the intracellular G protein interface. However, the dissociation 
kinetics proved to be (significantly) different between the states, up to 8-fold for 2-Cl-IB-MECA 
(Table 1), suggesting that dissociating from the receptor is influenced by the absence or presence of 
the G protein. We then performed further experiments in the absence of GTP, as we felt that for the 
case of the hA3 receptor this experimental condition provides us information on the more relevant 
high-affinity agonist binding state of the receptor. The mathematical modeling provided by Motulsky 
and Mahan32 does not allow the calculation of two receptor states with corresponding kinetic 
parameters. Hence, in a number of cases similar to ours it was decided to include GTP in the assays. 
For the adenosine A1 receptor, we included GTP in our assays, forcing the receptor to be in one 
lower affinity, G protein-uncoupled state only; with this restriction, the kinetic parameters of 
agonists were determined as conveniently as antagonists.37 Likewise, the team of Charlton included 
GTP in kinetic assays on the muscarinic M3 receptor.38 On the other hand, GTP was excluded in 
assays on the adenosine A2A receptor, as agonist affinity at this protein is insensitive to GTP in both 
equilibrium and kinetics assays.39  
Methodological aspects of the radioligand binding assays 
To ensure an accurate and robust kinetic quantification, experiments were performed at 10 oC, as 
reported and documented previously.35 Initially, a so-called dual-point competition association assay 
yielding KRI values for the hA3 receptor was performed as a “kinetic screening campaign” to increase 
throughput in comparison to the traditional, more elaborate, competition association experiments.35 
Although fast kinetics of agonist binding (e.g. LUF5501, Figure 2A) was determined accurately at a 






characteristics (MRS5679, Figure 2B) could not be reliably determined with the Motulsky-Mahan 
equations. Meanwhile, its large KRI value (5.56) undoubtedly reflects its slow dissociation.  
Besides the significant correlation between the agonists’ KRI values and dissociation rate constants 
(Figure 3A), the equilibrium Ki and kinetic KD values were also well correlated (Figure 3B). Despite 
this correlation there are large discrepancies in values between the equilibrium affinities (Ki) and 
kinetic KD values. In general, the kinetic pKD values are higher than pKi values, with differences from 
0.5 to 2.1 log-unit (LUF5501 and MRS5698), whilst the short RT agonists have smaller differences 
than long RT agonists. This phenomenon suggests that the affinities determined in the radioligand 
displacement studies may not reflect the true affinity of the compounds as many of them have 
residence times much longer than the (already long) incubation time of 240 min. In fact, this points 
to a general caveat in end-point assays in which the equilibrium characteristics of the probe, e.g., a 
radiolabeled or fluorescently tagged compound, determine the assay protocol without further 
consideration of the same characteristics of the unlabeled ligands to be tested.    
Furthermore, there was a significant correlation between kon (k3) and affinity values (Ki) of the 
agonists, but no relationship was found between koff (k4) and Ki (Figure 3C and 3D). Such correlation 
between affinity and on-rates has been reported in the case of other GPCR 40 and ion channels.41, 42 
However, in the current study, variations in association rate constants were approximately 10-fold 
(logkon: 5.0 to 6.0), much smaller than at the other targets mentioned above. In addition, all the 
association rates were well below the diffusion limit of around 107 M-1s-1, which had been observed 
previously for membrane-bound proteins.43  
Ligand optimization based on Structure−Kinetics Relationships (SKR) 
All the agonists examined in the current study have been reported, and the riboside MRS7294 was 
most recently disclosed as a hA3 receptor agonist.28 Most ribofurano derivatives (Table 2) had been 






more recently, showing generally improved affinities over the earlier compounds.26-29 Although most 
of these compounds have been described in the context of structure-affinity relationships (SARs), we 
reasoned that an extensive structure−kinetics relationships (SKRs) analysis is warranted since kinetic 
profiles are emerging indicators of in vivo functional efficacy.18, 20, 21, 45  
In the series of ribofurano derivatives (Table 2), the most outstanding agonist with respect to 
residence time was 2-Cl-IB-MECA (231 min). The underlying chemical features that prolonged the 
residence time in the ribofurano series are: i) a chlorine atom at the C2 position (R1 in Table 2, IB-
MECA vs 2-Cl-IB-MECA, 95 min vs 231 min; LUF5586 vs LUF5589 in KRI: 1.30 vs 1.66), ii) a bulky 
meta-iodobenzyl substitution at the N6 position of the adenine nucleobase (R2 in Table 2, MECA vs 
IB-MECA in KRI: 1.24 vs 1.55), and iii) an amide modification at the 5’ position (R3 in Table 2, 2-Cl-IB-
MECA vs LUF5595: 231 min vs 72 min; LUF5506 vs LUF5521 in KRI: 0.99 vs 2.06). Interestingly, slow 
dissociation kinetics of agonists can be maintained by introducing an extended linear side chain at 
the C2 position and removing the bulky substituent at the N6 position (i.e. N6-Me analogue MRS7294 
in RT: 125 min). The kinetic behavior of another known reference agonist, 2-(1-hexynyl)-N-
methyladenosine (HEMADO), also confirmed this observation from comparison with other 
research.45, 46  
More impressive kinetics were observed in the methanocarba series. From a previous study it was 
concluded that a possible H-bond interaction between the amide modification at the original 5’ 
position (-CONHCH3) and residues in the binding pocket of the hA3 receptor was a key feature of 
agonist kinetics.47 Comparing the kinetics of ribofurano MRS7294 and its methanocarba equivalent 
MRS5980 provides evidence the conformational-constrained (N)-methanocarba moiety as a 
ribofurano ring substitute adds to the slow dissociation of MRS5980, suggesting this rigid ring system 
fits even better in the ligand binding pocket. Additionally, the N1 atom on the adenine core is 
contributing to slow dissociation (1-deza MRS7140 vs MRS5980 in RT: 196 min vs 417 min). The N6 






larger n-propyl (MRS5980 vs MRS7154) and 3-chlorobenzyl substituent (MRS5644 vs MRS5655), with 
respect to both affinity and kinetics. Apparently, differences in lipophilicity between the N6-
substituents did not seem to matter either. Data for the R1 (C2 position) substituent were already 
commented on in the Results section. It is noteworthy that the 3,4-difluorophenyl fragment 
contributed to a long residence time of MRS5698, quite similar to the 2,4-difluorophenyl fragment 
we encountered in A2A receptor antagonists displaying long residence time.48  
So far the human A3 receptor has not been crystallized yet, although its most homologous relative, 
the adenosine A1 receptor, has.49 Homology models of the A3 receptor have been constructed, and 
their relevance has been recently reviewed and discussed.50 It appeared that the interaction of the 
extended and rigid 2-arylethynyl groups at the C-2 position (as in e.g., MRS5679 and MRS5644) with 
the A3 receptor required  an outward movement of TM2. Although the agonists’ path of binding to 
or dissociation from the A3 receptor is unknown, one could speculate that such reorganization of 
TM2 “locks” the C2-substituted agonist. This reasoning stems from a molecular dynamics simulation 
and site-directed mutation study of the ligand dissociation pathway from the human adenosine A2A 
receptor,51 for which we used a high resolution crystal structure.52 It taught us there may be a lid 
adjacent to the ligand binding pocket retaining the ligand for some time before the compound 
leaves the receptor. A follow-up study revealed that ligand dissociation correlated with the strength 
of the salt-bridge between His264 in EL3 and Glu169 in EL2.53 It would be interesting to learn 
whether a similar mechanism exists for the A3 receptor.   
Retrospective evaluation of selected agonists with complete kinetic profiles   
IB-MECA (RT = 95 min) and 2-Cl-IB-MECA (RT = 231 min) are two reference full agonists for the hA3 
receptor. Despite numerous reports about their controversial cardioprotection,54, 55 they have been 
taken into a series of clinical trials: for IB-MECA, in total 12 completed or planned trials have been 
reported related to inflammatory conditions (e.g., keratoconjunctivitis sicca, rheumatoid arthritis, 






hepatocellular carcinoma, hepatitis C).56, 57 Intuitively one would expect that long residence time hA3 
receptor agonists could be beneficial in chronic diseases, for instance to allow once daily dosing.  
More recently, the neuroprotective effect provided by hA3 receptor agonists has been receiving 
attention.11, 58 A number of agonists have been designed and evaluated both in in vitro and in vivo 
functional experiments, especially for the treatment of chronic neuropathic pain.26, 27, 29 MRS5698 in 
particular, having the longest residence time (1961 min) from our research, has been studied 
extensively in various pre-clinical animal models of neuropathic pain.59-61 We, however, hesitate to 
link the binding kinetics profile of MRS5698 with its in vivo effects, also because issues such as 
pharmacokinetics and species differences (human/rodent) may play an important but yet unknown 
role. 
The adenosine A3 receptor has a peculiar and rapid desensitization/internalization profile in cultured 
cells.6 However, the fast desensitization after A3 agonist exposure under in vitro conditions does not 
generalize to in vivo pain models. MRS5698 maintained full efficacy over a five-day period, with the 
drug administered either by daily injection or by an implanted mini-pump to provide a steady state 
plasma concentration.55 Prolonged MRS5698 exposure in the rat did not reduce its efficacy, as would 
be expected from agonist-induced desensitization alone. Thus, additional studies of agonist 
occupancy of the receptor and subsequent receptor processing are warranted to further explore this 
interesting target for combatting neuropathic pain.  
Kinetic Map  
Using the association (kon) and dissociation (koff) rate constants obtained from competition 
association experiments (Tables 2 and 3), a kinetic map (Figure 4) was constructed by plotting these 
values on the y-axis and x-axis, respectively. The dashed diagonal parallel lines represent the 
kinetically derived KD values (KD = koff/kon). Out of this map three subgroups emerged, which were 






composed of methanocarba derivatives (Figure 4, red) and ribofurano derivatives (Figure 4, blue), 
respectively. Group B is a mixture of these two compound classes, with the methanocarba 
derivatives mainly displaying smaller koff values. Thus, rigidifying the ribose ring with the bicyclic 
group consistently prolonged the dissociation time. This general division indicates a different mode 
of receptor-ligand interaction during the binding and unbinding process of the two ligand groups. It 
also seems there is a clear residence-time “cliff” between Groups A (having one rigid C2-
phenylethynyl or 4-biphenylethynyl group with or without one enlarged N6-benzyl group) and B 
(having multiple enlarged adenine substituents) in the kinetic map.  
In each subgroup, agonists exhibit koff values in a similar range, but have different kon values. As a 
consequence, variation in KD values in each group was observed (Group A: ~10-fold; Group B: ~100-
fold; Group C: ~3-fold). Previous SKR studies have primarily focused on optimizing dissociation rates 
and residence times for designing a kinetically favorable ligand. Yet recently, there has been 
increasing acknowledgement of the important role association rate constants may play in 
determining the efficacy of a drug as the result of increased rebinding or increased drug-target 
selectivity.21, 62 A kinetic map would thus allow for the selection of compounds with appropriate 
residence times whilst exploring the role of association rate constants.   
In summary, an agonist-related competition association assay at the hA3 receptor was validated, and 
a series of ribofurano and methanocarba derivatives were kinetically profiled for the first time. A kon-
koff-KD kinetic map was constructed and subsequently the agonists with complete kinetic profile were 
divided into three sub-groups based on their residence times. Longer residence times were 
associated with methanocarba (vs. ribose) and enlarged adenine N6 and C-2 (rigid arylalkynyl) 
substitutions. We identified agonists with very long residence times, but these may not be the most 
therapeutically favorable for treating various conditions in view of the fast desensitization of the 






necessarily longer than target turnover time, may be vital parameters in the development of hA3R 
agonists for therapeutic use.  
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About this chapter 
Scintillation Proximity Assay (SPA) is a radio-isotopic technology format used to measure a wide 
range of biological interactions, including drug-target binding affinity studies. The assay is 
homogeneous in nature, as it relies on a "mix and measure" format. It does not involve a filtration 
step to separate bound from free ligand as is the case in a traditional receptor-binding assay.  
For G protein-coupled receptors (GPCR), it has been shown that optimal binding kinetics, next to a 
high affinity of a ligand, can result in more desirable pharmacological profiles. However, traditional 
techniques to assess kinetic parameters tend to be cumbersome and laborious. We thus aimed to 
evaluate whether SPA can be an alternative platform for real-time receptor-binding kinetic 
measurements on GPCR.  
To do so we first validated the SPA technology for equilibrium binding studies on a prototypic class A 
GPCR, the human adenosine A1 receptor (hA1R). Differently to classic kinetic studies, the SPA 
technology allowed us to study binding kinetic processes almost real-time, which is impossible in the 
filtration assay. To demonstrate the reliability of this technology for kinetic purposes, we performed 
so-called competition association experiments. The association and dissociation rate constants (kon 
and koff) of unlabeled hA1R ligands were reliably and quickly determined, and agreed very well with 
the same parameters from a traditional filtration assay performed simultaneously.  
In conclusion, SPA is a very promising technique to determine the kinetic profile of the drug-target 
interaction. Its robustness and potential for high-throughput may render this technology a preferred 








Scintillation Proximity Assays (SPA) are a bead-based assay technology for radioligand binding 
studies in drug research.1, 2 The technology is homogeneous in nature, as it relies on a "mix and 
measure" format and avoids a filtration step to separate bound from unbound radiolabeled ligand as 
is the case in a traditional receptor-binding assay.3 SPA technology, therefore, allows the rapid and 
convenient assay of a wide range of molecular interactions in a homogeneous system.4, 5 With the 
help of a suitable radiolabeled probe the affinity of a compound for its drug target, such as G 
Protein-Coupled Receptors (GPCR), can be determined fast and reliably by SPA technology.6-9 
Nowadays in industry, SPA technology is routinely used for radioligand binding assays to determine 
ligand affinity in drug screening applications where high throughput is required.10  
Alongside classical affinity parameters such as IC50 and Ki values, drug-target binding kinetics, in 
particular the receptor-ligand residence time (RT), is emerging as an additional parameter to assess 
the therapeutic potential of drug candidates with respect to drug efficacy and safety.11-14 
Consequently, there is an increasing awareness of the importance of measuring the kinetics of 
drug−target interactions. In the research field of GPCR a number of structure-kinetics relationship 
(SKR) studies have been published that suggest that for educated compound triage for further 
studies binding kinetics should be included in the decision process.15-17 Therefore, a fast and trustful 
approach to determine kinetic parameters is urgently required. 
By definition, the RT is inversely proportional to the ligand dissociation-rate constant (koff). This rate 
constant together with the association-rate constant (kon) can both be retrieved from appropriate 
kinetic experiments following the principles laid out by Motulsky and Mahan.18 In that publication 
so-called competition association experiments are described, which are conventionally performed in 
the form of filtration assays. In this format the method consumes a great amount of radioligand, 
membrane protein and other materials. Besides, the tediousness and limited throughput of the 






So far there have been quite a few attempts to improve the efficiency of kinetic screening. For 
example, an insurmountable effect of slowly dissociating ligands in a functional IP-1 assay in SPA 
format on the neurokinin-1 (NK1) receptor has been described.19 In this case the costly functional 
methodology only allowed for the qualitative screening of the slowly dissociating ligands. Another 
kinetic screening approach in the form of SPA technology took the observation of a Ki (leftward) shift 
20 over time as proof for slowly dissociating compounds from different GPCR.6, 7 Although SPA 
technology was used in both studies, they were essentially equilibrium binding assays with long 
incubation times (10 h in gonadotropin-releasing hormone (GnRH) receptor,6 and 5 h in human CCR5 
receptor 7) that were inevitable to determine the kinetic effects with a read-out that was rather 
qualitative.      
Recently, a method called dual-point competition association assay that enables the relatively fast 
kinetic screening of series of compounds was introduced by Guo et al.21 By measuring radioligand 
binding at two different time points in the absence or presence of unlabeled competitors, the kinetic 
rate index (KRI) was obtained. Although both fast and slowly dissociating ligands can be 
characterized and discriminated with this index, it is still a rather qualitative measure, as the kon (k3) 
and koff (k4) values of the unlabeled ligands cannot be obtained. Thus, the resolution of a kinetic 
comparison for SKR through KRI values is not as high as with full kinetic parameters.17   
The true benefit of SPA technology relies in its separation-free approach, which could allow almost 
continuous kinetic measurements over time. Previously, a kinetic study of radioligand association 
and dissociation by SPA technology has been reported for the inositol trisphosphate receptor 
(InsP3R), a Ca2+ channel, and it indeed confirmed that SPA is a useful technique to determine fast kon 
and koff values that might have been difficult to obtain using traditional methods.22 However, SPA 
technology as a format to study the kinetics of radioligand binding to GPCR has not been reported in 






Therefore in the present study we aimed to fill this gap by converting a filtration-based kinetic 
radioligand binding assay to an SPA format, using a prototypical GPCR, the human adenosine A1 
receptor (hA1R), as an example. We firstly validated the SPA technology for equilibrium binding 
studies by comparing it to traditional filtration assays performed simultaneously. In these 
experiments both hA1R agonists and antagonists were tested, and their affinity determined with SPA 
technology was similar to the affinity determined in a filtration assay. In subsequent kinetic studies, 
the SPA technology was of great benefit, as it allowed us to follow radioligand binding over time in a 
single well, which is impossible in the filtration assay. We further demonstrated that advantage in 
the most laborious of all kinetic assays, the competition association experiment. The association and 
dissociation rate constants of unlabeled ligands for hA1R were reliably and quickly determined and 
agreed very well with the same parameters in a traditional filtration assay performed in parallel. 
 
Methods 
Chemicals and reagents. [3H]-1,3-Dipropyl-8-cyclopentyl-xanthine ([3H]-DPCPX, specific activity 113.4 
Ci·mmol-1) was purchased from ARC, Inc. (St. Louis, MO). The Wheat Germ Agglutinin-Polyvinyl 
toluene (WGA-PVT) SPA beads (RPNQ0001) were purchased from PerkinElmer (Waltham, MA). 
Adenosine deaminase (ADA) was purchased from Boehringer Mannheim (Mannheim, Germany). 1,3-
Dipropyl-8-cyclopentylxanthine (DPCPX, a selective hA1R antagonist),23 8-cyclopentyl-3-N-[3-((3-(4-
fluorosulphonyl)benzoyl)-oxy)-propyl]-1-N-propyl-xanthine (FSCPX, an irreversible hA1R 
antagonist),24 2-chloro-N6-cyclopentyladenosine (CCPA, a specific hA1R agonist),25 N6-
Cyclopentyladenosine (CPA, a specific hA1R agonist [25]),  5'-N-ethylcarboxamidoadenosine (NECA, a 
non-selective agonist for adenosine receptors)26 and guanosine-5'-triphosphate (GTP) were 
purchased from Sigma (St. Louis, MO). BCA (Bicinchoninic acid) protein assay kit was obtained from 
Pierce Chemical Company (Rockford, IL). LUF5834 (a hA1R partial agonist) was synthesized in our 






were obtained from Prof. Steve Hill (University of Nottingham, UK). All other chemicals were of 
analytical grade and obtained from standard commercial sources.  
Cell culture and membrane preparation. CHO cells stably expressing hA1R were grown in Ham’s F12 
medium containing 10% (v·v-1) normal adult bovine serum, streptomycin (100 μg∙mL-1), penicillin 
(100 IU·mL-1), and G418 (0.4 mg·mL-1) at 37 °C in 5% CO2. Cells were subcultured twice weekly at a 
ratio of 1:20 on 10-cm ø culture plates. For membrane preparation, cells were subcultured 1:10 and 
then transferred to 15-cm ø plates. Cells grown to 80% to 90% confluency were detached from 
plates by scraping them into 5 mL phosphate-buffered saline (PBS), collected, and centrifuged at 700 
g (3 000 rpm) for 5 min. Cell pellets derived from 30 plates were pooled and resuspended in 20 mL of 
ice-cold 25 mM Tris-HCl buffer (pH 7.4). An UltraThurrax (Heidolph Instruments, Schwabach, 
Germany) was used to homogenize the cell suspension. Membranes and the cytosolic fraction were 
separated by centrifugation at 100 000 g (31 000 rpm) in a Beckman Optima LE-80K ultracentrifuge 
(Beckman Coulter, Fullerton, CA) at 4 °C for 20 min. The pellet was resuspended in 15 mL of the Tris-
HCl buffer, and the homogenization and centrifugation step was repeated. Tris-HCl buffer (10 mL, pH 
7.4) was used to resuspend the pellet, and ADA was added (0.8 IU·mL-1) to break down endogenous 
adenosine. Membranes were stored in 250 μL aliquots at -80 °C. Concentrations of membrane 
protein were measured using the BCA method.28 
Radioligand displacement experiments. The displacement experiments were performed using 10 
concentrations of competing ligands in 25 μL of assay buffer (For antagonists: 50 mM Tris-HCl [pH 
7.4 at 25 oC]; for agonists: 50 mM Tris-HCl supplemented with 5 mM MgCl2 [pH 7.4]) in the presence 
of another 25 μL of assay buffer with a final concentration of 2.4 nM [3H]-DPCPX. At this 
concentration, total radioligand binding did not exceed 10% of that added to prevent ligand 
depletion. Nonspecific binding (NSB) was determined in the presence of 100 μM CPA. Each condition 






The SPA technology: A mixture of 5 μg protein membrane and 1 mg SPA bead was pre-coupled in a 
shaker (Vibrax VXR ,IKA) in a volume of 50 μL of assay buffer at room temperature for 30 min. Then 
together with the radioligand and competing ligands, the membrane-bead mixture was dispatched 
in an Isoplate-96 Microplate (Perkin Elmer, Groningen, the Netherlands), in a final reaction volume 
of 100 μL. The plate was incubated for 1 h inside the counting chamber of a 2450 MicroBeta2 Plate 
Counter (Perkin Elmer, Groningen, the Netherlands) at the ambient temperature of 28 oC. The 
binding values were recorded in corrected counts per minute (CCPM).  
The filtration assay: Membrane aliquots containing 5 μg protein were incubated together with the 
radioligand and competing ligands in a total volume of 100 μL assay buffer in a 96-well plate. After 1 
h incubation at room temperature, the incubation was terminated by rapid vacuum filtration to 
separate the bound and free radioligand through 96-well GF/B filter plates using a PerkinElmer 
Filtermate-harvester (Perkin Elmer, Groningen, the Netherlands). Filters were subsequently washed 
three times with ice-cold wash buffer (50 mM Tris-HCl [pH 7.4], supplemented with 5 mM MgCl2). 
After 30 min of dehydration of the filter plate at 50 oC, the filter-bound radioactivity was determined 
by scintillation spectrometry using the 2450 MicroBeta2 Plate Counter. The binding values were 
recorded in both counts per minute (CPM) and disintegrations per minute (DPM). 
Radioligand association and dissociation experiments. The SPA technology: The membrane-bead 
mixture was prepared as described under “Radioligand Displacement Experiments”. Once the 
membrane-bead mixture was added to the wells of an Isoplate-96 Microplate, measurements of 
radioligand bound to the receptor were started immediately and continued every 30 sec for 1 h, 
using the 2450 MicroBeta2 Plate Counter. Subsequently, radioligand dissociation was initiated by the 
addition of 10 μM unlabeled CPA. Another 1 h of measurements at every 30 sec was used to record 
the amount of radioligand still bound to the receptor. Samples were obtained as described under 






The filtration assay: Association experiments were performed by incubating membrane aliquots 
containing 5 μg of protein in a total volume of 100 μL of assay buffer at 28 °C with 2.4 nM [3H]-
DPCPX. The amount of radioligand bound to the receptor was measured at different time intervals 
during a total incubation of 1 h. Dissociation experiments were performed by preincubating 
membrane aliquots containing 5 μg of protein in a total volume of 100 μL of assay buffer for 1 h. 
After the preincubation, radioligand dissociation was initiated by the addition of 10 μM unlabeled 
CPA. The amount of radioligand still bound to the receptor was measured at various time intervals 
for a total of 1 h to ensure that full dissociation from hA1R was reached. Incubations were 
terminated and samples were obtained as described under Radioligand Displacement Experiments.  
Competition association experiments. The binding kinetics of unlabeled ligands was quantified using 
the competition association assay based on the theoretical framework by Motulsky and Mahan.18 In 
this experiment, one concentration of IC50 or three different concentrations of unlabeled competing 
ligands were tested—namely, at IC25, IC50, and IC75 determined from “Radioligand Displacement 
Experiments”. For (partial) agonists, 1 mM of GTP was present in the agonist assay buffer to ensure 
that agonist binding only occurred to the uncoupled form of hA1R.13 The assay was performed by 
incubating in a total volume of 100 μL of assay buffer at 28 °C with 2.4 nM [3H]-DPCPX.  
The SPA technology: The membrane-bead mixture was prepared as described under “Radioligand 
Displacement Experiments”. Once the membrane-bead mixture was added to the wells of an 
Isoplate-96 Microplate, measurements of radioligand bound to the receptor were started 
immediately and continued every 30 sec for 2 h, using the 2450 MicroBeta2 Plate Counter. Samples 
were obtained as described under Radioligand Displacement Experiments.  
The filtration assay: The competition association assay was initiated by adding membrane aliquots (5 
μg per well) at different time points for a total of 2 h in the absence or presence of competing ligand. 
Incubations were terminated and samples were obtained as described under Radioligand 






Data analysis. All values obtained are means of at least three independent experiments performed 
in duplicate. All experimental data were analyzed by using GraphPad Prism 6 (GraphPad Software, 
Inc., San Diego, CA), as in the description of previous work from our research group,21 including the 
following analysis: IC50 values obtained from competition displacement binding data were converted 
to Ki values using the Cheng-Prusoff equation 29, the kon and koff values for radiolabeled and 
unlabeled ligands were fitted and calculated, and the kon and koff values were used to calculate 
residence times (in min) and kinetic dissociation binding constants (kinetic KD). 
  
Results 
The affinity (Ki) of hA1R ligands in displacement experiments.  
The affinities of several hA1R ligands were determined by displacement experiments formatted with 
SPA technology or as filtration assays. The tested hA1R ligands showed concentration-dependent 
inhibition of specific [3H]-DPCPX binding, and the data of antagonists (DPCPX, FSCPX) or partial 
agonist (LUF5834) were best fitted to a one-state competition model, while the data of full agonists 
(CCPA, NECA) were best fitted with a two-state receptor model. Affinities of all ligands determined 
by both SPA technology and filtration assay are shown in Table 1. All compounds showed high 
affinities, with those of antagonists and partial agonist in the nanomolar range. The agonists 
displayed high, nanomolar affinity for the so-called high affinity state, and lower, submicromolar 
affinity for the low affinity state. The affinities of the hA1R ligands from these equilibrium 
experiments were in good agreement between SPA technology and filtration assay (Figure 1). Due to 
the irreversible binding characteristics of FSCPX only its “apparent” affinity could be determined, 








Table 1. Comparison of the affinity of representative hA1R antagonists and (partial) agonists obtained from 
displacement studies of specific [3H]-DPCPX binding from hA1R membranes by SPA technology or filtration 
assay, respectively. Values are means ± s.e.m of at least three independent experiments performed in 
duplicate. For full agonists CCPA and NECA, displacement curves were best analyzed with a two-state model, 
yielding Ki values for a high affinity state and a low affinity state of the receptor. 
 
Compound SPA Ki (nM) Filtration Ki (nM) 
FSCPX 0.9 ± 0.02a 1.6 ± 0.1a 
DPCPX 4.3 ± 0.4 3.3 ± 0.3 
LUF5834 6.2 ± 0.5 4.3 ± 0.6 
CCPA 
7.0 ± 1.1 (high) 8.3 ± 3.8 (high) 
861 ± 156 (low) 1010 ± 159 (low) 
NECA 
8.0 ± 2.3 (high) 7.8 ± 3.8 (high) 
282 ± 80 (low) 301 ± 39 (low) 
 
a “Apparent” affinity of this irreversibly binding antagonist. 
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Figure 1: Correlation of the negative logarithm of hA1R ligands’ affinity (pKi) determined by SPA and in a 
filtration assay  Agonists: CCPA, NECA, LUF5834; Antagonist: DPCPX, FSCPX. 
 
The association (kon) and dissociation rate constants (koff) of [3H]-DPCPX at hA1R.  
Receptor association and dissociation rates of [3H]-DPCPX were directly determined in classic 
radioligand association and dissociation experiments with either SPA technology or filtration assays. 






(Figure 2), indicating a relative fast kon of 0.40 ± 0.05 nM-1 ·min-1 by SPA technology and 0.24 ± 0.03 



















Figure 2: Association and dissociation kinetics of [3H]-DPCPX (2.4 nM) to and from hA1R stably expressed on 
CHO cell membranes (28 oC), measured in SPA technology (n=3, combined and normalized, Fig. 2A) or filtration 
assay (n=3, combined and normalized, Fig. 2B). 10 µM CPA was used as a displacer to initiate the dissociation. 
Association data was fitted in Prism 6 using one-phase exponential association. Dissociation data was fitted 
using one-phase exponential decay.   
 
Binding of the radioligand was reversible after the addition of 10 μM CPA and complete dissociation 
was reached after approximately 25 min (Figure 2). The koff of [3H]-DPCPX from the hA1R was 0.20 ± 
0.02 min-1 with SPA technology and 0.25 ± 0.01 min-1 in the filtration assay (Table 2). The kinetic KD 
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(koff/kon) of [3H]-DPCPX was 0.50 ± 0.08 nM (SPA) and 1.04 ± 0.14 nM (filtration) (Table 2). The 
residence time (RT, 1/koff) of [3H]-DPCPX was calculated as 5.0 ± 0.5 or 4.0 ± 0.2 min, determined by 
SPA or filtration, respectively. 
Table 2. Comparison of the kinetic rates of [3H]-DPCPX obtained from classic kinetic association and 
dissociation experiments from hA1R membranes at 28 oC by SPA assay and filtration assay. Values are means ± 
s.e.m of three independent experiments performed in duplicate. Equations used are as follows: kon = (kobs - 
koff)/[[3H]-DPCPX]; Kinetic KD = koff/kon; RT = 1/koff. RT is residence time. 
 
[3H]-DPCPX SPA Filtration 
kon (nM-1 ·min-1) 0.40 ± 0.05 0.24 ± 0.03 
koff (min-1) 0.20 ± 0.02 0.25 ± 0.01 
Kinetic KD (nM) 0.50 ± 0.08 1.0 ± 0.1 
RT (min) 5.0 ± 0.5 4.0 ± 0.2 
 
The Competition Association Assay at hA1R.  
With the established kon (k1) and koff (k2) values of [3H]-DPCPX binding from classic association and 
dissociation experiments, kon (k3) and koff (k4) values of unlabeled DPCPX were determined by fitting 
the values based on the mathematical model as previously described (see Methods). Three different 
concentrations of unlabeled DPCPX, lower than (IC25), equal to and higher than (IC75) its IC50 value, 
were tested (Figure 3). Its kon and koff values determined by this competition association method 
were 0.72 ± 0.16 nM–1·min–1 and 0.50 ± 0.01 min–1 by SPA (Figure 3A and Table 3) or 0.19 ± 0. 04 
nM–1·min–1 and 0.27 ± 0.03 min–1 by filtration (Figure 3B and Table 3), which were in good 
accordance with the k1 and k2 values determined in the classic association and dissociation 
experiments (Table 2 and Figure 2). Since the kinetic KD values and affinities (Ki) obtained from the 
different equilibrium and kinetic experiments are well comparable (Tables 1-3) this further verified 
that the competition association assay by SPA technology could be accurately used to determine the 
binding kinetics of unlabeled A1R ligands. 
We then used FSCPX, an irreversibly binding hA1R antagonist, as a further validation tool. In the 






negligible dissociation, which was observed in both SPA (Figure 4A) and filtration assay (Figure 4B). 
Its kon and koff values determined by the competition association method were 0.0047 ± 0.0007 nM–
1·min–1 and 0.0064 ± 0.0013 min–1 by SPA or 0.0019 ±  0.0003 nM–1·min–1 and 0.0060 ± 0.0020 min–1 
by filtration (Table 3).  
 
Table 3. Comparison of the kinetic rate constants, residence times (RT) and kinetic KD values of representative 
hA1R antagonists and (partial) agonists obtained from competition association experiments to hA1R expressed 
on CHO cell membranes at 28 oC by SPA assay and filtration assay. For (partial) agonists LUF5834, CCPA and 
NECA, 1 mM GTP was present in the assay. The kon (k3), koff (k4) values of the unlabeled compounds were 
determined in [3H]-DPCPX (2.4 nM) competition association experiments. RTs and kinetic KDs were determined 
in the same manner as described in Table 2.  
 















































167 ± 56 3.2 ± 0.4 
DPCPX 0.72 ± 0.16 0.50 ± 0.01 2.0 ± 0.1 0.69 ± 0.15 0.19 ± 0. 04 0.27 ± 0.03 3.7 ± 0.4 1.4 ± 0.1 
LUF5834 0.13 ± 0.05 0.50  ± 0.05 2.0 ± 0.1 3.9 ± 1.5 0.062 ± 0.006 0.23 ± 0.03 4.4 ± 0.5 3.7 ± 0.5 
CCPA 0.0094 ± 
0.0022 
0.73 ± 0.04 1.4 ± 0.1 78 ± 19 0.016 ± 0.002 1.5 ± 0.03 0.68 ± 
0.01 
92 ± 9 
NECA 0.0014 ± 
0.0004 
0.54 ± 0.06 1.9 ± 
0.02 
386 ± 36 0.0012 ± 
0.0001 
0.60 ± 0.04 1.7 ± 0.1 500 ± 8 
 
The other unlabeled ligands included the hA1R partial agonist LUF5834 and full agonists CCPA and 
NECA. Their kon and koff values were determined in both SPA and filtration assays, in the presence of 
1 mM GTP (Figures 5-7 and Table 3). The current mathematical model does not allow the calculation 
of two receptor states with corresponding kinetic parameters; the inclusion of GTP in the assay 
forces the receptor to be in one lower affinity, G protein-uncoupled, state only. With this restriction 
the kinetic parameters of both partial and full agonists were determined as conveniently as the two 
antagonists (Table 3). The kinetic profiles (kon and koff) of all hA1R ligands obtained by SPA were in 






nature, FSCPX was not included in the correlation. The correlation between kinetic KD values from 
either SPA or filtration assay was high too (Figure 8C). Finally, with data from all experiments at hand, 
we concluded that the equilibrium Ki and kinetic KD values from both SPA technology and filtration 
assay were also highly correlated (Figure 8D and 8E). 
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Figure 3: Competition association experiments with [3H]-DPCPX binding to hA1R stably expressed on CHO cell 
membranes (28 oC) in the absence or presence of 1.5 nM, 4.5 nM, and 14 nM of unlabeled DPCPX by SPA assay 































 % c tr l






























+  2 5  n M  F S C P X
  
 
Figure 4: Competition association experiments with [3H]-DPCPX binding to hA1R stably expressed on CHO cell 
membranes (28 oC) in the absence or presence of 25 nM FSCPX, measured in SPA technology (n=4, combined 
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Figure 5: Competition association experiments with [3H]-DPCPX binding to hA1R stably expressed on CHO cell 
membranes (28 oC) in the absence or presence of 8 nM, 25 nM, and 75 nM of unlabeled LUF5834 by SPA 
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Figure 6: Competition association experiments with [3H]-DPCPX binding to hA1R stably expressed on CHO cell 
membranes (28 oC) in the absence or presence of 210 nM, 620 nM, and 1860 nM of unlabeled CCPA by SPA 
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Figure 7: Competition association experiments with [3H]-DPCPX binding to hA1R stably expressed on CHO cell 
membranes (28 oC) in the absence or presence of 250 nM, 1069 nM, and 3334 nM of unlabeled NECA by SPA 
assay (n=3, one representative experiment, Fig. 7A) or filtration assay (n=3, combined and normalized, Fig. 7B).
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Figure 8: Correlation of the negative logarithm of hA1R ligands’ association rates (pkon, Fig. 8A) and dissociation 
rates (pkoff, Fig. 8B) determined by SPA (x-axis) and filtration assay (y-axis). Agonists: CCPA, NECA, LUF5834; 
Antagonist: DPCPX. Correlation of the negative logarithm of hA1R ligands’ kinetic KD (pKD) determined by SPA (y-
axis) and filtration (x-axis). For (partial) agonists LUF5834, CCPA and NECA only the low affinity state of the 
receptor was taken into account due to the presence of 1 mM GTP in the competition association experiments 
(Fig. 8C). Correlation of the negative logarithm of hA1R ligands’ affinity (pKi) from displacement studies of 
specific [3H]-DPCPX binding from hA1R membranes and the negative logarithm of hA1R ligands’ kinetic KD (pKD) 










In this study we developed and validated a method based on the principles of a scintillation proximity 
assay (SPA) for the determination of kinetic characteristics of GPCR ligands. The adenosine A1 
receptor was used as our workhorse, together with a number of reference ligands with divergent 
characteristics. In the following we discuss the benefits and relatively minor concerns of the 
approach.  
Advantages of SPA technology.  
We substituted a standard filtration assay by SPA technology to determine the kinetics of the drug-
receptor interaction. In that setting the most obvious improvement is that the event of ligand 
association and dissociation to and from the receptor can be measured almost in real-time without 
washing steps which are indispensable in a filtration assay. This improvement brings the benefit of 
great efficiency in kinetic radioligand binding experiments. 
For example, in the filtration format association and dissociation kinetics of [3H]-DPCPX to and from 
hA1R are determined separately, because it is impractical to perform both association and 
dissociation experiments in one 96-well plate. However in the SPA format only a single well is 
required to record such a full curve (Figure 2). This also brings impressively improved throughput in 
the competition association assay of unlabeled ligands with [3H]-DPCPX as the radioligand. In an 
individual filtration experiment to measure competition association a whole 96-well plate is used, 
allowing for 2 duplicate curves from 3 different concentrations of unlabeled ligand and a control 
curve. However, with SPA only a few wells are required to obtain the same results, as is shown in Figs 
3-7. This is due to the 6-detector panel operating simultaneously in the counter, allowing a rich data 






experiment by SPA is reduced to 1-2 days from almost one week of practical work by filtration, with 
the additional benefit of much less bench time.   
The SPA technology not only improved the speed and throughput of the kinetic radioligand binding 
experiments, but also provided more, more precise and more accurate data.  The competition 
association experiment is based on the Motulsky-Mahan model for competition association, which 
requires a substantial number of data points for plotting curves and subsequent analysis. In other 
words, the more data points obtained, the more accurate kon and koff can be determined. The SPA 
technology enables to acquire a great number (‘more’) of data points, from one well rather than 
separate tubes (‘more precise’). In this case of a 2-hour experiment, one well on a 96-well plate was 
sampled every 30 sec, yielding a total of 240 data points in one curve, while in the comparable 
filtration assay there are only a labor-intensive dozen or so (Figure 3-7).  A further reason of concern 
in the filtration assay is that the separation step only differentiates bound from unbound ligand, 
irrespective of whether the binding process itself consists of several steps 7, or that weaker 
interactions are broken such that only a fraction of receptor-ligand complexes might be detected 
after washing 30. In the absence of filtration steps SPA technology provides the possibility to collect 
this information without these caveats (‘more accurate’). Lastly, overall financial expenses are 
favorable. Although the beads come at a price, the hugely reduced number of wells makes the 
experiment very cost-effective. 
Differences in SPA technology from filtration assay.  
SPA is a homogeneous bead-based technique, in which the receptor membrane protein is coupled 
with a certain type of SPA bead. Although there are several approaches to add SPA beads to the 
reaction (such as a precoupled format, a simultaneous addition ("T=0") format, or delayed addition 
format 10), for kinetic experiments precoupling of the cell membranes with SPA beads is necessary. 
The convenience of doing so is that bead and membrane are treated as a single reagent, thus 






importantly, the membrane-bead ration needs to be optimized to generate a useful specific 
radioligand binding “window”. In our case, 5 µg of hA1R membrane protein was associated with 1 mg 
of WGA-PVT beads. Adding an excess of SPA beads would ensure that all the membrane is captured 
and a maximum signal is obtained, but the excess might equally contribute to an increased 
background signal 1. It should be realized that besides normal non-specific binding (NSB) another 
background signal called non-proximity effect (NPE) may play a role. This was clearly observed in 
kinetic assays. The NPE is to describe that if a radioligand stays in close proximity, the bead would be 
activated irrespective of whether the radioligand is bound to the bead or membrane-bead mixture 2. 
From Figure 2A it seems that [3H]-DPCPX did not fully dissociate from the hA1R as was the case in the 
filtration assay (Figure 2B), with an elevated baseline of approx. 10% of radioligand binding. This 
observation does not necessarily mean there was still 10% of [3H]-DPCPX binding to the hA1R, but 
rather indicates that some of the liberated [3H]-DPCPX stayed in the proximity of the bead, yielding a 
weak signal. 
In the SPA technology there is no need to add liquid scintillation fluid after harvesting as in filtration 
assays. As a consequence the typical CPM-DPM conversion from the spectrometer’s counting 
efficiency as a result of quenching cannot be done 31-33. As all events take place at the surface of the 
SPA bead 2 the light emitting process cannot be quenched. A further different and unique aspect of 
SPA technology and corresponding equipment is that samples are monitored from both top and 
bottom and a count is only a count when top and bottom detectors both record the light quant 
within a certain amount of time. It is possible that a light quant is emitted in the top of the well by 
dispersion by the beads, while this quant is not seen by the bottom detector. The counter has the 
possibility to make a correction for this and therefore the CPM measured with SPA are referred to as 
CCPM which stands for “corrected” CPM (the x-axis of Figure 5A, 6A and 7A) 33. 






 Despite the many benefits of using SPA technology there are also challenges in SPA radioligand 
binding studies. As mentioned above, the higher background signal of SPA consists of NSB and/or 
NPE. The NPE can be reduced by centrifuging the beads or allowing them to settle prior to counting, 
and by increasing the volume of the assay, but all these work-around solutions are either not feasible 
or impractical in kinetic radioligand binding experiments.  
Secondly, although not much of an issue in our current experiments, the window of specific binding 
may need further consideration. Along this vein one may try different SPA beads. There are two basic 
types of SPA beads: one is composed of plastic-based polyvinyltoluene (PVT), the other is silica-based 
yttrium silicate (Ysi). In general, PVT beads are bigger in size, in a regular ball shape, but lighter, while 
Ysi beads are crystal amorphous solids, which are heavier 2, 10. Although in our case of the hA1R we 
chose the PVT beads, it was recently reported that two types of Ysi beads were used for radioligand 
binding studies on the adenosine A2A receptor [34,35].Apart from the above mentioned beads 
designed for photomultiplier tube/well-based counters, there is another type of yttrium based beads 
optimized for sensitive imaging-based detectors,  the red-shifted yttrium oxide (YO) SPA bead. Both 
Ysi and YO SPA beads have been reported to enable HTS and to improve the filtration method [36,37]. 
It would be also interesting to use those Ysi beads to perform the radioligand binding kinetic studies. 
Thirdly, even in a fast operation the first 30 seconds of ligand association or dissociation cannot be 
recorded, as it takes time to have the spectrometer place the detectors above the wells and measure 
scintillations 7. This is not an issue in our case of the hA1R, but it can be crucial with fastly associating 
ligands. This could be improved by using an automatic injection module inside the counter, although 
this is currently not provided. Last, the temperature inside the counting chamber is fixed and slightly 
higher than room temperature (in our experiments the temperature was 28±1 oC). In a typical 
filtration assay kinetic radioligand binding experiments can be performed at lower or higher 






some scintillation counters it is possible to adjust temperature from 19 oC to 35 oC 34, a broader 
choice of assay temperatures would be highly advantageous. 
 
Conclusion 
We reported a rapid and reliable technique, the scintillation proximity assay (SPA) technology, for 
kinetic radioligand binding studies on a prototypic GPCR, the human adenosine A1 receptor (hA1R). 
The SPA technology was of great benefit, as it monitored the event of radioligand binding in a single 
well in almost real time, which is impossible in traditional filtration assays. Even in the otherwise 
most laborious of all kinetic assays, the competition association assay, the kinetic profiles (kon and koff) 
of unlabeled ligands for the hA1R were reliably and quickly determined, and agreed very well with the 
same parameters in a filtration assay performed simultaneously. In conclusion SPA is a very 
promising technique to determine the kinetic profiles of the drug-target interaction in the early 
phase of drug discovery. Its robustness and potential high-throughput may render this technology a 
preferred choice for further kinetic studies. 
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Chapter 7  
 







About this chapter 
In this thesis, the binding kinetics of ligands to several human GPCR, i.e. cannabinoid receptor 1 
(hCB1), adenosine A1 and A3 (hA1 and hA3) receptors, were studied to provide a better and multi-
faceted understanding of drug-target interactions. In this concluding chapter, new insights are 







Conclusions from this thesis 
Binding kinetics (i.e. knowledge of association and dissociation rate constants of ligands binding to 
and unbinding from their target) are gaining importance in the early phases of drug discovery. 
Therefore, throughout all the chapters of this thesis, we have characterized the binding kinetics of 
several series of compounds on different GPCR (i.e. hCB1, hA1 and hA3). Firstly, binding kinetics of 1,2-
diarylimidazol-4-carboxamide derivatives and 1-(4,5-diarylthiophene-2-carbonyl)-4-phenylpiperidine-
4-carboxamide derivatives as hCB1 receptor antagonists have been investigated in Chapters 2 and 3, 
respectively. Secondly, for the hA3 receptor, both antagonists (i.e. pyrido[2,1-f]purine-2,4-dione 
derivatives) and agonists (i.e. ribofurano and (N)-methanocarba derivatives) have been subjected to 
kinetic characterization (Chapters 4 and 5). Lastly, the binding kinetics of a few reference agonists 
and antagonists for the hA1 receptor that were obtained through a novel methodology have been 
compared with results stemming from traditional filtration assays (Chapter 6).  
First of all the spectrum of their kinetics, especially the residence times (RTs), varied significantly, 
although experimental conditions (e.g., temperature) were different. We found that the shortest RT 
antagonist at hCB1 receptor was rimonabant (14 min at 30 oC, from Chapter 2 and 3), the drug that 
was withdrawn from the market. The longest RT antagonist is a 1-(4,5-diarylthiophene-2-carbonyl)-4-
phenylpiperidine-4-carboxamide derivative (Chapter 3) with a RT of 2222 min (>36h at 30 oC). 
Another reported example of a ligand with such a rare long-lasting RT is tiotropium, a M3 muscarinic 
receptor antagonist.1 In the case of the hA3 receptor antagonists (Chapter 4), divergent RTs from 2.2 
min to 391 min at 10 oC were obtained; under similar experimental conditions the hA3 receptor 
agonists (Chapter 5) presented a greater range of RTs, from 10 min to 1961 min (>30h). In addition, 
the RTs variation (from 0.68 min to 167 min) of hA1 receptor reference ligands was also significant 
(Chapter 6), which were obtained at 28 oC. We speculate that variation in ligand dissociation rate 
constants may be due to the following three aspects: 1) the nature of the receptors (i.e. lipid hCB1R 






the ligand’s class-related binding mode (two series of hCB1R antagonists or two series of hA3R 
agonists).  
Interestingly, in the current thesis all the determined association rate constants are significantly 
below the so-called diffusion limit (i.e. 107 M-1s-1)2. This observation indicates that target engagement 
for ligands is more hampered than imposed by the diffusion limit alone. Specifically, the association 
rate constants of hA1 receptor ligands varied substantially (by 100-fold), which was similar to a 
previous report.3 In contrast, for hCB1 receptor and hA3 receptor ligands, the differences in 
association rate constants were less pronounced, approximately 5- to 30-fold, respectively. 
Interestingly, we found that hA3 receptor agonists’ association rate constants, albeit not that 
divergent, correlated significantly with their affinities. Such correlation between affinities and on-
rates has been reported in the case of other GPCR4 and ion channels.5, 6 It is therefore necessary to 
examine both association and dissociation rate constants of a ligand for better ligand optimization.  
Multiple binding kinetics assays have been performed in the present thesis. Especially, the 
radioligand competition association assay based on the Motulsky-Mahan model served as a working 
horse throughout all the research topics.7 Indeed, it turned out to be a good approach for the 
quantitative measurement of unlabeled (“cold”) ligands’ binding kinetics. However, this assay’s low-
throughput and the (safety) restrictions imposed by labeled (“hot”) ligands hamper its application in 
the kinetic profiling and concomitant structure kinetics relationships (SKR) studies. In the initial 
“kinetics screening” phase we adopted a simplified in-house validated competition association 
assay;3 by sampling only two assay (time) points per ligand. With that a kinetic rate index (KRI) value 
was determined as a semi-quantitative descriptor for a ligand’s dissociation rate. This relative high-
throughput assay could be generally applied for kinetics studies at diverse drug targets. This 
screening assay does have limitations, namely 1) it provides kinetics information on the dissociation 
rate only, and, 2) the resolution of KRI values is not high enough for detailed SKRs, unlike full kinetic 






assay (SPA), a homogenous technology with a “mix and measure” format, allowing monitoring of 
radioligand binding over time in a single well, from which association and dissociation rate constants 
of unlabeled ligands were reliably and quickly determined. Since this assay technology brings the 
benefit of greater efficiency in kinetic radioligand binding experiments, it can be of general use for 
kinetics studies at other drug targets as well.4 One  drawback of this technology is that the 
temperature of the microplate counter cannot be controlled (i.e. in our lab it was fixed at 28 ± 1 °C), 
preventing some targets from being kinetically investigated currently. In contrast, with a typical 
filtration assay, kinetic radioligand binding experiments can be performed at virtually any 
temperature, which allows for assay temperature optimization according to the characteristics of the 
radioligand—target interaction. Thus the SPA technology would greatly benefit from a counting 
device with temperature setting. 
Last but not least, this thesis provides substantial evidence that studying SKR is of great importance 
in the early phases of drug discovery. We have provided quite a few examples of ligands within the 
same chemical scaffold with very similar affinities that present very divergent binding kinetics. Thus 
detailed SKR analysis is able to offer added value to the traditional SAR. This can be exemplified by 
one of the hCB1 receptor antagonists, 14d (Chapter 2). On the basis of its high, picomolar affinity 
alone 14d seems a potent lead, but its close-to-unity KRI value indicates this may not be the case. 
Another example from Chapter 4: hA3 receptor antagonist 9 with a pKi = 8.5 would be considered a 
better ligand than antagonist 11 with a pKi = 8.2, according to traditional SAR. However, their RTs are 
28 min and 278 min, respectively, making antagonist 11 kinetically favorable. Thus, ignorance of the 
RT (by solely focusing on affinity) may lead to discontinuation of a compound that would likely 
perform better in vivo. Importantly the hA3 receptor agonist MRS5698 has been confirmed an 
interesting candidate lead compound for neuropathic pain, which might (in retrospect) be due to its 
optimal binding kinetics as shown in Chapter 5 (RT = 1961 min). Hence, the strategic combination of 
SAR and SKR analyses results in a better understanding of a ligand-receptor interaction, which 






during the course of ligand association and dissociation. This strategy may be generally applied for 
efficient drug design and provide improved drug candidates. 
Future perspectives 
Opportunities for binding kinetics on hCB1 receptor.  
The challenge in the development of hCB1R antagonists/inverse agonists as antiobesity drugs is their 
poor safety profile. Our strategy has been described in Chapters 2 and 3: a potent hCB1R antagonist 
should not only be periphery-selective but also have a slow dissociation profile from the receptor. 
There might be other strategies as well. One approach is developing an allosteric modulator, aiming 
to “fine-tune” the pharmacological activity of the endogenous orthosteric agonists.9 In this case, a 
negative allosteric modulator (NAM) would be aimed for,10 potentially having certain advantages 
over orthosteric ligands, like an increased target selectivity and the ability to maintain the spatial and 
temporal signaling profile of the endogenous ligands.11-13 Existing (positive) allosteric modulators 
such as ORG27569 tend to act as non-competitive antagonists in functional assays. The reason why is 
not entirely clear, but may be due to increased receptor desensitization induced by the compound,11 
also indicating that there is no clear cut between allosteric and orthosteric efficacy, as observed in 
previous research.14, 15 Thus, development of a true NAM and a subsequent NAMs-hCB1 binding 
kinetics study may provide additional ligand-receptor information, yielding a better understanding of 
a NAM’s mechanism of action and, possibly, NAMs as drug candidates. 
Another direction is developing neutral hCB1R antagonists to avoid some side effects because since 
the withdrawal of rimonabant the scientific community has been debating the compound’s inverse 
agonism in this respect.16, 17 Some of the compounds reduced peripheral nervous system (PNS) 
disorders. However, no improvement in reducing CNS side effects was observed, which might be due 
to the fact that their bioavailability was not restricted to the periphery.18, 19 Another possible 






arrestin recruitment) was neglected,20 i.e. the neutral antagonists developed so far were not neutral 
with respect to all relevant signaling pathways. To date, the concept of biased signaling has gained 
increasing attention in the GPCR field,21, 22 and the first evidence is mounting that binding kinetics can 
have a profound impact on this phenomenon.23, 24 
Opportunities for binding kinetics on hA3 receptor.  
There is no doubt that the hA3 receptor possesses tremendous therapeutic potential and clinical 
indications, due to its overexpression on cancer and inflammatory cells.25-29 However, the hA3 
receptor has a peculiar and rapidly changing expression profile in cultured cells.30 Moreover, certain 
hA3 receptor ligands have been described as cytoprotective or cytotoxic merely depending on the 
concentration employed, highlighting the difficulties that arise when one aims to characterize hA3 
receptor compounds.31,32 Such observed “dichotomy” in different therapeutic applications might be 
significantly influenced by both ligand RTs and desensitization/internalization-related receptor 
vulnerability (i.e. receptor-turnover): would such rapid receptor turnover off-set some agonist’s long 
RT? For instance, IB-MECA (with a RT of 95 min at 10 oC, in Chapter 5) has been proven safe and well 
tolerated but its anti-inflammatory effect may be hampered by its relatively quick onset of 
internalization of about 35 min – 60 min at 37 oC by different cellular assays. 33, 34 For other longer RT 
antagonists and agonists as determined in the current thesis (e.g., MRS5698), further cellular 
investigation is required, since knowledge of binding kinetics and the effect this has on 
internalization/desensitization will help to determine which kinetic profile is needed for an hA3 
receptor ligand to display a beneficial therapeutic profile. 
Another interesting, but complicating factor may be hA3 receptor homodimerization. This has 
recently been well illustrated by fluorescently labelled ligand-receptor binding kinetics studies on 
intact cells.35-37 A ligand’s binding kinetics on the hA3 receptor dimer is significantly different from its 






be profoundly influenced. It would be of great interest to test our hA3 receptor ligands in such a 
system and provide binding kinetics profiles for receptor dimers as well.  
General opportunities in binding kinetics for GPCR and beyond.  
• Assays and technologies for binding kinetics.  
A comprehensive overview of biochemical and biophysical assays and technologies for assessing 
ligand-receptor binding kinetics was described in a recently published review (Table 1).38 Currently, 
the most recognized and most straightforward kinetic profiling approach is applying a radioligand 
binding filtration assay using membrane proteins, as described throughout the current thesis. 
Although this method is sensitive and selective, it suffers from constraints imposed by the probe: a) 
high affinity, b) optimal/fixed experimental temperature (in most cases below physiological 37 oC), c) 
optimal/fixed incubation duration, d) quantification of competing ligands. In the (near) future better 
kinetic assays and technologies will be the standard such as a real-time homogeneous assay enabling 
high-throughput measurements, as exemplified by scintillation proximity assays (SPA) in Chapter 6. 
On the other hand, a few emerging non-radioactive assays (TR-FRET, BRET and SPR) indeed have 
advantages of real-time measurement of target binding kinetics,  even in a high-throughput capacity. 
However, there are still quite a few disadvantages, such as the use of modified ligands (probes) or 
targets, fixed temperatures, and half-lives of fluorescent emission (photo bleaching). Advantages and 
disadvantages of the current techniques to measure drug-target binding kinetics are summarized in 
Table 1. 
Table 1. Emerging experimental methods for kinetic profiling. Adapted and modified from ref. 38. 
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• From binding kinetics to functional dynamics 
According to the medical definitions from the Merriam-Webster Dictionary, “kinetics” literally means 
the rate of change in a system effected by forces upon motions,39 whilst “dynamics” describes 
“forces and their relation primarily to the motion but sometimes also to the equilibrium of bodies”.40 
In other words, kinetics emphasizes rates (e.g., ligands with a fast or slow association/dissociation 
to/from receptors); dynamics focuses on patterns of changes in systems (e.g., receptors, signaling 
pathways, cells, full bodies) after impact from external forces (e.g., all kinds of interactions), and such 
changes include equilibrium. Thus, there is a causal relation between “kinetics” and “dynamics”. 
Likewise, this entire thesis hypothesizes that, in GPCR, binding kinetics, more specifically RTs, are 





Figure 1. “Dynamic” functional assays are required for better translation of binding kinetics, as opposed to the 
currently much applied end-point functional assays.  
 
Indeed, a positive correlation between agonist efficacy and residence time has been observed in case 
of the muscarinic acetylcholine M3 receptor41 and adenosine A2A receptor.42 In contrast, no such 
correlation was observed for the adenosine A1 receptor.43 There is a high chance that the effects of 
binding kinetics may not be perfectly depicted in classic functional assays under equilibrium 
conditions (e.g., with respect to Emax). For instance, Emax induced by an agonist can be dynamic over 
time.44 Besides, receptor turnover (e.g., hA3R has a peculiar and rapid desensitization/internalization 






kinetics, insurmountability assays have been described as functional confirmation in this thesis 
(Chapters 2, 3 and 4). Such assays require complicated validation and optimization steps, especially 
for a long RT antagonist, where different preincubation times can lead to both insurmountable and 
surmountable effects, which also indicates the existence of functional dynamics. Therefore, dynamics 
of the functional effect shall be taken into account for further investigations. A simple rationale is 
presented below (Figure 1). 
Methods for measuring and quantifying individual signaling pathways in real-time (e.g., Gα-protein, β-
arrestin, cAMP) are emerging, which depict dynamic functional effects at a specific signaling 
pathway.11, 45, 46 Moreover, binding kinetics-driven functional dynamics has been described as 
“apparent biased signalling”.23 However, the reported methods are performed under distinct 
experimental conditions due to practical reasons (e.g., temperature, cell type, sampling methods), 
questioning the robustness of these apparent bias observations. Quite recently, a proximity labeling 
technique called “APEX” (affinity purification coupled with mass spectrometry) has been introduced 
which may provide new insights into the kinetics of GPCR signaling.47 Not only does it enlarge the 
signaling network,48 but it also offers high time resolution into GPCR signaling in living cells.49 In this 
way the dynamics of multiple signaling pathways can be carefully demonstrated and accurately 
quantified. Last but not least, by combining such detailed dynamic assessment technology with 
morphological label-free technology (e.g., xCELLigenceTM), better insights in cell signaling can  be 
translated from binding kinetics. 
• Motulsky-Mahan model, the perfect one?    
Throughout the thesis, the Motulsky-Mahan model has been the mathematic foundation for the 
quantification of binding kinetics.50 This model has been applied as an “Occam's razor” by simplifying 
the ligand-target interaction as a single and reversible binding interaction. Indeed such simplification 
is sufficient for unlabeled (cold) reversible ligands that competitively bind with the radioligand to the 






are GPCR agonists which are able to bind more than one receptor conformation (e.g. active state and 
inactive state). Another example are bitopic ligands which might bind a target in different 
orientations.51 Thus, kinetic quantification of GPCR agonists, irreversible binders and bitopic ligands 
faces difficulties when applying the Motulsky & Mahan model.  In the future, more and more 
quantification-driven investigations of ligand-receptor binding kinetics, from both theoretical and 
experimental perspectives, shall be performed to further understand the mechanism of any ligand-
target interaction.  
• “The great divide” between in vitro binding kinetics and in vivo pharmacokinetics (PK) and 
pharmacodynamics (PD) 
Although most of the current studies in this thesis have not been translated to in vivo studies (except 
for some ligands from Chapter 5 by others 52), one of the more outspoken differences between most 
in vitro and in vivo studies is the experimental temperature. Some slowly dissociating ligands were 
identified in vitro at temperatures (much) lower than mammals’ body temperature (i.e. 37 oC), thus, 
their binding kinetic parameters in vivo will be (much) faster. Of note, the ranking of a series of drug 
candidates should not be changed under such temperature maneuver by translation from in vitro to 
in vivo. Still, a slowly dissociating ligand only leads to long-lasting in vivo effects, when its dissociation 
rate from the target exceeds the rate of free drug elimination from the effect compartment (Figure 
2), ensuring pharmacodynamics (PD) outlasts pharmacokinetics (PK).53 
Another overlooked pharmacological effect is target rebinding (Figure 2), which means that a freshly 
dissociated ligand re-associates to the same or neighboring target. Prominent rebinding might be an 
important factor in dictating the duration of a ligand’s in vivo effect, even if a ligand-target complex’s 
lifetime is short. In this thesis, the RT of rimonabant, a hCB1 receptor antagonist, was determined to 
be 14 min (Chapters 2 and 3). However in a previous study its RT was reported to be much longer 






relatively short RT determined in vitro, one could speculate that in vivo the rimonabant-related CNS 






Figure 2. The binding kinetics in vivo is influenced by the rates of both free drug elimination (kelm) from the 
effect compartment (the box) and rebinding. A slow dissociation rate (koff) of a ligand exceeding its kelm shall 
result in a long lasting in vivo effect,  ensuring pharmacodynamics (PD) outlasts pharmacokinetics (PK). kon is the 
association rate constant of a ligand to its target, koff the dissociation rate constant. 
Besides, recent theoretical studies on PK/PD has shown that such rebinding could persist by 
increased (local) concentrations of the drug, resulting from a high target association rate constant.55, 
56 On the other hand, an increased drug concentration can also lead to increased off-target binding 
and thus decreased selectivity.56 Therefore, it is necessary to examine both association and 
dissociation rate constants of a ligand to its target for better translating  in vitro binding kinetics to in 
vivo PK/PD.  In this thesis, rimonabant has the slowest kon among the antagonists tested in Chapter 2, 
but the fastest in Chapter 3, and thus is it appealing to further compare these antagonists’ in vivo PK 
profile, concerning their rebinding and target occupancy. By combining data from different 
perspectives, the quality of the translation from in vitro to in vivo could be evaluated thoroughly.   
Last but not least, species differences are another issue when translating in vitro findings to in vivo 
effects, which has been reported for both hCB1 receptor and hA3 receptors. 57-59 Thus, in binding 
kinetics, we suggest to perform an in vitro investigation of the “kinetic hits” in the species that will be 
used in later in vivo studies, next to obtaining data for the human receptor.60 In this way,  species 
variability can be predicted before the actual in vivo studies, and if needed, another lead compound 








The entire thesis evolves around the concept of ligand-receptor binding kinetics for the early phase 
of drug design and discovery. We extensively investigated this concept at two potential drug targets, 
the cannabinoid 1 receptor and adenosine A3 receptor. We provide evidence that binding kinetics 
investigations on GPCR add indispensable information on these drug-target interactions. Besides, we 
propose that structure-kinetics relationship studies, next to the more traditional structure-affinity 
relationship studies, can improve the final decision and selection process of new chemical entities. 
Finally, we validated the scintillation proximity assay as a robust tool for high-throughput binding 
kinetics determination. 
Hopefully, all findings from this thesis have brought new insights at a molecular understanding of 
ligand-receptor binding kinetics, and will offer suggestions for the design of better ligands with an 
appropriate kinetic profile, new technologies for rapid kinetic assessment, and ultimately suitable 
evaluation schemes for a better translation towards effective and safe drugs. 
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The present thesis focuses on the pharmacological concept of drug-target interaction, which dates 
back to the beginning of modern pharmacology. In Chapter 1, a general introduction provides 
evidence that a traditional equilibrium metrics-based rationale (i.e. optimization of drug affinity leads 
to better efficacy and safety)  is unable to prevent current high attrition rates in the early phase of 
drug discovery. In the past decade drug-target binding kinetics (i.e. association and dissociation rate 
constants, residence time) has been gaining more and more attention, which constitutes a paradigm 
shift to better predict parameters of drug efficacy and safety. We decided to investigate binding 
kinetics of G protein-coupled receptors (GPCR), since GPCR are involved in various critical physiological 
and pharmacological functions, being the target of about 30% of all drugs on the market. Both the 
human cannabinoid receptor 1 (hCB1) and the human adenosine A1 and A3 (hA1 and hA3) receptors 
were chosen as prototypical GPCR as well as potential drug targets. Historical aspects of drug-target 
binding kinetics is also summarized in Chapter 1. 
In Chapters 2 and 3, our binding kinetic study was focused on the human cannabinoid hCB1 receptor, 
which is one of the “main actors” in the endocannabinoid system (ECS). In the particular case of 
obesity, the ECS, including the hCB1 receptor, is overactive with increased levels of endocannabinoids 
in plasma, and in central and peripheral tissues. Therefore, blockade of the hCB1 receptor is a potential 
approach for the treatment of obesity. Rimonabant, a hCB1 receptor inverse agonist, was developed 
by Sanofi-Aventis and introduced on the market in Europe in 2006. However, it was quickly withdrawn 
from the market due to the risk of unacceptable psychiatric side effects. Although researchers have 
experienced many setbacks on this drug target, the intensive drug discovery efforts have never been 
terminated. In Chapter 2, we performed an extensive structure- kinetics relationship (SKR) study, in 
addition to a traditional structure-affinity relationship (SAR) analysis, on a series of 1,2-diarylimidazol-
4-carboxamide derivatives developed as hCB1 receptor antagonists. The compounds show high 
affinities and a diverse range of kinetic profiles at hCB1 receptor. In Chapter 3, another series of 1-
(4,5-diarylthiophene-2-carbonyl)-4-phenylpiperidine-4-carboxamide derivatives, and rimonabant as a 
comparison were selected for SKR analysis and further molecular pharmacological investigation. This 
study shows that hCB1 receptor antagonists can have very divergent kinetics (the difference in 
residence time in Chapter 3 is 159-fold, while 18.5-fold in Chapter 2), which are not correlated to their 
equilibrium affinities. Furthermore, their dissociation rates appear to define their (in vitro) 
pharmacological effect. For both Chapters 2 and 3, based on the recently resolved hCB1 receptor 
crystal structures, we propose that the differences in dissociation can be explained by a different 
binding mode of long residence time antagonists compared to short residence time antagonists (i.e. 
rimonabant) in which “unfavorable” water molecules are displaced. We learned that, next to affinity, 
additional knowledge of binding kinetics is useful for selecting new hCB1 receptor antagonists in the 
early phases of drug discovery for the treatment of obesity. 
Next, we explored binding kinetics on the human adenosine A3 (hA3) receptor in Chapters 4 and 5. The 
hA3 receptor has been suggested as a viable drug target in inflammatory diseases and in cancer. So far, 
a number of selective hA3 receptor agonists (e.g. IB-MECA and 2-Cl-IB-MECA) inducing anti-
inflammatory or anticancer effects are under clinical investigation. In Chapter 4, we expand on a series 
of pyrido[2,1-f]purine-2,4-dione derivatives as hA3 receptor antagonists, and many compounds 
showed high affinities and a diverse range of kinetic profiles. From a kon-koff-KD kinetic map we divided 
the antagonists into three subgroups, providing a possible direction for the further development of 
hA3R antagonists. Additionally, we performed a computational modelling study that sheds light on the 
crucial receptor interactions dictating the compounds’ binding kinetics. In Chapter 5 hA3 receptor 
agonists are under binding kinetics investigation. We first validated a kinetic assay for agonists. Then, 
two series of ribofurano and methanocarba ([3.1.0]bicyclohexane) adenosine derivatives were 
evaluated for both their affinity and kinetics. Afterwards, a retrospective evaluation linking residence 
times and in vivo efficacies was discussed.  Last but not least, from a kon-koff-KD kinetic map we divided 
the agonists into three subgroups, providing a possible direction for the further development of hA3R 
agonists. 
In Chapter 6, the application of a novel radio-isotopic technology in binding kinetics is described for 
the human adenosine A1 receptor. Compared to the classic radioligand binding experiment, its 
robustness and potential for high-throughput screening may render this technology a preferred choice 
for further kinetics studies.    
In the last Chapter 7, the binding kinetics investigations described in this thesis provide a better and 
multi-faceted understanding of drug-target interactions, and future perspectives are outlined. 
Hopefully, all findings from this thesis have brought new insights at a molecular understanding of 
ligand-receptor binding kinetics, and will offer suggestions for the design of better ligands with an 
appropriate kinetic profile, new technologies for rapid kinetic assessment, and ultimately suitable 















Dit proefschrift richt zich op het farmacologische concept van drug/target interactie, dat teruggaat tot 
het begin van de moderne farmacologie. In Hoofdstuk 1 geeft een algemene inleiding het bewijs dat 
een op traditionele evenwichts bepalingen gebaseerde redenering (optimalisatie van geneesmiddel-
affiniteit leidt tot een betere werkzaamheid en veiligheid) niet in staat is om de huidige hoge uitval in 
de vroege ontwikkelingen fase van geneesmiddelen te voorkomen. In het afgelopen decennium heeft 
de bindingskinetiek van het geneesmiddel met het doelwit (met name de associatie- en 
dissociatiesnelheidsconstanten, en de verblijftijd) meer en meer aandacht gekregen, hetgeen een 
paradigma verschuiving is om parameters van effectiviteit en veiligheid van een geneesmiddel beter 
te voorspellen. We besloten om de bindingskinetiek van G-eiwit-gekoppelde receptoren (GPCR) te 
onderzoeken, aangezien GPCR betrokken zijn bij verschillende belangrijke fysiologische en 
farmacologische functies, en het doelwit zijn van ongeveer 30% van alle geneesmiddelen op de markt. 
Zowel de menselijke cannabinoïde receptor 1 (hCB1) en de humane adenosine A1- en A3 (hA1- en hA3) 
-receptoren werden gekozen als prototypes voor een GPCR en als potentiële doelen voor 
geneesmiddelen. Historische aspecten van de bindingskinetiek van geneesmiddel en receptor worden 
ook samengevat in Hoofdstuk 1. 
In Hoofdstuk 2 en 3 was onze studie van de kinetiek van de binding gericht op de menselijke 
cannabinoïde hCB1-receptor, een van de 'belangrijkste actieve onderdelen' van het 
endocannabinoïdesysteem (ECS). In het specifieke geval van obesitas is de ECS, inclusief de hCB1-
receptor, overactief met verhoogde niveaus van endocannabinoïden in plasma en in centrale en 
perifere weefsels. Daarom is blokkade van de hCB1-receptor een potentiële benadering voor de 
behandeling van obesitas. Rimonabant, een inverse agonist voor de hCB1-receptor, is ontwikkeld door 
Sanofi-Aventis en op de Europese markt geïntroduceerd in 2006. Het werd echter snel uit de handel 
genomen vanwege het risico van onaanvaardbare psychische bijwerkingen. Hoewel onderzoekers veel 
tegenslagen hebben ondervonden de ontwikkeling van dit medicijn, zijn de intensieve inspanningen 
voor het ontdekken van geneesmiddelen nooit gestopt. In Hoofdstuk 2 hebben we naast een 
traditionele structuur-affiniteitsrelatie (SAR) -analyse ook een uitgebreide structuur-kinetische relatie 
(SKR) studie uitgevoerd, betreffende een reeks 1,2-diarylimidazol-4-carboxamidederivaten 
ontwikkeld als hCB1-receptorantagonisten . De verbindingen vertonen hoge affiniteiten en een 
diverse reeks kinetische profielen bij de hCB1-receptor. In Hoofdstuk 3 werd een andere reeks 1- (4,5-
diarylthiofeen-2-carbonyl) -4-fenylpiperidine-4-carboxamidederivaten en rimonabant als vergelijking 
geselecteerd voor SKR-analyse en verder moleculair farmacologisch onderzoek. Deze studie toont aan 
dat antagonisten voor de  hCB1-receptor een zeer uiteenlopende kinetiek kunnen hebben (het verschil 
in verblijftijd in Hoofdstuk 3 is 159-voudig, terwijl 18,5 in Hoofdstuk 2), die niet gecorreleerd zijn aan 
hun evenwichtsaffiniteiten. Bovendien lijken hun dissociatiesnelheden hun (in vitro) farmacologische 
effect te bepalen. Voor zowel Hoofdstuk 2 als Hoofdstuk 3, gebaseerd op de recentelijk opgeloste 
kristalstructuren van de hCB1-receptor, stellen we voor dat de verschillen in dissociatie verklaard 
kunnen worden door een andere bindingswijze van antagonisten met lange verblijftijd in vergelijking 
met antagonisten met een korte verblijftijd (zoals rimonabant) waarin "ongunstige " watermoleculen 
worden verplaatst. We hebben geleerd dat, naast affiniteit, aanvullende kennis van bindingskinetiek 
nuttig is voor het selecteren van nieuwe antagonisten voor de hCB1-receptor in de vroege fasen van 
geneesmiddelontdekking voor de behandeling van obesitas. 
Vervolgens hebben we bindingskinetiek onderzocht op de humane adenosine A3 (hA3) receptor in 
Hoofdstuk 4 en 5. De hA3-receptor is gesuggereerd als een bruikbaar doelwit voor geneesmiddelen 
bij ontstekingsziekten en bij kanker. Tot nu toe is een aantal selectieve hA3-receptoragonisten 
(bijvoorbeeld IB-MECA en 2-Cl-IB-MECA) die ontstekingsremmende of antikanker effecten induceren, 
onder klinisch onderzoek. In Hoofdstuk 4 gaan we dieper in op de eigenschappen van een reeks pyrido 
[2,1-f] purine-2,4-dion-derivaten als hA3 antagonisten. Veel verbindingen vertoonden hoge 
affiniteiten en een breed scala aan kinetische profielen. Van een kon-koff-KD-kinetische kaart verdeelden 
we de antagonisten in drie subgroepen, die een mogelijke richting voor de verdere ontwikkeling van 
hA3R-antagonisten aangaven. Daarnaast hebben we een onderzoek met een computermodel 
uitgevoerd dat licht werpt op de cruciale receptor interacties die de bindingskinetiek van de 
verbindingen veroorzaken. In Hoofdstuk 5 is de bindings kinetiek van agonisten voor de hA3-
receptoronderzocht. We hebben eerst een kinetische test voor agonisten gevalideerd. Vervolgens 
werden twee reeksen van ribofurano en methanocarba ([3.1.0] bicyclohexaan) adenosinederivaten 
beoordeeld op zowel affiniteit als kinetiek. Daarna werd een retrospectieve evaluatie besproken die 
verblijftijden en in vivo-werkzaamheid koppelt. Last but not least, van een kon-koff-KD kinetische kaart 
verdeelden we de agonisten in drie subgroepen, wat een mogelijke route voor de verdere 
ontwikkeling van hA3R-agonisten biedt. 
In Hoofdstuk 6 wordt de toepassing van een nieuwe radio-isotopentechnologie in bindingskinetiek 
beschreven voor de humane adenosine A1-receptor. In vergelijking met de klassieke radioligand-
bindings assay, kan vanwege de robuustheid en het potentieel voor high-throughput screening aan 
deze technologie de voorkeur worden gegeven voor verdere kinetische studies. 
In het laatste Hoofdstuk 7 bieden de onderzoeken van de bindingskinetiek, die in dit proefschrift 
worden beschreven, een beter en veelzijdig begrip van interacties tussen geneesmiddelen en doelen 
(receptoren), en worden toekomstige perspectieven geschetst. Hopelijk hebben alle bevindingen uit 
dit proefschrift nieuwe inzichten opgeleverd in het moleculaire aspect van de ligand-receptor 
bindingskinetiek, en zullen ze suggesties bieden voor het ontwerp van betere liganden met een 
geschikt kinetisch profiel, nieuwe technologieën voor snelle kinetische beoordeling en uiteindelijk 
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